 
 Cover page 
 
  
 
Official Title: 
 
PROTOCOL ID-078A302 - Multi-center, double-b lind, randomized, placebo-controlled, 
parallel-group, polysomnography study to  assess the efficacy and safety of  
ACT-541468 in adult and elderly s ubjects with insomnia disorder 
 
   
Study Registry ID: [REMOVED] 
  
 
 
Date of document: 
 
8 November 2018 
 
 
 
TPL-100601_v01  
ACT- 541468  
Insomnia Disorder 
Protocol ID-078A302 
Multi -center, double -blind, randomized, placebo -controlled, parallel -group, 
polysomnography study to assess the efficacy and safety of ACT-541468 in adult and 
elderly subjects with insomnia disorder  
Study Phase:  3 
EudraCT Number : 2017 -004643 -20 
Status and version:  Final Versio n 5 
Date:  8 November  2018  
Document type : Amended g lobal protocol  
Idorsia  document number 
(Doc No.): D-18.262
Confidentiality statement  
The information contained in this document, especially unpublished data, is the property of the sponsor of 
this study, Idorsia Pharmaceuticals Ltd. It is therefore provided to you in confidence as an investigator, 
potential investigator, or consultant, for review by you, your personnel, and an independent ethics committee 
or institutional review board. It is understood that this information will not be disclosed to others without 
written authorization from Idorsia Pharmaceuticals Ltd, except to the extent necessary to obtain informed 
consent from those persons to whom the study treatment may be administered.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 2/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
SPONSOR CONTACT DETAILS 
Sponsor  Idorsia Pharmaceuticals Ltd  
Hegenheimermattweg 91  
CH-4123 Allschwil 
Switzerland  
 +41 58 844 00 00  
Clinical Trial Physician  Contact details of the Clinical T rial Physician can 
be found in the Investigator Site File 
Medical Emergency Hotline  
Toll phone number Site-specific toll telephone numbers and toll -free 
numbers for the Medical Emergency Hotline can 
be found in the Investigator Site File 
  
CONTRACT RESEARCH ORGANIZATIONS INFORMATION 
Some study activities will be delegated to Contract Research Organizations (CROs). A 
list of site -specific contact details can be found in the Investigator Site File.  
 
  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 3/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
SIGNATURE PAGE FOR IDORSIA PHARMACEUTICALS LTD 
Hereinaf ter called Idorsia  
 
Treatment name / number ACT -541468 
Indication 
Insomnia Disorder 
Protocol number,  study title  
ID-078A302 
Multi- center, double -blind, randomized, placebo -controlled, parallel -group, 
polysomnography study to assess the efficacy and safety of ACT -541468 in adult and 
elderly subjects with insomnia disorder.  
I approve the terms and conditions relating to this study as defined in this protocol. I 
confirm that the information contained in this protocol is consistent with the current risk-benefi t evaluation of ACT -541468, and with the ethical and scientific principles 
governing clinical research as set out in the Declaration of Helsinki and the Internat ional 
Council for Harmonisation (ICH) Good Clinical Practice (GCP) guidelines . 
 
 
Title  Name  Date  Signature  
  

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 4/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
INVESTIGATOR SIGNATURE PAGE 
Treatment name / number 
ACT -541468 
Indication Insomnia Disorder 
Protocol number, study title  
ID-078A302 
Multi- center, double -blind, randomized, placebo -controlled, parallel -group, 
polysomnography study to assess the efficacy and safety of ACT -541468 in adult and 
elderly subjects with insomnia disorder. 
I agree to the terms and conditions relating to this study as defined in this protocol, the 
Case Report Form, and any other protocol -related documents. I fully understand that any 
changes instituted by the investigator(s) without previous agreement with the sponsor would constitute a protocol deviation, including any ancillary studies or procedures performed on study subjects (other than those procedures necessary for the well -being of 
the subjects).  
I agree to conduct this study in accordance with the Declaration of Helsinki principles, ICH  
GCP guidelines, and applicable regulations and laws. I confirm herewith that the sponsor is allowed to enter and utilize my professional contact details and function in an electronic database for internal purposes and for submission to health authorities worldwide. 
I am participating  in the following sub-study (only for sites in Germany and the USA): 
PAtient Preferences StUdy in InSomnia (PAUSe)  
 
Principal 
Investigator  Country  Site 
number Town  Date   Signature  
 
       
 
  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 5/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
TABLE OF CONTENTS 
LIST OF ABBREVIATION S AND ACRONYMS  ..........................................................12  
NON- SUBSTANTIAL GLOBAL AMENDMENT 4  .......................................................16  
PROTOCOL SYNOPSIS ID-078A302 .............................................................................18  
PROTOCOL  ......................................................................................................................32  
1 BACKGROUND  .........................................................................................................32  
1.1 Insomnia disorder .........................................................................................32  
1.1.1  Definition  ..........................................................................................32  
1.1.2  Epidemiology ....................................................................................32  
1.1.3  Treatment  ..........................................................................................33  
1.1.4  Unmet medical need  .........................................................................34  
1.2 Study treatment: ACT -541468 .....................................................................35  
1.2.1  The orexin system  .............................................................................35  
1.2.2  ACT -541468 properties ....................................................................35  
1.2.2.1  Nonclinical data  .......................................................................35  
1.2.2.2  Clinical studies  ........................................................................36  
1.3 Purpose and rationale of the study ................................................................39  
1.3.1  Purpose of the study ..........................................................................39  
1.3.2  Rationale for the study ......................................................................39  
1.4 Summary of known and potential risks and benefits ....................................40  
1.4.1  ACT -541468 .....................................................................................40  
1.4.2  Safety and risk -minimization measures taken in the present 
study ..................................................................................................41  
2 STUDY OBJECTIVES  ...............................................................................................41  
2.1 Primary objective  ..........................................................................................42  
2.2 Secondary objectives ....................................................................................42  
2.3 Safety objectives  ...........................................................................................42  
3 OVERALL STUDY DESIGN AND PLAN  ...............................................................42  
3.1 Study design .................................................................................................42  
3.1.1  Study periods ....................................................................................42  
3.1.1.1  Screening phase  .......................................................................42  
3.1.1.2  Treatment phase  ......................................................................43  
3.1.1.3  Safety follow -up phase ............................................................43  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 6/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
3.1.2  Study duration ...................................................................................44  
3.1.3  Sub- study – Patient Preferences  .......................................................45  
3.2 Study design rationale ..................................................................................46  
3.2.1  Core study .........................................................................................46  
3.2.2  Patient preferences sub -study ...........................................................47  
3.3 Study committees  .........................................................................................47  
4 SUBJECT POPULATION ..........................................................................................48  
4.1 Subject population description .....................................................................48  
4.2 Rationale for the selection of the study population ......................................48  
4.3 Inclusion criteria  ...........................................................................................49  
4.4 Exclusion criteria  ..........................................................................................50  
4.5 Criteria for women of childbearing potential ...............................................52  
4.5.1  Definition of childbearing potential ..................................................52  
4.5.2  Acceptable methods of contraception ...............................................53  
5 TREATMENTS  ..........................................................................................................54  
5.1 Study treatment  .............................................................................................54  
5.1.1  Investigational treatment and matching placebo: Description 
and rationale ......................................................................................54  
5.1.2  Study treatment administration  .........................................................54  
5.1.2.1  Study treatment administration at site visits  and at home .......54  
5.1.2.2  Missed doses ............................................................................54  
5.1.3  Treatment assignment  .......................................................................54  
5.1.4  Blinding ............................................................................................55  
5.1.4.1  Run-in and run-out periods ......................................................55  
5.1.4.2  Double- blind treatment period  ................................................55  
5.1.5  Unblinding ........................................................................................56  
5.1.5.1  Unblinding for final analyses ..................................................56  
5.1.5.2  Unblinding for IDMC review ..................................................56  
5.1.5.3  Unblinding for suspected unexpected serious adverse reactions  ...................................................................................56
 
5.1.5.4  Emergency procedure for unblinding ......................................56  
5.1.6  Study treatment supply .....................................................................57  
5.1.6.1  Study treatment packaging and labeling  .................................57  
5.1.6.2  Study treatment distribution and storage .................................57  
5.1.6.3  Study treatment dispensing .....................................................57  
5.1.6.4  Study tre atment return and destruction ...................................57  
5.1.7  Study treatment accountability and compliance with study treatment  ...........................................................................................58
 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 7/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
5.1.7.1  Study treatment accountability  ................................................58  
5.1.7.2  Study t reatment compliance  ....................................................58  
5.1.8  Study treatment dose adjustments and interruptions ........................59  
5.1.9  Premature discontinuation of study treatment  ..................................59  
5.1.10  Study- specific criteri a for interruption / premature 
discontinuation of study treatment ....................................................60  
5.2 Previous and concomitant therapy ................................................................60  
5.2.1  Definitions  ........................................................................................60  
5.2.2  Reporting of previous/concomit ant therapy in the eCRF  .................60  
5.2.3  Allowed concomitant therapy ...........................................................61  
5.2.4  Forbidden concomitant therapy ........................................................61  
5.2.5  Forbidden concomitant diet and activities ........................................61  
6 STUDY ENDPOINTS  ................................................................................................62  
6.1 Primary efficacy endpoints  ...........................................................................62  
6.2 Secondary endpoints .....................................................................................62  
6.3 Other efficacy endpoints ...............................................................................63  
6.4 Exploratory endpoints ...................................................................................63  
6.5 Safety endpoints  ...........................................................................................64  
6.6 Pharmacokinetic endpoints ...........................................................................65  
6.7 Patient preferences exploratory endpoints ....................................................65  
7 VISIT SCHEDULE AND STUDY ASSESSMENTS ................................................66  
7.1 Study visits  ...................................................................................................66  
7.1.1  Screening  ..........................................................................................66  
7.1.2  Unscheduled visits ............................................................................66  
7.2 Study assessments  .........................................................................................70  
7.2.1  Demographics ...................................................................................72  
7.2.2  Efficacy assessments  .........................................................................72  
7.2.2.1  Polysomnography ....................................................................72  
7.2.2.2  Sleep diary  ...............................................................................74  
7.2.2.3  Insomnia Severity Index© ........................................................74  
7.2.2.4  Patient Global Assessment of Disease Severity (daytime 
symptoms)  ...............................................................................75  
7.2.2.5  Patient Global Impression of Change (daytime 
symptoms)  ...............................................................................75  
7.2.2.6  Patient Global Impression of Change (night- time 
symptoms)  ...............................................................................75  
7.2.2.7  Patient Global Impression of Severity (night- time 
symptoms)  ...............................................................................76  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 8/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
7.2.2.8  Insomnia Daytime Symptoms and Impacts Questionn aire .....76  
7.2.3  Safety assessments  ............................................................................76  
7.2.3.1  Weight and height ...................................................................76  
7.2.3.2  Physical examination  ...............................................................76  
7.2.3.3  Vital signs  ................................................................................77  
7.2.3.4  Coding sub- test© ......................................................................77  
7.2.3.5  Sheehan Disability Scale© .......................................................77  
7.2.3.6  Columbia Suicide Severity Rating Scale©...............................77  
7.2.3.7  Benzodiazepine Withdrawal Sy mptom Questionnaire  ............78  
7.2.3.8  Mini International Neuropsychiatric Interview© .....................78  
7.2.3.9  Mini Mental State Examination© ............................................78  
7.2.3.10  Neurological examinations  ......................................................79  
7.2.3.11  Epworth Sleepiness Scale© ......................................................79  
7.2.3.12  ECG assessment  ......................................................................79  
7.2.4  Patient preferences questionnaire  .....................................................80  
7.2.5  Laboratory assessments  ....................................................................80  
7.2.5.1  Type of laboratory ...................................................................80  
7.2.5.2  Laboratory tests  .......................................................................81  
7.2.6  Pharmacokinetic assessments  ...........................................................82  
8 STUDY COMPLETION AND POST -STUDY TREATMENT / MEDICAL 
CARE  ..........................................................................................................................82  
8.1 Study completion as per protocol .................................................................82  
8.2 Premature withdrawal from study  ................................................................82  
8.3 Premature termination or suspension of the study ........................................83  
8.4 Medical care of subjects after study completion / withdrawal from 
study ..............................................................................................................84  
9 SAFETY DEFINITIONS AND REPORTING REQUIRE MENTS  ...........................84  
9.1 Adverse events  ..............................................................................................84  
9.1.1  Definition of adverse events .............................................................84  
9.1.2  Intensity of adverse events  ................................................................85  
9.1.3  Relationship to study treatment ........................................................86  
9.1.4  Reporting of adverse events ..............................................................86  
9.1.5  Follow-up of adverse events .............................................................86  
9.2 Serious adverse events  ..................................................................................87  
9.2.1  Definitions of serious adverse events ...............................................87  
9.2.2  Reporting of serious adv erse events  .................................................87  
9.2.3  Follow-up of serious adverse events .................................................88  
9.2.4  After the 30 -day follow-up period ....................................................88  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 9/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
9.2.5  Reporting procedures ........................................................................88  
9.3 Pregnancy  .....................................................................................................89  
9.3.1  Reporting of pregnancy ....................................................................89  
9.3.2  Follow-up of pregnancy ....................................................................89  
9.4 Study safety monitoring  ................................................................................89  
10 STATISTICAL METHODS  .......................................................................................89  
10.1  Analysis sets  .................................................................................................90  
10.1.1  Screened Analysis Set  .......................................................................90  
10.1.2  Full Analysis Set ...............................................................................90  
10.1.3  Per-Protocol Set ................................................................................90  
10.1.4  Safety Set  ..........................................................................................90  
10.1.5  Treatment Withdrawal Set  ................................................................90  
10.1.6  Pharmacokinetic Analysis Set  ..........................................................90  
10.1.7  Patient Preferences Analysis Set  .......................................................90  
10.1.8  Usage of the analysis sets  .................................................................91  
10.2  Variables  .......................................................................................................91  
10.3  Description of statistical analyses  .................................................................91  
10.3.1  Analysis of the primary and secondary efficacy variables  ...............91  
10.3.1.1  Overall testing strategy  ............................................................91  
10.3.1.2  Hypotheses and statistical model ............................................94  
10.3.1.3  Handling of missing data  .........................................................94  
10.3.1.4  Supportive/sensitivity analyses  ...............................................94  
10.3.2  Analysis of other efficacy variables  ..................................................95  
10.3.3  Analysis of the safety variables  ........................................................95  
10.3.4  Analysis of pharmacokinetic variables  .............................................96  
10.3.5  Subgroup analyses ............................................................................97  
10.3.6  Analysis of the patient preferences variable  .....................................97  
10.4  Interim analyses  ............................................................................................97  
10.5  Sample size  ...................................................................................................97  
11 DATA HANDLING  ....................................................................................................99  
11.1  Data collection  ..............................................................................................99  
11.2  Maintenance of data confidentiality  ...........................................................100  
11.3  Database management and quality control  .................................................100  
12 PROCEDURES AND GOOD CLINICAL PRACTICE  ...........................................101  
12.1  Ethics and Good Clinical Practice  ..............................................................101  
12.2  Independent Ethics Committee / Institutional Review Board  ....................101  
12.3  Informed consent ........................................................................................102  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 10/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
12.4  Compensation to subjects and investigators ...............................................103  
12.5  Protocol adherence/compliance  ..................................................................103  
12.6  Protocol amendments .................................................................................103  
12.7  Essential documents and retention of documents .......................................103  
12.8  Monitoring ..................................................................................................104  
12.9  Investigator Site File  ...................................................................................105  
12.10  Audit ...........................................................................................................106  
12.11  Inspections ..................................................................................................106  
12.12  Reporting of study results and publication .................................................106  
13 REFERENCES  ..........................................................................................................108  
14 APPENDICES  ...........................................................................................................115  
 
 
LIST OF TABLES 
 Table 1
 Visit and assessment schedule  .....................................................................67  
Table 2  Sample size assumptions for primary and secondary endpoints .................98  
  
LIST OF FIGURES 
 Figure 1
 Study design.................................................................................................44  
Figure 2  Hypothesis testing strategy  ..........................................................................93  
Figure 3  Effect of testing multiple null hypotheses on power at a given sample size ...............................................................................................................99
 
          
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 11/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
LIST OF APPENDICES 
 
Appendix 1  Alcohol restrictions during the study .........................................................115  
Appendix 2  Caffeine content of common beverages ....................................................116  
Appendix 3  Forb idden and restricted concomitant medications ...................................117  
Appendix 4  Coding sub- test© ........................................................................................120  
Appendix 5  Insomnia Severity Index© ..........................................................................121  
Appendix 6  Sheehan Disability Scale© .........................................................................122  
Appendix 7  Benzodiazepine Withdrawal Symptom Questionnaire ..............................123  
Appendix 8  Sleep Diary  ................................................................................................124  
Appendix 9  Patient Global Assessment of Disease Severity and Patient Global Impr ession of Change, daytime symptoms ................................................126
 
Appendix 10  Patient Global Impression of Severity (PGI- S) and Patient Global 
Impression of Change (PGI-C), night- time symptoms  ..............................127  
Appendix 11  Insomnia Daytime Symptoms and Impacts Questionnaire ........................128  
Appendix 12  Epworth Sleepiness Scale© ........................................................................132  
Appendix 13  Mini Mental State Examination© ...............................................................133  
Appendix 14  PAtient preferences st Udy in in Somnia (PAUSe)  .....................................135  
 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 12/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
LIST OF ABBREVIATIONS AND ACRONYMS 
AE  Adverse event  
AESI   Adverse event of special interest  
AHI  Apnea/hypopnea index 
ALT   Alanine aminotransferase 
AST   Aspartate aminotransferase 
AV  Atriove ntricular  
BMI   Body mass index 
BP  Blood pressure 
bpm  Beats per minute  
BRA   Benefit -risk assessment  
BWSQ   Benzodiazepine Withdrawal Symptom Questionnaire 
CBT   Cognitive behavioral therapy 
CFR   Code of Federal Regulations (US)  
CNS   Central nervous system  
CR  Controlled- release  
CRA   Clinical Research Associate  
CRO   Contract Research Organization  
CSR   Clinical Study Report  
C-SSRS©  Columbia Suicide Severity Rating Scale© 
CV%   Coefficient of variation  
CYP   Cytochrome P450 
DB  Double-blind 
DCE   Discrete Choice Experiment  
DoA  Delegation of Authority 
DORA  Dual orexin receptor antagonist 
DSM -5  Diagnostic and Statistical Manual of Mental Disorders, Fifth 
Edition  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 13/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
ECG   Electrocardiogram /graphy  
eCRF   Electronic Case Report Form  
EDS   Excessive daytime sleepiness  
EMA   European Medicines Agency 
Emax  Maximum effect  
EODBT   End-of-Double-Blind Treatment  
EOS   End-of-Study 
EOT   End-of-Treatment  
ESS©  Epworth Sleepiness Scale© 
FAS  Full Analysis Set 
FDA   Food and Drug Administration 
GABA   Gamm a-aminobutyric acid 
GCP   Good Clinical Practice  
HR  Heart rate  
IB  Investigator’ s Brochure  
ICF  Informed consent f orm 
ICH  International Council for Harmonisation 
IDMC   Independent Data Monitoring Committee 
IDSIQ   Insomnia Daytime Symptoms and Impac ts Questionnaire 
IEC  Independent Ethics Committee 
IRB  Institutional Review Board  
IRT  Interactive Response Technology 
ISAC   Independent Statistical Analysis Center  
ISB  Independent Safety Board  
ISF  Investigator Site File  
ISI©  Insomnia Severity I ndex© 
LPS  Latency to Persistent Sleep  
MAR   Missing at random 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 14/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
MedDRA   Medical Dictionary for Regulatory Activities  
MINI©  Mini International Neuropsychiatric Interview© 
MMSE©  Mini Mental State Examination© 
NOAEL   No-observed -adverse -effect level  
PAUSe  PAtient Preferences StUdy in InSomnia  
PD  Pharmacodynamic(s)  
PGA-S  Patient Global Assessment of Disease Severity  
PGI-C  Patient Global Impression of Change 
PGI-S  Patient Global Impression of Severity  
PI  Principal Investigator  
PK  Pharmacokine tic(s)  
PLMAI   Periodic limb movement with arousal index  
PPS  Per-Protocol Set 
PSG  Polysomnography 
PT  Preferred Term  
QS  Quality System 
QTc  Corrected QT interval  
QTcB   QT interval corrected with Bazett ’s formula  
QTcF   QT interval corrected with Fridericia’ s formula  
REM   Rapid eye movement 
RSI  Reference Safety Information  
RUT   Random utility theory 
SAE   Serious adverse event  
SAP  Statistical Analysis Plan  
SD  Standard deviation 
SDS©  Sheehan Disability Scale© 
SIV  Site Initiation Visit 
sLSO  Subjective Latency to Sleep Onset  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 15/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
SMAA  Stochastic multicriteria acceptability analysis  
SOC   System Organ Class  
SpO 2  Blood oxygen saturation level by pulse oximetry 
SQ  Sleep quality  
sTST  Subjective Total Sleep Time  
SUSAR   Suspected unexpected serious adverse reaction  
sWASO   Subjective Wake After Sleep Onset  
SWS   Slow wave sleep  
t½  Half-life 
TEAE  Treatment -emergent adverse event  
TST  Total Sleep Time  
ULN   Upper limit of normal 
USPI   United States Package Insert  
VAS   Visual analog scale(s)  
WASO   Wake After Sleep Onset  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 16/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 17/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 18/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
PROTOCOL SYNOPSIS ID-078A302 
TITLE  Multi -center, double -blind, randomized, placebo -controlled, parallel -
group, polysomnography study to assess the efficacy and safety of 
ACT -541468 in adult and elderly subjects with insomnia disorder 
OBJECTIVES  Primary objectives  
To evaluate the efficacy of 10 mg and 25 mg  ACT -541468 on 
objective sleep parameters in subjects with insomnia disorder.  
Secondary objectives  
To evaluate the efficacy of 10 mg and 25 mg ACT -541468 on 
subjective sleep p arameters and next -day functioning in subjects with 
insomnia disorder. 
Safety objectives  
To assess the safety and tolerability of ACT -541468 in subjects with 
insomnia disorder  during treatment and upon treatment 
discontinuation.  
DESIGN  Multi -center, doub le-blind, randomized, placebo -controlled, 
parallel -group, Phase 3 study. 
PHASES The study comprises the following 3 phases: the screening phase, the 
treatment phase, and the safety follow-up phase. The screening phase starts  with the signature of the informed consent 
form at Visit 1 and ends at Randomization ( Visit 4 )
, provided the 
subject fulfills all the eligibility criteria. It includes the Screening 
period and the Run- in period. The screening phase last s 20 to 31 days.  
The Screening period  starts with Visit 1 and ends at Visit 2.  During 
the Screening period , the investigator verif ies eligibility criteria and 
eligible subjects perform a one -night polysomnography ( PSG) 
assessment. The S creening period lasts 7 to 18 days to allow time to 
perform all requir ed procedures at V isit 1, the PSG assessment  and 
collect the minimum number of eDiary entries (i.e. , 7 days) between 
Visit 1 and V isit 2.  
The Run-in period  starts with Visit 2 and ends at Randomization 
(i.e., Visit 4 ). At Visit 2 eligible subject s are allocated a 
single -blinded placebo treatment that is taken daily . During  the 
Run-in period subjects come to the site for Visit 3 , which  consists of 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 19/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
2 PSG nights  and is performed when the subject has completed the 
eDiary for at least 7 days  and eligibility is confirmed . The Run-in 
period lasts 13 to 24 days, to allow collect ion of  the minimum number 
of eDiary ent ries (i.e., 7 days) , perform 2 PSG  night s at V isit 3, and 
receive the eligibility confirmation from the PSG central reader.  
The double -blind (DB) trea tment phase  lasts 3 months. It starts at 
Randomization (V isit 4). DB study treatment is taken daily. A safety 
telephone call is performed at Visit 5  to collect information about 
adverse events ( AEs) and concomitant medication s. Sleep parameters 
of each sub ject are objectively assessed with 2 consecutive PSG 
nights at Visit 6 and Visit 8. A safety visit without PSG night will be 
performed at Visit 7. An eDiary is completed every day during the 
treatment phase.  
End-of-Double -Blind -Treatment (EO DBT) is reached  in the 
second morning of V isit 8. 
The safety follow -up phase  starts after EODBT. It consists of a 
single -blind placebo run- out period of 7 days and a safety follow -up 
period.  
The Run-out period  starts in the evening of V isit 9. Visit 9 consists 
of one PSG night on single -blind placebo treatment. Visit 9 is 
followed by 6 days at home with single -blind placebo treatment. The 
eDiary  is completed every day during the Run- out period. The end of 
the Run- out period ( End-of-Treatment  [EOT ]) is reached after all 
visit assessments have been performed at Visit 10. 
The Safety follow -up period starts after EOT  and ends 30 days after  
the last dose of DB study treatment intake for subjects that are not 
enrolled in the ID-078A303 extension study. 
Subjects who complete DB study treatment and the Run-out period 
are eligible to enter the ID -078A303 extension study (if approved by 
the national health authorities and local Independent Ethics 
Committees / Institutional Review Boards ). For these subjects, the 
safety follow -up period ends on the date of enrolment into 
ID-078A303.  
End-of-Study  (EOS)  for an individual  subject is defined as the date 
of the 30- day follow -up telephone call ( Visit 11) or the date of 
enrolment into the ID -078A303 extension study. If a subject is 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 20/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
prematur ely discontinued from study treatment EOS is performed as 
planned on Day 115. If a subject withdraws consent and does not 
wish to participate in the study any longer, EOS is the date of consent withdrawal for this subject. If a subject is declared lost to follow-up, 
EOS is the date of last successful contact for this subject.  
PLANNED 
DURATION Approximately 18 months from first subject, first visit to last subject, 
last visit.  
SITE(S)  / 
COUNTRY(IES)  The study will be conducted at approximately 75 sites in 
10 countries. 
SUBJECTS / 
GROUPS  Approximately 900 subjects will be randomized to either 10  mg or 
25 mg ACT -541468, or to placebo, in a 1:1:1 ratio. Treatment 
allocation will be stratified by age into 2 categories: <  65 and ≥ 65 
years. Approximately 40% of subjects will be elderly subject s (≥ 65 
years old), of which approximately 5% will be above  75 years old.  
These percentages will be monitored by the sponsor through the IRT. 
INCLUSION 
CRITERIA  Criteria assessed at V isit 1: 
1. Signed informed consent prior to any study -mandated procedure . 
2. Male or female aged ≥ 18 years.  
3. Insomnia disorder according to Diagnostic and Statistical Manual 
of Mental Disorders, Fifth  Edition  (DSM -5) criteria, as follows: 
3.1 The predominant complaint is dissatisfaction with sleep 
quantity or quality, assoc iated with one (or more) of the 
following symptoms: 
• Difficulty initiating sleep.  
• Difficulty maintaining sleep, characterized by frequent 
awakenings or problems returning to sleep after 
awakenings.  
• Early -morning awakening with inability to return to 
sleep.  
3.2 The sleep disturbance causes clinically significant distress 
or impairment in social, occupational, educational, 
academic, behavioral, or other important areas of 
functioning. 
3.3 The sleep difficulty occurs despite adequate opportunity for 
sleep.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 21/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
3.4 The insomnia is not better explained by and does not occur 
exclusively during the course of another sleep- wake 
disorder (e.g., narcolepsy, a breathing -related sleep 
disorder, a circadian rhythm sleep- wake disorder, a 
parasomnia).  
3.5 The insomnia is not at tributable to the physiological effects 
of a substance (e.g., a drug of abuse, a medication). 
3.6 Coexisting mental disorders and medical conditions do not 
adequately explain the predominant complaint of insomnia. 
3.7 S elf-reported history of all the following on at least 3 nights 
per week and for at least 3 months prior to V isit 1: 
3.7.1 ≥ 30 min to fall asleep, and 3.7.2 Wake time during sleep ≥ 30 min, and 
3.7.3 Subjective Total Sleep T ime ( sTST) ≤ 6.5 h 
4. Insomnia S everity Index
© score ≥ 15. 
5. Ability  to communicate well with the investigator, to understand 
the study requirements and, as  judged by the investigator , to be 
alert and oriented to person, place, time, and situation. 
Criteria assessed at V isit 3 
6. Meeting all the following sleep parameters on at least 3 nights out 
of 7 nights on the sleep diary completed at home between V isit 2 
and V isit 3: 
6.1 ≥ 30 min to fall asleep, and 6.2 Wake time during sleep ≥ 30 min, and 
6.3 sTST of ≤ 6.5 h 
7. 
Usual bedtime between 21:30 and 00:30 as reported on sleep 
diary completed between V isit 2 and V isit 3. 
8. Regular time in bed between 6 and 9 h as reported on sle ep diary 
completed between V isit 2 and V isit 3. 
9. Meeting all the following sleep parameters on the 2 PSG nights 
at Visit 3: 
9.1 Mean Latency to Persistent S leep ( LPS) ≥ 20 min (with 
neither  of the two nights < 15 min), and 
9.2 Mean Wake After Sleep Onset  (WASO) ≥ 30 min (with 
neither  of the two nights < 20 min), and 
9.3 Mean Total Sleep T ime ( TST) < 420 min 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 22/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
Criteria assessed at Visit 1, Visit 2, and Visit 4 
10. For women of childbearing potential, the following are  required: 
• Negative serum pregnancy test (Visit 1). 
• Negative urine pregnancy test (V isit 2, Visit 4). 
• Agreement to use the contraception scheme as required by 
the protocol from Screening up to at least 30 days after last DB study treatment intake.  
EXCLUSION 
CRITERIA  Criteria assessed at V isit 1 
1. Body mass index below 18.5 or above 40.0 kg/m2. 
2. Any lifetime history of sleep -related breathing disorder, including 
chronic obstructive pulmonary disease and sleep apnea. 
3. C ognitive behavioral therapy (CBT)  for any indication is  allowed  
only if the CBT  started at least 1 month prior to Visit 3 and the 
subject  agrees to continue this CBT throughout the study. 
4. Self-reported  usual daytime napping ≥ 1 h per day, and ≥ 3 days 
per week.  
5. Acute or unstable psychiatric conditions (including but not 
restricted to anxiety disorder, major depression, bipolar disorder, 
schizophrenia, obsessive compulsive disorder, or depression ) that 
are diagnosed by the Mini International Neuropsychiatric 
Interview© or that require pharmacological treatment for these 
disorders. N.B.: subjects with a history of major depressive 
disorder currently without any symptoms and not requiring 
treatment are eligible.  
6. Mini Mental State Examination© score < 25 in subjects 
≥ 50 years.  
7. Shift work within 2 weeks prior to the screening visit, or planned 
shift work during the study.  
8. Travel  across  ≥ 3 time zones within 2 weeks prior to the screening 
visit, or planned travel across ≥ 3 time zones during the study.  
9. Unstabl e medical condition, significant medical disorder or acute 
illness , ECG, hematology or biochemistry test results within 
1 month prior to the screening visit, which, in the opinion of the 
investigator , could affect the subject ’s safety or interfere with the  
study assessments.  
10. Treatment with central nervous system -active drugs prohibited by 
this protocol within  5 half-lives  of the respective drug (or 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 23/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
2 weeks, whichever is longer) prior to V isit 1, including over -the-
counter medication and herbal medicines . 
11. Diagnosis of alcohol or substance use disorder within 2 years 
prior to the screening visit or inability to refrain from drinking 
alcohol for at least 3 consecutive days. 
12. Heavy tobacco use (at least one pack of cigarettes a day  or 
inability to ref rain from  smoking during the night).  
13. Caffeine consumption ≥ 600 mg per day or any caffeine 
consumption after 4 pm.  
14. Treatment with another investigational drug within 3 months 
prior to Visit 1, previous treatment with ACT -541468 or previous 
randomization in any trial involving  ACT -541468. 
15. Known hypersensitivity or contraindication to drugs of the same 
class  as the study treatment or to any excipients of the study drug 
formulation. 
16. Not able or willing to stop treatment  with moderate or strong 
cytochrome P450 (CYP)3A4 inhibitors, or t reatment with 
moderate or strong CYP3A4 inducers, within at least 1 week prior 
to Visit 2. 
17. Not able or w illing to stop consumption of grapefruit, Seville 
(bitter) oranges or juices from those fruits within at least 1  week 
prior to Visit 2.  
Criteria as sessed at PSG visit between Visit 1 and Visit 2  
18. Periodic limb movement disorder with arousal index (PLMAI) 
≥ 15/h (assessed on the 1st PSG night), restless legs syndrome, 
circadian rhythm disorder, rapid eye movement ( REM ) behavior 
disorder, or narcolepsy.  
19. Apnea/hypopnea index ≥ 15/h according to American Academy 
of Sleep Medicine criteria or event associated with blood oxygen 
saturation level by pulse oximetry (SpO 2) < 80%, as assessed on 
the 1st PSG night. 
Criteria assessed at V isit 1 and V isit 3 
20. Aspartate aminotransferase and/or alanine aminotransferase > 2 × 
upper limit of normal ( ULN ) and/or direct bilirubin >  1.5 × ULN.  
21. Severe renal impairment: known or defined as estimated 
creatinine  clearance < 30 mL/min /1.73 m2, according to the 
4-variable Modification of Diet in Renal Disease formula.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 24/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
22. Hematology or biochemistry test results deviating from the 
normal range to a clinically relevant extent as per judgment of the 
investigator.  
23. Any of the following conditions related  to ECG abnor malities: 
• A prolonged QT interval corrected with Bazett ’s formula 
(QTcB) or QT interval corrected with Fridericia ’s formula 
(QTcF) (greater than 450 ms). If QTcB or QTcF is greater than 450 
ms on the first ECG, a second ECG recording will be 
performed afte r at least 30 min. If QTcB or QTcF is greater 
than 450 ms on the second ECG, the subject is not eligible.  
• A history of additional risk factors for torsade de pointes (e.g., 
heart failure, hypokalemia, family history of long QT 
syndrome). 
• ECG with clinical ly significant atrioventricular (AV) 
conduction disturbance (e.g., second- or third -degree AV 
block), sick sinus syndrome, bradycardia (resting pulse 
< 40 bpm), or accessory bypass tract ( e.g., Wolff -Parkinson-
White).  
Criteri on assessed at V isit 1, Visit 2, Visit 3 and Visit 4  
24. Any of the following conditions related to suicidality:  
• Any suicidal ideation with intent, with or without a plan, at 
screening, i.e., answering “Yes” to questions 4 or 5 on the 
suicidal ideation section of the lifetime (V isit 1) and visit 
(Visit 2, V isit 3, Visit 4 ) version of the Columbia Suicide 
Severity Rating Scale© (C-SSRS©). 
• History of suicide attempt on the suicidal behavioral section 
of the lifetime version of the C -SSRS© (Visit 1).  
Criteria assessed at V isit 1, PSG visit between Visit 1 and 
Visit  2, V isit 2, Visit 3 and V isit 4 
25. For female subject s: pregnant, lactating or planning to become 
pregnant during projected duration of the study. 
26. Positive urine drug test (for benzodiazepines, barbiturates, 
cannabinoids , opiates, amphetamines, phencyclidine or cocaine) 
or presence of alcohol in exhaled breath as detected by 
breathalyzer test.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 25/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
STUDY 
TREATMENTS Investigational treatment  
ACT -541468 tablets at strengths of 10 mg and 25 mg will be 
administered orally, once daily in the evening during the DB 
treatment period.  
Placebo  
ACT -541468- matching placebo will be administered orally, once 
daily in the evening during the single -blind run- in period, the DB 
treatment period and the single-blind run-out period. 
ENDPOINTS Primary  efficacy endpoints  
The primary efficacy endpoints of this study are defined as: 
• the change from baseline to Month 1 in WASO  (sleep 
maintenance)  
• the change from baseline to Month 3 in WASO  
• the change from baseline to Month 1 in LPS (sleep onset) 
• the chang e from baseline to Month 3 in LPS   
Baseline is defined as mean  of the 2 PSG nights at V isit 3. Month 1 
and Month 3 are defined a s the mean of th e 2 PSG nights at Visit 6 
and Visit 8, respectively.  
LPS (min) is the time from start of recording to the beginn ing of the 
first continuous 20 epochs (i.e., 10 min) scored as non- awake, i.e., 
epochs scored as either sleep stage 1  (S1), sleep stage 2 (S2), sleep 
stage 3 (slow wave sleep) or REM, as determined by PSG.  
WASO is the time (min) spent awake after onset of  persistent sleep 
until lights on , as determined by PSG.  
Secondary efficacy endpoints  
The secondary efficacy endpoints of this study are defined as: 
• the change from baselinea to Month 1b in sTST.  
• the change from baselinea to Month 3c in sTST.  
• the change f rom baselinea to Month 1b in Insomnia Daytime 
Symptoms and Impacts Questionnaire ( IDSIQ ) sleepiness 
domain score. 
• the change from baselinea to Month 3c in IDSIQ sleepiness 
domain score.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 26/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
a Baseline is the mean value based on the screening sleep diary  / 
IDSIQ  entries performed at home  in the 7 days immediately 
preceding the first PSG at V isit 3. 
b ‘Month 1’ is the mean value based on the sleep diary  / IDSIQ  entries 
performed at home in the 7 days immediately preceding the first PSG 
at Visit 6. 
c ‘Month 3’ is the mean value based on the sleep diary  / IDSIQ  entries 
performed at home in the 7 days immediately preceding the first PSG at Visit 8. 
Safety endpoints  
In addition to the standardized collection of AEs, safety data specific 
to insomnia and its treatment will be assessed as follows:  
• Withdrawal effects  
(physical dependence) upon treatment 
discontinuation will be assessed based on the changes from last assessment on DB treatment (V isit 8, 2
nd morning) to run -out 
period in the Benzodiazepine Withdrawal Sympt om 
Questionnaire ( BWSQ ) total score ( Visit 9 and Visit 10), the 
occurrence of relevant AEs and marked ECG abnormalities.  
• Rebound insomnia will be assessed based on objective sleep 
parameters (WASO, LPS, and TST) at Visit 9 as compared to 
Visit 3. It will a lso be assessed using subjective sleep parameters 
(subjective WASO [sWASO] , subjective Latency to Sleep Onset 
[sLSO], and sTST) from run -out period as compared to baseline. 
• Next -day residual effect s will be assessed based on changes from 
baseline (V isit 3) to Month 1 and Month 3 in: 
– Coding sub- test©  
– Sheehan Disability Scale© (SDS©) 
– Scores on the visual analog scale ( VAS; mm)  
• Serious adverse events  up to 30 days after DB study treatment 
discontinuation or until enrollment into the extension study. 
• Treatment -emergent AEs ( TEAEs ) up to 30 days after DB study 
treatment discontinuation or until enrollment into the extension 
study. 
• AEs leading to premature discontinuation of the DB study 
treatment.  
• AEs of special interest  (AESIs)  after adjudication by an 
Independent Safety Board ( ISB): 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 27/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
– narcolepsy -like symptoms (i.e. , excessive daytime sleepiness 
[EDS ], cataplexy and complex sleep behavior events 
including hallucinations/sleep paralysis)  
– suicide/self -injury. 
• Change from baseline (V isit 3) to Month 1 (V isit 6) and Month 3 
(Visit 8) in vital signs (mean of the 2 PSG nights in systolic and 
diastolic blood pressure [BP]  and pulse rate).  
• Change from baseline (V isit 1) to Month 3 (V isit 8) in body 
weight.  
• Marked ECG abnormalities on DB  study treatment.  
• Change from baseline (V isit 3) to Month 3 (V isit 8) and the end 
of run -out (Visit 10) in ECG variables . 
• Marked laboratory abnormalities on DB  study treatment.  
• Change from baseline (V isit 3) to Month 1 (V isit 6) and Month 3 
(Visit 8) in laboratory variables . 
• Occurrence of su icidal ideation and/or behavior on DB study 
treatment based on C- SSRS©. 
ASSESSMENTS Refer to the schedule of assessments in  Table 1. 
STATISTICAL 
METHODOLOGY  Analysis of the primary and secondary efficacy endpoints  
The Type I err or rate will be controlled for the testing of multiple null 
hypotheses associated with the two primary endpoints (LPS and 
WASO)  and two other endpoints (sTST and IDSIQ) assessed at 1 and 
3 months of treatment , and the two dose levels included in this study , 
i.e., 10 mg and 25 mg. 
The eight statistical null hypotheses associated with the primary 
efficacy endpoints are: 
Sleep maintenance:  
• H1WASO : Higher Dose – Placebo = 0 for WASO at Month 1 
• H2WASO : Higher Dose – Placebo = 0 for WASO at Month 3 
• H3WASO : Lower Dose – Placebo = 0 for WASO at Month 1 
• H4WASO : Lower Dose – Placebo = 0 for WASO at Month 3 
Sleep onset:  
• H1LPS: Higher Dose – Placebo = 0 for LPS at Month 1 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 28/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
• H2LPS: Higher Dose – Placebo = 0 for LPS at Month 3  
• H3LPS: Lower Dose – Placebo = 0 for LPS at Month 1 
• H4LPS: Lower Dose – Placebo = 0 for LPS at Month 3 
The eight statistical null hypotheses associated with the secondary 
efficacy endpoints are: 
Sleep quantity: 
• H1sTST: Higher Dose – Placebo = 0 for sTST at Month 1 
• H2sTST: Higher Dose – Placebo = 0 for s TST at Month 3 
• H3sTST: Lower Dose – Placebo = 0 for sTST at Month 1 
• H4sTST: Lower Dose – Placebo = 0 for sTST at Month 3 
Next -day performance: 
• H1IDSIQ: Higher Dose – Placebo = 0 for IDSIQ sleepiness 
domain score at Month 1 
• H2IDSIQ: Higher Dose – Placebo = 0 for IDSIQ sleepiness 
domain score at Month 3 
• H3IDSIQ: Lower Dose – Placebo = 0 for IDSIQ sleepiness 
domain score at Month 1 
• H4IDSIQ: Lower Dose – Placebo = 0 for IDSIQ sleepiness 
domain score at Month 3 
where ‘Higher Dose ’, ‘Lower Dose ’, and ‘ Placebo ’ represent the 
mean change from baseline for the given endpoint (WASO, LPS, 
sTST or IDSIQ sleepiness domain score) and time  point (Month 1 or 
Month 3) for the 25 mg, 10 mg, and placebo treatment group, 
respectively.  
Each null hypothesis will be tested against the alternative hypothesis: 
that ACT -541468 improves WASO/LPS/sTST/  IDSIQ sleepiness 
domain score at the given dose (10 or 25 mg) and time point (Month 
1 or Month 3) compared to placebo. 
The order of testing and the alpha level applied to each null 
hypothesis will be based on the Bonferroni -based gatekeeping 
procedure [Bretz  2009] , which will control the study -wise Type  I 
error at a two -sided 5% significance level. To account for the 
concurrent evaluation (multiple comparison) of two distinct endpoint 
categories (i.e., sleep maintenance and sleep onset) , a Bonferroni 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 29/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
correction is applied. Both endpoint categories will be tested at half 
of the two- sided 5% significance level. This supports the sponsor ’s 
intention  to make a superiority claim versus  placebo for efficacy in 
either sleep maintenance and/or sleep onset . The remaining 
hypotheses will be tested following the gatekeeping strategy moving 
from Month 1 to Month 3 for higher dose ACT -541468 vs placebo 
and then from Month 1 to Month 3 for lower dose ACT -541468 vs 
placebo. The pre -specified proportion of alpha that will be distributed 
once a given null hypothesis (node) is rejected is shown on the arrow 
in the directed graph. If a certain null  hypothesis cannot be rejected,  
the alpha level used for that test is absorbed at that node and not 
distributed further. 
The main analysis will be performed using the FAS.  
A longitudinal data analysis method (i.e., linear mixed effects model) 
will be used for the analysis of change from baseline i n WASO, LPS, 
sTST, and IDSIQ scores, separately.  All available data, regardless of 
occurrence of intercurrent events (e.g., study treatment 
discontinuation, the use of prohibited medication), will be included in the model. 
Analysis of the safety endpoints  
Adverse events:  The number (%) of subjects experiencing a TEAE 
(including serious adverse events , AE SIs after adjudication by the 
ISB, and AE s leading to premature discontinuation of the DB study 
treatment) will be summarized by System Organ Class  and/or 
Preferred Term , and maximum intensity.  
Laboratory data:  Observed values and changes from baseline to 
Month 1 and Month 3 in both hematology and blood chemistry 
laboratory parameters will be summarized. The number (%) of 
subjects having a marked laboratory a bnormality during DB study 
treatment will be tabulated.  
Vital signs  and weight:  Observed values and changes from baseline 
to Month 1 and Month 3 in vital signs (mean of the two PSG nights 
in systolic and diastolic BP and pulse rate)  and observed values and  
changes from baseline to Month 3 in body weight  will be 
summarized.   
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 30/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
Electrocardiograms:  Observed values and changes from baseline to 
Month 3 for each ECG parameter ( QTcB, QTcF , heart rate, PR, QRS) 
will be summarized. T he number (%) of subjects with a marked ECG 
abnormality during DB study treatment will be tabulated . 
Withdrawal symptoms:  The BWSQ total score will be summarized 
using descriptive statistics for the observed values and changes from 
the last assessment on DB treatment (V isit 8, 2nd morning) to the 
beginning and the end of the treatment withdrawal period (in the 
morning at V isit 9 and at V isit 10, respectively). The number (%) of 
subjects having, separately, an AE and a marked ECG abnormality 
during the treatment withdrawal period will be tabu lated.  
Insomnia rebound effect:  The changes fro m baseline to the treatment 
withdrawal period (V isit 9, run- out) in objective sleep parameters 
(WASO, LPS, and TST) will be summarized using descriptive 
statistics. The changes from baseline (mean value based on the 
screening sleep diary entries performed at home in the 7 days 
immediately preceding the first PSG at V isit 3) to the treatment 
withdrawal period (after PSG night at V isit 9) in subjective sleep 
parameters (sWASO, sLSO, and sTST) will be summarized using descriptive statistics . 
Next-day residual effects:  
Observed values and changes from 
baseline to Month 1 and Month 3 in Coding sub- test©, SDS©, and 
VAS scores (mm) assessing morning sleepiness, daytime alertness, 
and daytime ability to function, will b e summarized.  
C-SSRS©: Number (%) of subjects with suicidal ideation, suicidal 
behavior, and/or self -injurious behavior without suicidal intent based 
on the C -SSRS© during DB treatment will be tabulated. Shifts from 
baseline showing any changes in suicidal  ideation and suicidal 
behavior during DB treatment will also be provided. 
STUDY 
COMMITTEES  An Independent Data Monitoring Committee (IDMC) will have 
overall responsibility for safeguarding the interests of subjects by 
monitoring safety and efficacy data obtained in the study , and making 
appropriate recommendations based on the reported data . This will 
ensure that the study is being conducted to the highest scientific and 
ethical standards. The IDMC will be fully operational prior to the 
enrollment of the first subject into the study. The composition and 
operation of the IDMC is described in the IDMC charter. 
ACT-541468 
Insomnia disorder 
Protocol ID-078A302 
Version 5 8 November 2018, 
page 31/154 Confidential  EudraCT 2017-004643-20 
Doc No D-18.262 
 
 An ISB will review and adjudicate in a blinded manner AESIs, i. e., 
narcolepsy-like symptoms (i.e., EDS, cataplexy and complex slee p 
behavior events including halluci n a t i o n s  /  s l e e p  p a r a l y s i s ) ,  o r  
suicide/self-injury. The composition and operation of the ISB i s 
described in the ISB charter. 
SUB-STUDY A sub-study will be performed to collect patient preferences da ta. 
The Discrete Choice Experime nt methodology aims to collect 
preferences for selected treatment outcomes in a subgroup of su bjects 
in the USA and Germany, using th e questionnaire for the PAtient  
Preferences StUdy in InSomnia (PAUSe) developed by Idorsia. The  
PAUSe sub-study aims to enroll at least 360 subjects within the  
Phase 3 program (i.e., ID-078A301 and ID-078A302). 
STUDY 
EXTENSION Subjects who completed the study until EOT will have the possibility 
to participate in the extension study ID-078A303. The 9-month ID-078A303 study will be available at each site and subjects wi ll be 
treated for up to 12 months overall (i.e., including the treatm ent 
period of the confirmatory trial). 
 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 32/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
PROTOCOL 
1 BACKGROUND 
1.1 Insomnia disorder 
1.1.1 Definition  
The definition of insomnia disorder used in the protocol is the one described in the 
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM -5) 
[APA 2013]:  
“Insomnia disorder  is a predominant complaint of dissatisfaction with sleep quantity or 
quality, associated with difficu lty initiating or maintaining sleep, or early morning 
awakening. Furthermore, the sleep disturbance is associated with significant social or functional distress or impairment. Sleep difficulty occurs at least 3 nights per week and is present for at least 3 months, and occurs despite adequate opportunity for sleep. The insomnia (a) is not better explained by, and does not occur exclusively during the course 
of another sleep -wake disorder, (b) it is not attributable to the physiological effect of a 
substance, and (c) is not explained by co -existing mental disorders or medical conditions.” 
1.1.2 Epidemiology 
Insomnia is a common problem. Population- based epidemiological studies suggest that 
30% or more of the general population complain of sleep disruption and approx imately 
10% of the general population have complaints of sleep disruption with associated symptoms of distress or daytime functional impairment consistent with the diagnosis of insomnia disorder [NIH 2005, Roth 2007] . Insomnia symptoms (diffi culties initiating 
sleep, early -morning awakenings, and dissatisfaction with sleep) increase with age. Factors 
associated with aging and not with age per se, such as depressed mood, respiratory 
symptoms, poor perceived health and physical disability are associated with the decrease 
in ability to sleep [Ohayon  2001] .  
Insomnia disorder results in difficulty falling asleep or difficulty maintaining sleep, characterized by multiple or long awakenings du ring the  sleep period, or early -morning 
awakenings. Difficulty maintaining sleep is the most common problem among patients with insomnia, occurring in approximately two- thirds of them [Neubauer  2014] . Studies 
have shown that the most common symptoms are combined  difficulties to  both fall and to 
stay asleep [Hohagen 1994] . Elderly patients are more likely to suffer from chronic 
insomnia characterized by difficulty maintaining sleep , rather  than difficulty initiating 
sleep [McCall  2004].  
Insomnia is associated with impairment in cognitive functioning, daytime fatigue, increased accident risk , and difficulties in interpersonal relationships [Balter  1991, 
Ancoli- Israel  1999, Rosenthal 1993, Zammit 1999, Fortier -Brochu  2014] . Insomnia 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 33/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
increases utilization of medical care [Simon  1997, Léger  2002, McCall  2004] , has been 
correlated with chronic health issues and perceptions of poor health [Balter  1991, 
Ancoli- Israel  1999, Rosenthal 1993, Zammit 1999, Fortier -Brochu 2014] , and in elderly 
subjects may also precipitate falls [McCall  2004].  Numerous studies have shown an 
association between insomnia and psychiatric disorders, specifically depression, anxiety , 
and other significant mental health conditions [ Ford  1989, Benca 2004] .  
1.1.3 Treatment  
The current standards of care encompass non -pharmacological therapies and 
pharmacot herapy [Schutte-Rodin 2008].  
Non-pharmacological (psychological and behavioral) standard -of-care therapies for 
insomnia include a variety of treatment methods, such as cognitive behavioral therapy (CBT), stimulus control and re laxation training [Schutte-Rodin 2008] . Sleep hygiene 
therapy is often added to these treatment modalities.  
Prescription sleep medications (hypnotics) indicated for the treatment of insomnia include benzodiazepines, non-benzodiazepine benzodiazepine receptor agonists, melatonin agonists, the orexin receptor antagonist suvorexant, and low-dose doxepin.  
Benzodiazepines are a class of medications that bind to multiple gamma -aminobutyric acid 
(GABA) type A receptor subtypes [Lieberman  2007] . Drugs in this class, which includes 
flurazepam, temazepam, trialozam, estazolam, and quazepam, were previously commonly 
prescribed for insomnia. While the efficacy of these medications has been well documented, their usefulness is limited by adverse effects such as daytime sedation (e.g., morning or next -day hangover), cognitive impairment (including anterograde amnesia), 
motor dyscoordination, abuse liability , and dependence [Holbrook 2000, Buscemi  2007] . 
Benzodiazepines also alter sleep architecture: they prolong stage 2 sleep and may slightly reduce the relative amount of rapid eye movement (REM) sleep [Treat  Guidel Med  Lett 2009] . The ir use has been associated with tolerance development 
and rebound insomnia upon withdrawal of medication [ Kales  1978, Petursson 1981] .  
Non-benzodiazepine benzodiazepine receptor agonists have a more targeted action on one 
or more GABA type A receptor subtypes , but the availability of these treatments highly 
varies across regions. Zolpidem, zolpidem controlled- release (CR) and zaleplon show 
affinity for the alpha -1 receptor subtype, while eszopiclone shows affinity for the alpha -2 
and - 3 receptor subtypes [Nutt 2006 ]. All of these drugs reduce latency to sleep onset, but 
zolpidem CR and eszopiclone have also been shown to reduce Wake After Sleep Onset (WASO), reflecting an improvement in sleep maintenance [Ambien
® USPI , 
Lunesta® USPI ]. Although they have less impact on sleep architecture, possibly by virtue 
of their receptor selectivity, the drugs in this group have similar adverse effects as the 
benzodiazepines. I n 2007 the US Food and Drug Administration ( FDA ) requested that all 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 34/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
manufacturers of hypnotic drug products strengthen their product labeling to include stronger language related to potential risks. These risks include severe allergic r eactions 
(i.e., anaphylaxis) and complex sleep -related behaviors, which may include sleep-driving 
[FDA  2007] .  
Newer hypnotics that do not act at the GABA receptor have been developed. The melatonin receptor agonist ramelteon is approved for insomnia in the US and in Japan, but not in Europe. Ramelteon reduces sleep latency and increases Total S leep Time (TST), but has 
no effect on WASO [Kuriyama  2014] , making it an inappropriate treatment for people with 
sleep maintenance problems [Simpson 2008 ]. Ramelteon is devoid of next -day residual 
effects, withdrawal or rebound insomnia and does not appear to be associated with abuse liability.  
Suvorexant is an oral dual orexin receptor antagonist (DORA) that was approved in the USA, Japan and Australia for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Suvorexant is contraindicated in patients with narcolepsy. Next -day effects, including impaired driving performance, have been reported 
at 20 mg [Belsomra
® USPI ]. Next -day residual effects might be related to the long half -
life (t ½ = 12 hours) of suvorexant [Citrome  2014] . Rebound insomnia or withdrawal  signs 
upon drug discontinuation were not observed in clinical trials [ Herring  2016].  
Use of sleep medications increases with age and is highest in the elderly [Ohayon 2002, 
Ohayon 2010] . Despite the increased risk of falls, non-benzodiazepine benzodiazepine 
receptor agonists  and generic antidepressants are among the most prescribed classes of 
medications for elderly patients in the US.  
1.1.4 Unmet medical need  
CBT is generally the recommended first-line treatment for insomnia disorder  
[Schutte-Rodin 2008] . However, this may not be the ideal course of treatment for all 
patients. Many patients with insomnia are not interested in CBT, and when they are, access to CBT m ay be limited by the lack of therapists with adequate training and experience, and 
the fact that  CBT is time -consuming, costly , and its reimbursement is highly challenging 
[Pigeon 2007, Schutte-Rodin 2008] .  
Insomnia disorder is a chronic disease and currently available treatments are limited to 
short- term use with the exception of eszopiclone and suvorexant (in the US). Caution and 
dose reduction are also often advised in the elderly. Pharmacological trea tments that 
address sleep onset problems alone do not provide relief to people with sleep maintenance difficulties, and treatments indicated for those with sleep maintenance problems may be associated with risks of cognitive impairment, postural instabilit y, or next -day residual 
sedation that may impair driving [Neubauer  2014 ]. Moreover, the use of benzodiazepines 
and benzodiazepine receptor agonists is associated with an increased risk of falling 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 35/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
[McCall  2004] leading to hip and femur fractures, increased disability , and use of 
healthcare resources.  
Overall, there is a need for a long -term pharmacological treatment for insomnia disorder 
that addresses the most prominent and pressing symptoms of insomnia without negatively impacting next-day functioning.  
1.2 Study treatment: ACT-541468 
1.2.1 The orexin system  
The orexin system is involved in the regulation of sleep and arousal by the central nervous system (CNS) and is currently being targeted in the development of new therapies for sleep 
disorders. 
The neuropeptides orexin- A and orexin -B are synthesized in the lateral hypothalamic areas 
[de Lecea 1998]  and activate the orexin -1 and orexin -2 receptors [Kilduff 2000] . Nerve 
fibers from orexin neurons make projections to the basal forebrain, corticolimbic 
structures, and brainstem, particularly to those regions related to waking and regulation of sleep [Hagan  1999, Sakurai  2007] . Infusing exogenous orexins into cerebral ventricles in 
rats leads to enhanced behavioral activity, arousal, delayed onset of sleep, and maintenance of cortical activation [Hagan  1999, Samson  2010] . Orexin -produci ng neurons are active 
during wakefulness and fall quiet during sleep [Sakurai  2007] . Orexin -A levels in the 
cerebrospinal fluid of several species fluctuate according to circadian rhythms, being highest during active wake periods [ Zeitzer  2003, Desarnaud  2004].  
The absence of o rexins is implicated in the genesis of narcolepsy, due to findings of low 
cerebral spinal fluid orexin levels in most patients with unequivocal narcolepsy with 
cataplexy  [Mignot 2002]  and near- complete destruction  of orexin neurons in post- mortem 
brains of patients with narcolepsy -cataplexy  [Thannickal 2000] , coupled with the 
observation of behavioral phenotypes c onsistent with narcolepsy in multiple animal models 
of orexin deficiency or dysfunction [ Lin 1999] .  

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 36/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 37/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 38/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 39/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
1.3 Purpose and rationale of the study 
1.3.1 Purpose of the study  
The main purpose of this Phase 3 study is to confirm that at least one dose of ACT -541468 
is well tolerated and efficacious in promoting sleep onset and/or sleep maintenance in 
subjects with insomnia disorder.  
1.3.2 Rationale for the study 
The orexin system is involved in the regulation of sleep and arousal. In two Phase 2 studies 
in subjects with insomnia disorder, ACT -541468 has shown objective and subjective 
improvements in sleep onset and sleep maintenance.  
The dose levels of 10 and 25 mg of ACT -541468 planned for this study were both 
investigated in Phase 2 studies . The 10 mg dose is considered the minimal effective dose, 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 42/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
2.1 Primary objective 
To evaluate the efficacy of 10 mg and 25 mg ACT -541468 on objective sleep parameters 
in subjects with insomnia disorder. 
2.2 Secondary objectives 
To evaluate the efficacy of 10 mg and 25 mg ACT-541468 on subjective sleep parameters 
and next- day functioning in subjects with insomnia disorder. 
2.3 Safety objectives 
To assess the safety and tolerability of ACT -541468 in subjects with insomnia disorder  
during treatment and upon treatment discontinuation. 
3 OVERALL STUDY DESIGN AND PLAN  
3.1 Study d esign 
This is a 3 -month, multi- center, double -blind, randomized, placebo-controlled, 
parallel -group, Phase 3 study to assess the efficacy and safety of two doses ( 10 mg and 
25 mg) of ACT -541468 in subjects with insomnia disorder.  
Approximately 900 subject s will be randomized to either 10 mg or 25 mg of ACT -541468, 
or to placebo, in a 1:1:1 ratio. Treatment allocation will be stratified by age into 2 categories: < 65 and ≥ 65 years. Approximately 40% of subjects will be elderly subjects (≥ 65 years old), of  which approximately 5% will be above  75 years old. These percentages 
will be monitored by the sponsor through the Interactive Response Technology ( IRT) 
system . 
The study will be conducted at  approximately 75 sites in 10 countries. 
In addition, a sub-study to collect data on the subject’s preferences will be performed, 
aiming to enroll at least 360 subjects both from the USA and Germany who are part of the approximately 1800 subjects enrolled in both ID-078A301 and ID -078A302 studies .  
3.1.1 Study periods  
The stu dy comprises the following 3 phases: the screening phase, the treatment phase , and 
the safety follow -up phase [ see Figure 1]. 
3.1.1.1 Screening phase  
The screening phase start s with the signature of the informed c onsent f orm (ICF) at Visit 1 
and ends at Randomization at Visit 4, pr ovided the subject fulfills all eligibility criteria. It 
includes the Screening  period and the Run- in period. The screening phase last s 20 to 
31 days.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 43/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
The Screening period  starts with Visit 1 and ends with Visit 2. During the screening 
period, the  investigator verifies  the eligibility criteria and eligible subjects perform a 
one-night PSG assessment.  The Screening period last s 7 to 18 days to allow time to perform 
all required procedures at Visit 1 , the PSG assessment and collect the minimum number of 
eDiary entries (i.e., 7  days) between Visit 1 and Visit 2 . 
The Run -in period  starts with Visit 2 and ends at  Randomization (i.e., Visit 4). At Visit 2 
eligible subjects are allocated a single -blinded placebo treatment that is taken daily. During 
the Run- in period subjects come to the site for Visit 3 , which consists of 2 PSG nights and 
is performed when the subject has completed the eDiary for at least 7 days and eligibility 
is confirmed. The Run- in period last s 13 to 24 days, to allow collection of  the minimum 
number of eDiary entries (i.e., 7 days), perform 2  PSG nights at Visit 3, and receive the 
eligibility confirmation from the PSG central reader .  
3.1.1.2 Treatment phase 
The DB treatment phase lasts 3 mont hs. It starts at Randomization (Visit 4). DB study 
treatment is  taken daily. A safety telephone call is performed at Visit 5 to collect 
information about AEs and concomitant medications. Sleep parameters of each subject are 
objectively assessed with 2 cons ecutive PSG nights  at Visit 6 and Visit 8. A safety visit 
without PSG night will be performed at Visit 7. An eDiary is completed every day during 
the treatment phase. 
End-of-Double -Blind -Treatment (EO DBT) is reached in the second morning of V isit 8. 
3.1.1.3 Safety follow-up phase 
The safety follow -up phase  starts after EODBT. It consists of a single -blind placebo Run-
out period of 7 days and a S afety follow -up period.  
The Run-out period  starts in the evening of Visit 9. Visit 9 consists of one PSG night on 
single -blind placebo treatment. Visit 9 is followed by 6 days at home with single -blind 
placebo treatment. The eDiary is completed every day during the Run-out period. The end 
of the Run- out period  (End-of-Treatment [ EOT ]) is reached after all visit assessments h ave 
been performed at Visit 10. 
The Safety follow -up period starts after EOT  and ends 30 days after last  dose of  DB study 
treatment intake  for subjects that are not enrolled in the ID-078A303 extension study. 
Subjects who complete DB study treatment and the Run-out period are eligible to enter the 
ID-078A303 extension study (if approved by the national health authorities  and local 
Independent Ethics Committees / Institutional Review B oards [ IECs/ IRBs]). For these 
subjects, the S afety follow -up period ends a t the date of enrolment into ID -078A303. 
ACT-541468 
Insomnia disorder 
Protocol ID-078A302 
Version 5 8 November 2018, 
page 44/154 Confidential  EudraCT 2017-004643-20 
Doc No D-18.262 
 
 End-of-Study  (EOS)  for an individual subject is def ined as the date of the 30-day  
follow-up telephone call (Visit 11, Day 115) or the date of enrollment into the ID-078A303 
extension study. If a subject is prematurely discontinued from study treatment, EOS is 
performed as planned on Day 115. If a subject withdraws consent and does not wish to participate in the study any longe r, EOS is the date of consent  withdrawal for this subject. 
If a subject is declared lost to  follow-up, EOS is  the date of last successful contact for this 
subject.  
The visit schedule and protocol-m andated procedures are perform ed according to the table 
of assessments [Table 1] and a re described in Section 6.7. 
The overall study design is  depicted in Figure 1. 
Figure 1 Study design  
 
V = Visit; ▬ = polysomnography n ights; EODBT = End-of-Double-Bl ind-Treatment; EOS = End-of-Study; EOT = 
End-of-Treatment. 
 
3.1.2 Study duration 
The study starts with the signature of the ICF at Visit 1 for t he first subject enrolled and 
ends with the EOS of the last subject. Anticipated total study time is approximately 
18 months. Each subject will be treated for approximately 3 months. For an  individual subject who 
does not decide to continue in the extension study, the study i s completed with the EOS 
visit (safety follow-up telephone call at the end of follow-up)  and the maximum duration 
of participation in the study of t his subject is expected to be  approximately 5 months.  
Subjects who completed the study until EOT are eligible to part icipate in the extension 
study ID-078A303. After the comp letion of the Run-out period, the 9-month ID-078A303 
extension study will be available at each site, depending on he alth authority / IEC / IRB 

ACT-541468 
Insomnia disorder 
Protocol ID-078A302 
Version 5 8 November 2018, 
page 45/154 Confidential  EudraCT 2017-004643-20 
Doc No D-18.262 
 
 approval, and subjects will be treated for up to 12 months over all (i.e., including the 
treatment period of the confirma tory trial). For the subjects w ho decide to participate in the 
extension study, ID-078A302 is comp leted with the enrollment in to ID-078A303. 
3.1.3 Sub-study – Patient Preferences 
A sub-study will be performed to collect patient preferences da ta.  
The Discrete Choice Experiment (DCE) methodology aims to collec t preferences for 
selected treatment outcomes in a subgroup of subjects in the US A and Germany, using the 
questionnaire for the PAtient Preferences StUdy in InSomnia (PA USe) developed by 
Idorsia. The PAUSe sub-study aims to enroll at least 360 subjec ts within the Phase 3 
program (i.e., ID-078A301 and ID-078A302). 
The questionnaire will present s ubjects with the following trea tment outcomes: 
• Time to fall asleep 
• Total time asleep 
• Next day impairment 
• Dizziness/grogginess during the daytime 
• Abnormal thinking and behavioral changes 
• Falls in the night 
• Dependence 
The design of the DCE questionn aire was carried out in steps 1−3 below: 
1. Qualitative pilot (n = 24), where a mobile ethnography platf orm was used over a period 
of 10 days to collect patient expe riences with insomnia in inte ractive sessions. This was 
followed by face-to-face interviews with patients to further di scuss themes that 
emerged during the 10 days of inter active sessions (completed).  
2. Qualitative pilot (n = 24), where face-to-face interviews were conducted to ensure that 
the DCE outcomes and levels are associated with patients’ exper i e n c e s  w i t h  ( a n d  
expectations for) insomnia, and th a t th e p ro p o s ed  su rv ey  a ccu ra tely describes these 
outcomes in an easily understand able manner (completed). 
3. Quantitative pilot (n = 200), where an online survey was con ducted to elicit preferences 
from patients, using the PAUSe questionnaire. The data from the  quantitative pilot will 
be used to update the priors of the Bayesian model and finalize  the design of the 
sub-study. 
This sub-study has the following objectives: 1) To describe the  stated preferences of 
insomnia disorder subjects withi n a clinical trial by applying the DCE technique; 2) To 
describe the impact of treatment on the preferences of insomnia  subjects; 3) To describe 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 46/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
the relationship between demographic, disease characteristics, previous medical history  
and elici ted preferences among insomnia subjects. 
In addition, the results of the sub- study may contribute to the construction of a  
patient -oriented benefit -risk assessment model.  
3.2 Study design rationale 
3.2.1 Core study  
This is a multi- center, double -blind, randomized, placebo -controlled, parallel -group study.  
In accordance with the European Medicines Agency ( EMA ) guideline on medicinal 
products for the treatment of insomnia [EMA  2011]  and the FDA guideline for the clinical 
evaluation of hypnotic drugs [ FDA  1977] , the study includes  a placebo as a comparator to 
support the evaluation of the efficacy of each dose of ACT -541468. Moreover, it is an 
acceptable approach for a non -life-threatening condition.  
A parallel -group design is a we ll-established study design to assess efficacy and safety in 
medical conditions, recommended by health authorities [EMA  2011, FDA  1977].  
The subjects will receive either a 10 or 25 mg daily dose of ACT -541468, or pla cebo DB 
study treatment. The doses to be tested for this study are based on a comprehensive set of data from Phase  1 and Phase 2 studies. A higher dose ( 50 mg) will be tested along with the 
25 mg dose in another separate  Phase 3 study (i.e., ID -078A301). A ll three doses selected 
for this program have a favorable benefit-risk profile based on data collected so far during Phase 1 and Phase 2 studies in adults and elderly subjects. This will allow appropriate 
investigation of the sustained effect of ACT -541468 on sleep parameters and next -day 
performance as well as an optimized characterization of the safety profile of ACT -541468 
over a 3 -month period, allowing full characterization of the benefit /risk ratio.  
The goal of the placebo run -in period is to increase the proportion of subjects in the clinical 
trial who will benefit due to taking active treatment, partly by reducing the placebo effect that will occur during the DB phase of the study and also aims to ensure sufficient stability 
of the subjects ’ insomni a disorder and may reduce the impact of regression toward the 
mean.  
A run -out of 7 days is appropriate to assess withdrawal symptoms as it covers more than 
5 half -lives of ACT -541468. The  duration of the run- out period is also compliant with the 
FDA guida nce [FDA  1977] , stating that a minimum of 3 nights of placebo withdrawal is 
necessary to assess withdrawal effects. To assess withdrawal symptoms, AEs and ECG abnormalities will be collected during the 7 -day run -out period and subjects will complete 
the Benzodiazapine Withdrawal Symptom Questionnaire ( BWSQ ) at Visit 9 and Visit 10. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 47/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
One PSG night is planned after the first day of treatment discontinuation and the sleep diary completed in the 3 days following treatment discontinuation will allow assess ment of  
rebound insomnia on objective and subjective parameters, respectively. Thus, this 7- day 
run-out period allows to capture long -term withdrawal effects, as well as shorter -term 
potential rebound symptoms.  
3.2.2 Patient preferences sub -study  
Measuring patient preferences as an input to healthcare decisions has its foundations in two  
fields related to behavioral decision making, namely ‘decision theory’ and ‘decision  
analysis’. Research by Pauker et al. demonstrated that it was feasible to use d ecision  
analysis to understand individual treatment choices which were complicated by multiple  
uncertainties and personal values [Pauker  1981] . Increased understanding of individual  
values and preferences is critical for a number of reasons. Firstly, it enables the  
development of patient -specific recommendations and reliable decision aids, which are  
helpful both for patients and for doctors in advising patients and their carers or families.  
Secondly, understanding of patients’ preferences is the basis for shared decision-making, 
which in turn encourages patient compliance and health outcomes [Bowling 2001] . Lastly,  
understanding of preferences for health outcomes allows the design of transparent health policies,  and informs resource allocation in healthcare, as these preferences can inform the  
judgment of cost- effectiveness of different treatments, for different patients [Coyle  2001].  
DCEs are a form of stated preference method used by econo mists to explore how people  
make trade -offs between an intervention’s outcomes. They involve participants responding 
to a number of survey questions, in which they choose between alternative interventions, each described by a level of performance against t he outcomes that influence choices. DCE  
has its microeconomic foundation in random utility theory (RUT), assuming that products can be valued in terms of their constituent outcomes and that respondents act in a utility  
maximizing manner, making choices contingent upon the outcome levels described in the  
exercise [Clark 2014, Tervonen 2017] . Consequently, the choice data can be analyzed  
using econometric methods compatible with RUT, which estimate how participants’ utility  
is influenced by changes in intervention outcomes. DCEs are frequently used in healthcare  
to address a wide range of health policy -related concerns, including identifying the  
trade- offs patients make when choosing between treatments, which can in turn be used to 
determine the probability that patients would prefer one treatment or another [Bridges  2011, Clark 2014].  
3.3 Study committees 
An IDMC has overall responsibility for safeguarding the interests of  subjects by 
monitoring safety and efficacy data obtained in the study and making appropriate recommendations based on the reported data, thus ensuring that the study is being conducted to  the highest scientific and ethical standards. The IDMC will be full y 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 48/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
operational prior to enrollment of the first subject into the study. The composition and operation of the IDMC is described in the IDMC charter. 
An ISB will review and adjudicate in a blinded manner AE SIs, i.e., narcolepsy -like 
symptoms ( EDS, cataplexy and complex sleep behavior events inc luding 
hallucinations/sleep paralysis), or suicide/self -injury . The composition and operation of the 
ISB is described in the ISB charter.  
4 SUBJECT POPULATION 
4.1 Subject population description 
This study will enroll adult an d elderly  (≥ 18 years), male and female subjects with 
insomnia disorder according to Diagnostic and Statistical Manual of Mental Disorders, 
Fifth  Edition ( DSM -5). For more details on inclusion and exclusion criteria, see 
Sections  4.3 and 4.4.  
Insufficient sleep quantity is defined in this study by self -reported history of ≥ 30 min to 
fall asleep, of wake time during sleep ≥ 30 min and of s ubjective TST ( sTST) ≤ 6.5 h during 
the night. Those 3 self-reported parameters must be present on at least 3 nights per week 
for at least 3 months prior to the screening visit and on the sleep diary sleep data collected 
during the period between Visit 2 and V isit 3. They will also be validated by objective 
PSG-based criteria collected from the V isit 3 PSG nights spent in a sleep laboratory during 
the run- in. Poor Sleep Quality (SQ) is defined as  an Insomnia Severity Index© (ISI©) score 
≥ 15 at screening.  
4.2 Rationale for the selection of the study population 
In this study, adult (18–64 years) and elderly (≥ 65 years) subjects with insomnia as def ined 
by DSM -5 will be included [see definition in S ection  1.1.1] , unless subject ’s insomnia is 
associated with major comorbidities, especially comorbid neurological, affective or psychiatric disorders (e.g., severe or uncontrolled depression, anxiety or dementia) that may interfere with the efficacy and safety in the trial.  
Elderly people exhibit a different sleep pattern to younger adults [Ohayon 2004]  and the 
sensitivity of elderly and younger adults to the PD properties of a compound may therefore differ in the long term. Thus, randomization will be stratified by age in both pivotal studies 
to ensure that tested doses are given to a proportion of elderly subjects (i.e., 40% with age 
≥ 65 years) and to ensure balance of the treatment group s within strata is achieved . 
Concomitant pharmacological treatments for insomnia or concomitant CNS -related 
medication s are not allowed in the study. This approach will favor optimizing the 
evaluation of the safety and efficacy profile of ACT -541468 by avoiding any potential 
confounding effects due to background co- medications.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 49/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
4.3 Inclusion criteria 
For inclusion in the study, all of the following inclusion criteria must be fulfilled. It is not 
permitted to waive any of the criteria for any subject.  
Criteria assessed at V isit 1 
1. Signed informed consent prior to any study-mandated procedure. 
2. Male or female aged ≥ 18 years.  
3. Insomnia disorder according to DSM- 5 criteria  as follows :  
3.1 The predominant complaint is dissatisfaction with sleep quantity or quality , 
associated with one (or more) of the following symptoms: 
• Difficulty initiating sleep.  
• Difficulty maintaining sleep, characterized by frequent awakenings or 
problems returning to sleep after awakenings. 
• Early -morning awakening with inability to return to sleep.  
3.2 The sleep disturbance causes clinically significant distress or impairment in 
social, occupational, educational, academic, behavioral, or other important areas 
of functioning. 
3.3 The sleep  difficulty occurs despite adequate opportunity for sleep. 
3.4 The insomnia is not better explained by and does not occur exclusively during the course of another sleep -wake disorder (e.g., narcolepsy, a breathing -related 
sleep disorder, a circadian rhythm sleep -wake disorder, a parasomnia).  
3.5 The insomnia is not attributable to the physiological effects of a substance (e.g., a drug of abuse, a medication). 
3.6 Coexi sting mental disorders and medical conditions do not adequately explain 
the predominant complaint of insomnia. 
3.7 Self-reported history of all the following on at least 3 nights per week and for at 
least 3 months prior to V isit 1: 
3.7.1 ≥ 30 min to fall asleep, and 3.7.2 Wake time during sleep ≥ 30 min, and 3.7.3 sTST ≤ 6.5 h 
4. ISI
© score ≥ 15. 
5. Ability to communicate well with the investigator, to understand the study requirements and judged by the investigator to be alert and oriented to person, place, time, and situation. 
Criteria assessed at V isit 3 
6. Meeting all the following sleep parameters on at least 3 nights out of 7 nights on the sleep diary completed at home between V isit 2 and V isit 3: 
6.1 ≥ 30 min to fall asleep, and 6.2 Wake time  during sleep ≥ 30 min, and 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 50/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
6.3 sTST of ≤ 6.5 h 
7. Usual bedtime between 21:30 and 00:30, as reported on sleep diary completed between 
Visit 2 and V isit 3. 
8. Regula r time in bed between 6 and 9 h, as reported on sleep diary completed between 
Visit 2 and V isit 3. 
9. Meeting all the following sleep parameters on the 2 PSG nights at Visit 3: 
9.1 Mean LPS ≥ 20 min (with none of the two nights < 15 min), and 
9.2 Mean WASO ≥ 30 min (with none of the two nights < 20 min), and 9.3 Mean TST < 420 min 
Criterion  assessed at V isit 1, Visit 2, and V isit 4 
10. For women of childbearing potential, the following is required: 
• Negative serum pregnancy test (Visit 1). 
• Negative urine pregnancy test (V isit 2, Visit 4). 
• Agreement to use the contraception scheme as required by the protocol fr om 
Screening up to at least 30 days after last study treatment intake.  
4.4 Exclusion criteria 
Criteria assessed at V isit 1 
1. Body mass index (BMI) below 18.5 or above 40.0 kg/m2. 
2. Any lifetime history of sleep -related breathing disorder, including chronic obstruc tive 
pulmonary disease and sleep apnea.  
3. Cognitive behavioral therapy (CBT) for any indication is  allowed  only if the CBT  
started at least 1  month prior to V isit 3 and the subject  agrees to continue this CBT 
throughout the study. 
4. Self-reported usual daytime napping ≥ 1 hour per day, and ≥ 3 days per week. 
5. Acute or unstable psychiatric conditions (including but not restricted to anxiety 
disorder, major depression, bipolar disorder, schizophrenia, obsessive compulsive disorder or depression) that are diagnosed  by the Mini International Neuropsychiatric 
Interview
© (MINI©) or that require pharmacological treatment for these disorders. 
N.B.: subjects with a history of major depressive disorder currently without any 
symptoms and not requiring treatment are eligible . 
6. Mini Mental State Examination© (MMSE©) score < 25 in subjects ≥ 50 years.  
7. Shift work within 2 weeks prior to the screening visit, or planned shift work during the 
study.  
8. Travel  across  ≥ 3 time zones within 2 weeks prior to the screening visit, or planned 
travel across ≥ 3 time zones during study. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 51/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
9. Unstable medical con dition, significant medical disorder or acute illness, ECG, 
hematology or biochemistry test results within 1  month prior to the screening visit, 
which , in the opinion of the investigator , could affect the subject ’s safety or interfere 
with the study assessments . 
10. Treatment with CNS -active drugs prohibited by this protocol for 5  half-lives of the 
respective drug ( or 2 weeks , whichever  is longer ) prior to V isit 1, including 
over-the-counter medication and herbal medicines.  
11. Diagnosis of alcohol or substance use  disorder within 2 years prior to the screening 
visit or inability to refrain from drinking alcohol for at least 3 consecutive days. 
12. Heavy tobacco use (at least one pack of cigarettes  a day or inability to refrain from 
smoking during the night ).  
13. Caffeine consumption ≥ 600 mg per day or any caffeine consumption after 4 pm. 
14. Treatment with another investigational drug within 3 months prior to V isit 1, previous 
treatment with ACT -541468 or previous randomization  in any trial involving  
ACT -541468. 
15. Known hypersensitivity or contraindication to drugs of the same class as the study treatment or to any excipients of the study drug formulation.  
16. Not able or willing to stop treatment with  moderate or strong CYP3A4 inhibitors, or 
treatment with moderate or strong CYP3A4 inducers, within at least 1 week prior to 
Visit 2. 
17. Not able or willing to stop consumption of grapefruit, Seville (bitter) oranges or juices from those fruits within at least 1  week prior to Visit 2.  
Criteria assessed at PSG visit between Visit 1 and Vis it 2 
18. Periodic limb movement disorder with arousal index (PLMAI) ≥ 15/h (assessed on the 1
st PSG night), restless legs syndrome, circadian rhythm disorder, REM behavior 
disorder, or narcolepsy.  
19. Apnea/hypopnea index (AHI) ≥ 15/h according to American Academy of Sleep Medicine criteria or event associated with blood oxygen saturation level by pulse 
oximetry (SpO
2) < 80%, as assessed on the 1st PSG night. 
Criteria assessed at V isit 1 and V isit 3 
20. AST and/or ALT > 2 ×  ULN and/or direct bilirubin > 1.5 ×  ULN.  
21. Severe renal impairment: known or defined as estimated creatinine clearance 
< 30 mL/min /1.73m2, according to the 4- variable Modification of Diet in Renal 
Disease formula . 
22. Hematology or biochemistry test results deviating from the normal range to a clinically relevant extent as per judgment of the investigator.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 52/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
23. Any of the following conditions related to ECG abnormalities : 
• A prolonged QT interval corrected with Bazett ’s formula (QTcB) or QT interval 
corrected with Fridericia ’s formula (QTcF) (greater than 450 ms ). If QTcB or QTcF 
is greater than 450  ms on the first ECG, a second ECG recording will be performed 
after at least 30 min. If QTcB or QTcF is greater than 450 ms on the second ECG, the subject is not eligible.  
• A history of additional risk factors for torsade de pointes (e.g., heart failure, hypokalemia, family history of long QT syndrome). 
• ECG with clinically significant atrioventricular (AV) conduction disturbance (e.g., second or third- degree AV block), sick sinus syndrome, bradycardia (resting pulse 
< 40 bpm), or accessory bypass tract ( e.g., Wolff-Parkinson- White).  
Criteri on assessed at V isit 1, Visit 2, Visit 3 and Visit 4  
24. Any of the following conditions related to suicidality:  
• Any suicidal ideation with inte nt, with or without a plan, at s creening , i.e., 
answering “Yes” to questions 4 or 5 on the suicidal i deation section of the lifetime  
(Visit 1) and visit (V isit 2, Visit 3, Visit 4 ) version of the C- SSRS
©. 
• History of suicide attempt on the suicidal behavioral  section of the lifetime version 
of the C- SSRS© (Visit 1).  
Criteria assessed at V isit 1, PSG visit between V isit 1 and V isit 2, Visit 2, Visit 3 and 
Visit 4 
25. For female subject s: pregnant, lactating or planning to become pregnant during 
projected duration of the study. 
26. Positive urine drug test (for benzodiazepines, barbiturates, cannabinoids, opiates, amphetamines, phencyclidine or cocaine) or presence of alcohol in exhaled breath as 
detected by breathalyzer test.  
4.5 Criteria for women of childbearing potential 
4.5.1 Definition of childbearing potential  
A woman is considered to be of childbearing potential unless she meets at least one of the following criteria:  
• Previous bilateral salpingectomy, bilateral salpin go-oophorectomy or hysterectomy, 
• Postmenopausal (defined as 12 consecutive months with no menses without an alternative med ical cause [ICH M3 definition]), 
• Premature ovarian failure (confirmed by a specialist), XY genotype, Turner syndrome, uterine agenesis, 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 53/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
The reason for not being of childbearing potential will be recorded in the electronic Case 
Repo rt Form ( eCRF ). 
4.5.2 Acceptable methods of contraception  
For w omen of childbearing potential [see definition in Section 4.5.1] , any of the following 
acceptable birth control methods are required: 
• Combined (estrogen- and progestogen-containing) hormonal contraception associated 
with inhibition of ovulation: 
– Oral 
– Intravaginal 
– Transdermal  
• Progestogen -only hormonal contraception associated with inhibition of ovulation: 
– Oral 
– Injectable  
– Implantable 
• Intrauterine device  
• Intra uterine hormone- releasing system  
• Vasectomized male partner with documented post-vasectomy confirmation of the 
absence of sperm in the ejaculate.  
• Bilateral tubal occlusion (tubal occlusion / ligation at least 6 weeks prior to 
screening).  
• Sexual  abstinence from intercourse with a male partner only when this is in line with 
the preferred lifestyle of the subject and if locally accepted as a reliable method of contraception. 
Rhythm methods , the use of a female condom, cervical cap , diaphragm  or the partner ’s use 
of a condom are not considered acceptable methods of contraception for this study. 
The method of birth control used must be recorded in the hospital charts.  To ensure compliance, the study personnel must remind women of childbearing potential 
at each v isit to use the methods of contraception defined for this study. The reminders must 
be documented in the hospital chart. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 54/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
5 TREATMENTS 
5.1 Study treatment  
The study drugs are ACT -541468 and ACT-541468- matching placebo.  
5.1.1 Investigational treatment and matching placebo: Description and rationale  
ACT -541468 or matching placebo will be administered as tablets, orally, once daily in the 
evening during the DB treatment period. ACT -541468- matching placebo will be 
administered as well during the run- in and the run-out period. At home, the study treatment 
will be taken at bedtime to mimic real life drug intake habits and at the site visits, the study 
treatment will be administered at least 2 h after the last meal and approximately 30 min before lights off  to avoid a potential  delay in ACT -541468 effects when administered with 
food which might bias objective endpoints. 
ACT -541468 is supplied by Idorsia as film -coated tablets at strengths of 10 mg and 25 mg. 
The rationale for the selection of these ACT -541468 doses is described in Section  1.3.2. 
The ACT -541468- matching placebo is supplied by Idorsia as identical tablets, formulated 
with the same inactive ingredients (excipients).  
5.1.2 Study treatment administration  
The t ablet must not be broken or crushed. The date and time of treatment intake will be 
recorded in the sleep diary by the subject when taken at home and by the site personnel in 
the patient ’s chart and  the eCRF during the PSG nights. At Visit 2, the date of single -blind 
placebo treatment dispens ing will also be recorded in the patient’ s chart and the eCRF.  
5.1.2.1 Study treatment administration at site visits and at home  
During the PSG visits at the site , 1 tablet of study treatment will be taken at least 2 h after 
the last meal and approximately 30 min (± 5 min) before lights off, in the evening of each 
PSG night. 
At home, the tablet will be taken at bedtime.  
5.1.2.2 Missed doses 
If one or more doses have been missed, the next dose must be taken in the evening of the 
following day. 
5.1.3 Treatment assignment  
Each of the study sites will b e assigned a unique site number  and every subject will receive 
a unique subject number which identifies the subject throughout the study. At Visit 1, after the ICF has been signed, the investigator/delegate will contact the IRT 
system  to get a subject number allocated to the subject.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 55/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
During the run- in and run -out periods, subjects will receive single -blind placebo treatment. 
At Visit 2 and V isit 9, the investigator/delegate contacts the IRT system to assign the 
treatment wallet  number. 
On the day of randomization (V isit 4), after having verified that the subject meets all 
inclusion criteria and none of the exclusion criteria, the investigator/delegate contacts the 
IRT to randomize the subject. The IRT assigns the treatment wallet number , which matches 
the treatment arm assigned per the randomization list.  
Subjects will be randomized in a 1:1:1 ratio to 10 or 25 mg of ACT -541468, or placebo, 
respectively (i.e., approximately 300 subjects per arm). Treatment allocation will be 
stratified b y age into 2 categories: < 65 and ≥ 65 years.  
The randomization list is generated by an independent Contract Research Organization (CRO) and kept strictly confidential. 
5.1.4 Blinding  
5.1.4.1 Run-in and run-out periods 
During run -in and run- out periods, placebo treatment will be administered in a single -blind 
fashion. The subjects will remain blinded to the study treatment until the end of the 
ID-078A303 extension study . Subject s must not be informed about the change in treatment 
at the end of run- in and at the beginning  of run -out. The investigator and study personnel, 
the monitors, Idorsia personnel, and CROs involved in the conduct of the study will be 
unblinded to the treatment provided during the run -in/run-out periods.  
5.1.4.2 Double- blind treatment period 
From Randomization until EO DBT, the study will be performed in a DB fashion. The 
subjects, the investigator and s ite personnel, and the monitors will remain blinded to the 
study treatment until the end of the ID -078A303 extension study. Idorsia personnel 
responsible for c linical study supply distribution will monitor the depot stock levels in 
collaboration with the study team based on recruitment data and site activation. Site stocks will be maintained according to the settings in the IRT system.  
Until the time of unblinding for final data analysis, the randomization list is kept strictly confidential, and accessible only  to the  IRT vendor and sponsor authorized persons (e. g., 
Quality assurance, Systems and compliance personnel, Bioanalytical Laboratory group) the Independent Statistical Analysis Center ( ISAC ) and the IDMC, who are not involved 
in the conduct of the study. 
The investigational treatment and its matching placebo are indistinguishable, and all 
treatment wallet s will be packaged in the same way.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 56/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
To minimize the  possibility of systematic unblinding, the results of PK data will not be 
communicated to the investigator and site study personnel, the subjects  and Clinical 
Research Associates ( CRAs ) until the end of the ID -078A303 extension study . Results will 
be trans ferred by the sponsor Bioanalytic al Laboratory g roup (for the PK data) to the 
sponsor and CRO personnel involved in the conduct of the study only after database lock. 
5.1.5 Unblinding  
5.1.5.1 Unblinding for final analyses 
Randomization information will be made available  for data analysis only after database 
lock, in accordance with Idorsia Quality System (QS) documents. 
5.1.5.2 Unblinding for IDMC review 
An ISAC, not otherwise involved in the design, conduct and analysis of the study, will 
have access to the randomization code i n order to prepare unblinded reports for IDMC 
review meetings during the course of the trial. The randomization code will be made available to the ISAC in accordance with the sponsor’s QS documents. 
5.1.5.3 Unblinding for suspected unexpected serious adverse react ions 
If a suspected unexpected serious adverse reaction (SUSAR) occurs for a subject 
participating in the study, Idorsia Global Drug Safety will request the unblinding of the treatment assignment. The treatment assignment will not be communicated to site personnel or to the Idorsia Clinical Trial Team. Unblinded SUSAR information will be provided to respective health authorities and IECs/IRBs  only. SUSARs will be reported to 
investigators in a blinded fashion. 
5.1.5.4 Emergency procedure for unblinding  
The investigator, study personnel and Idorsia personnel must remain blinded to the 
subject ’s treatment assignment. The identity of the study treatment may be revealed only 
if the subject experiences a medical event, the management of which would require knowledge of t he blinded treatment assignment. In this case, the investigator can receive 
the unblinded treatment assignment through the IRT. In these situations, the decision to unblind resides solely with the investigator. Whenever  possible, and if it does not interfe re 
with (or does not delay) any decision in the best interest of the subject, the investigator is invited to discuss the intended unblinding with Idorsia personnel. 
The occurrence of any unblinding during the study must be clearly justified and explained 
by the investigator. In all cases, Idorsia personnel must be informed of the unblinding 
procedure as soon as possible before or after the unblinding. 
The circumstances leading to unblinding must be documented in the Investigator Site File 
(ISF) and e CRF.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 57/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
5.1.6 Study treatment supply  
Manufacture, labeling, packaging, and supply of study treatment will be conducted according to Good Manufacturing Practice, GCP, and any local or national regulatory requirements.  
All study treatment supplies are to be used only in accordance with this protocol, and not for any other purpose. 
5.1.6.1 Study treatment packaging and labeling 
Study treatment (including placebo during run -in and run- out period) is provided as tablets 
and supplied in wallets . All pack types are childproof wallets con taining 35  tablets.  
Study treatment is labeled to comply with the applicable laws and regulations of the 
countries in which the study sites are located. 
5.1.6.2 Study treatment distribution and storage 
Study treatment supplies must be kept in an appropriate, secur e area and stored according 
to the conditions specified on the label (i.e., 8–25 °C). Temperature measurement devices 
for study treatment storage area are required.  
5.1.6.3 Study treatment dispensing  
The subjects will receive sufficient study treatment to cover t he period up to the next 
scheduled visit. Subjects are asked to return all used, partially used, and unused study 
treatment wallets  at each visit. If a treatment wallet  is lost or damaged, a replacement wallet  
can be requested through the Treatment Replacement module of the IRT system. The 
protocol- mandated study  treatment dispensing procedures may not be altered without prior 
written approval from Idorsia . In exceptional circumstances (e.g., if the subject lost the 
study treatment between two visits, or if  the subject is unable to return to the site due to a 
medical emergency  / hospitalization at another hospital), unscheduled dispensing and 
delivery of study treatment may occur outside of a scheduled visit. An accurate record of 
the date and amount of stud y treatment dispensed to each subject must be available for 
inspection at any time.  
5.1.6.4 Study treatment return and destruction  
The protocol -mandated study treatment return procedures may not be altered without prior 
written approval from Idorsia. On an ongoing  basis and/or on termination of the study, the 
CRA will collect used and unused treatment wallets , which will be sent to the warehouse, 
where Idorsia personnel or a deputy will check treatment reconciliation. In certain circumstances, used and unused study  treatment containers may be destroyed at the site 
once study treatment accountability is finalized and has been checked by Idorsia personnel or the deputy, and written permission for destruction has been obtained from Idorsia. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 58/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
5.1.7 Study treatment accountability and compliance with study treatment  
5.1.7.1 Study treatment accountability  
The inventory of study treatment dispensed to and returned by the subject (i.e., study  
treatment accountability) must be performed by site personnel at each visit and before dispensing f urther study treatment. It is to be recorded by site personnel on the study  
treatment dispensing and accountability log and in the eCRF, and checked by the CRA during site visits and at the end of the study. The study treatment accountability log in the eCRF will include at least the following information for each study treatment unit (i.e ., 
wallet ) dispensed to the subject: 
• Dispensed subject wallet  number. 
• Date and number of tablets dispensed. 
• Date and number of tablets returned. 
All study treatment supplies, including partially used or empty wallets  must be retained at 
the site for review by the CRA.  
If the subject forgets to bring the remaining study treatment to a study visit, he/she must be instructed to not take any tablets from the remaining study tre atment wallet  and to return it 
at the next visit.  
5.1.7.2 Study treatment compliance 
Study treatment compliance is based on study treatment accountability. Subjects also report 
their compliance in the eDiary every morning. Study treatment compliance for the R un-in 
period, the DB treatment period (Day 1 to EO DBT) and the R un-out period will be 
separately calculated for each of these periods by site personnel using the below formula 
and entered in the eCRF:  
Compliance = [(number of tablets dispensed – number of table ts returned) / total number 
of tablets that needs to be taken during the period
*] × 100 
* The period is defined as number of day s during which study treatment  should be taken as per actual visit 
dates . 
During the DB treatment period ( Day 1  to EO DBT), compl iance is expected to be at least 
70%. Compliance values below this will be considered as a protocol deviation which will be reported in the Clinical Trial Management System by the CRA. The investigator must 
discuss the non- compliance with the subject to clarify the reasons and to take appropriate 
actions to avoid re -occurrence. This discussion and its outcome must be documented in the 
source documents. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 59/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
5.1.8 Study treatment dose adjustments and interruptions  
Study treatment dose adjustments are not permitted.  
Study treatment may be temporarily interrupted in response to an AE, a diagnostic or 
therapeutic procedure, a laboratory abnormality, or for administrative reasons. Study- specific criteria for interruption of study treatment are described in Section  5.1.10. 
If study treatment is interrupted by the subject for any reason, she/he must immediately inform the investigator.  
Interruptions of study treatment must be kept as short as possible.  
Study treatment interruptions  must be recorded in the e CRF.  
5.1.9 Premature discontinuation of study treatment  
The decision to prematurely discontinue study treatment may be made by the subject, the 
investigator, or Idorsia personnel. The main reason for discontinuation must be documented in the eCRF and in the subject’ s medical charts (e.g., AE, lack of efficacy).  
A subject has the right to prematurely discontinue study treatment at any time, without any justification, by withdrawal from study treatment only or by withdrawal from any furthe r 
participation in the study (i.e., premature withdrawal from the study [see Section  8.2]). 
Although a subject is not obliged to give his/her reason for prematurely withdrawing from the treatment or the study, i t is recommended that the investigator makes a reasonable effort 
to ascertain the reason(s), while fully respecting the subject ’s rights.  
The investigator must discontinue study treatment for a given subject if, on balance, he/she believes that continued administration would be contrary to the best interests of the subject.  
Study- specific criteria for discontinuation of study treatment are described in 
Section  5.1.10. 
A subject who prematurely discontinues study treatment is NOT  considered as withdrawn 
from the study and will be followed up until the planned EOS  (Day 115), provided that the 
subject ’s consent for this limited participation in the study has not been withdrawn. The 
subject is recommended to return for safety assessments  [see Table 1] within one week of 
his/her last DB study treatment intake  (N.B. , next day residual assessments will only be 
performed if the subjects  can be assessed within 24 h of last DB study drug intake) . All 
subjects withdrawn from study treatment are encouraged to follow planned study procedures (e.g. , visits, sleep diary and questionnaire completion) until EOS. In this case, 
the run- out period (including Visit 9 and Visit 10) will not be performed, and subjects will 
directly enter the follow -up period after Visit 8 (considered as EOT in the event  of 
premature discontinuation). The phone call will be performed as planned 30 days (+ 7 days) 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 60/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
later, at Visit 11. This will decrease the amount of missing data whi ch is important from a 
study integrity perspective.  Subjects who prematurely discontinue study treatment or  the 
study for any reason will not be replaced. 
A subject who prematurely discontinues study treatment and withdraws consent to 
participate in any fu rther study assessments is considered as withdrawn from the study and 
no further assessment will be collected after informed consent withdrawal. Subjects who die or are lost to follow -up are also considered as withdrawn from the study. Withdrawal 
from the study and follow -up medical care of subjects withdrawn from the  study are  
described in Sections  8.2 and 8.4,  respectively.  
5.1.10 Study -specific criteria for interruption / premature discontinuation of study 
treatment  
At each visit, if there are signs of any AEs, the investigator must evaluate whether continuing treatment at home is compatible with the subject’s lifestyle and does not affect the subject ’s safety. The investig ator has the responsibility to decide whether it is safe for 
the subject to continue treatment in the study. 
If a subject becomes pregnant while on study drug, study drug must be permanently discontinued. The investigator must counsel the subject and discuss the risks of continuing with the pregnancy and the possible effects on the fetus. 
Female subjects participating in the study and wishing to become pregnant during the study 
must discontinue study drug and continue contraception for at least 1 month.  
5.2 Previous and concomitant therapy 
5.2.1 Definitions  
A previous therapy is any treatment for which the end date is prior to signing ICF. 
A therapy that is study -concomitant is any treatment that is ongoing or initiated after 
signing of informed consent, or initiated up to EOS.  
A therapy that is study treatment- concomitant is any treatment that is either ongoing at the 
start of DB study treatment or is initiated during the DB treatment period until 1 day after 
the last dose of DB  treatment.  
5.2.2 Reporting of previous/conco mitant therapy in the eCRF  
The use of all study -concomitant therapy (including contraceptives and traditional and 
alternative medicines, e.g., plant -, animal -, or mineral -based medicines) will be recorded 
in the eCRF. Previous therapy must be recorded in the eCRF if discontinued less than 30 days prior to signing of the ICF. The generic name, start/end dates of administration (as 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 61/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
well as whether it was ongoing at start of treatment and/or EOS), route, dose, and indication will be recorded in the eCRF.  
5.2.3 Allow ed concomitant therapy  
CBT consists of a combination of cognitive therapy, behavioral , and educational 
interventions and is ideally delivered by a specially trained physician or a qualified psychotherapist. Given the shortage of certified sleep therapists, access to CBT is limited, 
particularly in Europe [ Pigeon  2010, Schutte-Rodin 2008].  CBT  for any indication  is only 
allowed i f the treatment started at least 1 month prior to V isit 3 and the subject  agree s to 
continue this CBT throughout the study . Details about subject ’s CBT or reason why CBT 
was not considered by the subject must be recorded in the eCRF. Initiation of CBT during the course of the study is not allowed. 
Therapies considered necessary for t he subject ’s well -being and not categorized as 
prohibited concomitant medications can be used in this study. However, initiation of new 
medication is to be discouraged and concomitant medication will preferably not be changed during the study. Non- sedating  antihistamines (cetirizine, loratadin e, desloratadine, 
fexofenadine and levocabastine) may be used a maximum of twice weekly for allergic 
symptoms. Inhaled or nasal corticosteroids are permitted. 
5.2.4 Forbidden concomitant therapy  
Subjects must not be withdraw n from medically necessary therapies in order to participate 
in the study. They must rather be considered as non- eligible to the study, both due to their 
medical condition and due to their requirement for these therapies. Several forbidden 
therapies are associated with excluded medical disorders (e.g., cardiovascular disease, Parkinson’ s disease, stroke).  
The following concomitant therapies are forbidden during the study: 
• Treatment with another investigational drug until EOS.  
• Study-prohibited CNS -active med ications from for 5 half -lives of the respective drug 
(but at least 2 weeks) prior to V isit 1 and until 24 hours after EOT  [see Appendix 3] . 
• Treatment with moderate or strong CYP3A4 inhibitors, or moderate or strong CYP3A4 
inducers until 24 hours after EOT  [see Appendix 3] .  
5.2.5 Forbidden concomitant diet and activities  
The following activities and diet are forbidden during the study: 
• Consumption of grapefruit, Seville (bitter) oranges or juices from those fruits  from 
1 week prior to V isit 2 until 24 h after the end of run-out period. 
• Caffeine consumption ≥ 600 mg caffeine/day or consumption of any caffeine after 
4 pm (after 2 pm on PSG nights) [see  Appendix 2] . 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 62/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
• Alcohol consumption [ see Appendix 1]  
− > 2 drinks a day 
− less than 3 hours before going to bed on non-PSG nights 
− within 24 hours prior to PSG night and during all PSG visits 
• Heavy tobacco use (at least  one pack of cigarettes a day or inability to refrain from 
smoking during the night).  
• Driving or engaging in activities that require operating vehicles  or dangerous 
machinery within 8  hours following study treatment intake for adult and elderly 
subjects.  
6 STUDY ENDPOINTS 
The ID -078A302 trial is designed to assess safety and efficacy of ACT -541468 on 
objective and subjective endpoints.  
6.1 Primary efficacy endpoints 
The primary efficacy endpoints of this study are defined as: 
• the change from baseline to Month 1 in WASO (sleep maintenance) 
• the change f rom baseline to Month 3 in WASO 
• the change from baseline to Month 1 in LPS (sleep onset) 
• the change from baselin e to Month 3 in LPS  
Baseline is defined as the mean of the 2 PSG nights at Visit 3 . Month 1 and Month 3 are 
defined as the mean of the 2 PSG nights at Visit 6 and Visit 8, respectively.  
LPS (min) is the time from start of recording to the beginning of the  first continuous 
20 epochs (i.e., 10 min) scored as non- awake, i.e., epochs scored as either sleep stage 
1 (S1), sleep stage 2 (S2), sleep stage 3 (slow wave sleep  [SWS] ) or REM, as determin ed 
by PSG.  
WASO is the time (min) spent awake after onset of persistent sleep until lights on , as 
determined by PSG.   
6.2 Secondary endpoints  
The secondary efficacy endpoints of this study are defined as: • the change from baseline
a to Month 1b in sTST  
• the change from baselinea to Month 3c in sTST  
• the change from baselinea to Month 1b in Insomnia Daytime Symptoms and Impacts 
Questionnaire ( IDSIQ ) sleepiness domain score 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 63/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
• the change from baselinea to Month 3c in IDSIQ sleepiness domain score  
a Baseline is the mean value based on the screening sleep diary  / IDSIQ  entries perform ed 
at home in the 7 days immediately preceding the first PSG at Visit 3. 
b ‘Month 1’ is the mean value based on the sleep diary  / IDSIQ  entries performed at home 
in the 7 days immediately preceding the first PSG at Visit 6. 
c ‘Month 3’ is the mean value based on the sleep diary  / IDSIQ  entries performed at home 
in the 7 days immediately preceding the first PSG at Visit 8. 
6.3 Other efficacy endpoints 
• Change from baseline (mean of the 2 PSG nights at V isit 3) to Month 1 (mean of the 
2 PSG nights at Visit 6) and Month 3 (mean of the 2 PSG nights at V isit 8) in TST. 
• Change from baselinea to Month 1b and Month 3c in subjective WASO ( sWASO). 
• Change from baselinea to Month 1b and Month 3c in subjective Latency to Sleep Onset 
(sLSO ). 
• Change from baselinea to Month 1b and Month 3c in IDSIQ scores  (i.e., Total score; 
alert/cognition and mood domain scores). 
a Baseline is the mean value based on the screening sleep diary  / IDSIQ  entries performed 
at home in the 7 days immediately preceding the first PSG at Visit 3. 
b ‘Month 1’ is the mean value based on the sleep diary  / IDSIQ  entries performed at home 
in the 7 days immediately preceding the first PSG at Visit 6. 
c ‘Month 3’ is the mean value based on the sleep diary  / IDSIQ  entries performed at home 
in the 7 days immediate ly preceding the first PSG at V isit 8. 
6.4 Exploratory endpoints 
For each variable, multiple aspects will be considered in the analysis, in particular changes 
from baseline at different time points.  
• WASO over time (by hour of the night and by quarter of the night) on each PSG night.  
• Change from b aseline (V isit 3) to Month 1 and Month 3 in SQ. SQ is the sleep quality 
as determined by scores on the VAS (mm) in the morning. 
• Change from baseline (V isit 3) to Month 1 and Month 3 in duration of TST in each 
sleep sta ge (S1, S2, SWS and REM).  
• Change from baseline (V isit 3) to Month 1 and Month 3 in sleep architecture assessed 
as percentage of TST in each sleep stage (S1, S2, SWS , and REM) over the whole 
night, and for each quarter of the night.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 64/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
• Change from baseline ( Visit 3) to Month 1 and Month 3 in mean numbers of shifts from 
S2, SWS or REM to S1 or awake. 
• Change from baseline (V isit 3) to Month 1 and Month 3 in ISI© scores.  
• Change from baseline (V isit 3) to Month 1 and Month 3 in mean number of awakenings 
(defined as the number of awakenings between first epoch and last epoch not scored 
wake) as measured by PSG (will be summarized for the whole night, for each quarter 
of the night, and for each hour of the night). 
• Change from baseline (V isit 3) to Month 1 and Month 3 in mean number of 
self-reported awakenings.  
• Change from baseline (V isit 3) to Month 1 and Month 3 in Sleep Efficiency (defined 
as 100 ×  ([TST / time in bed]).  
• Change from baseline (V isit 1) to Month 1 and Month 3 in Patient Global Assessment 
of Disease Severity ( PGA -S) scores  (daytime symptoms) . 
• Change from baseline (V isit 3) to Month 1 and Month 3 in Patient Global Impression 
of Change ( PGI-C) scores  (daytime symptoms) . 
• Change from baseline (Visit 3) to Month 1 and Month 3 in PGI-C scores  (night- time 
symptoms). 
• Change from baseline (Visit 3) to Month 1 and Month 3 in Pati ent Global Impression 
of Severity (PGI -S) scores  (night- time symptoms) . 
6.5 Safety endpoints  
In addition to the standardized collection of AEs, safety data specific to insomnia and its 
treatm ent will be assessed as follows:  
• Withdrawal effects  (physical dependence) upon treatment discontinuation will be 
assessed based on the changes from last assessment on DB treatment ( Visit 8, 
2nd morning) to run- out period in the BWSQ total score ( Visit 9 and V isit 10), the 
occurrence of relevant AEs and marked ECG abnormalities.  
• Rebound insomnia will be assessed based on objective sleep parameters (WASO , LPS  
and TST) at Visit 9 as compared to Visit 3 . It will also be assessed using subjective 
sleep parameters (sWASO, sLSO and sTST) from run-out period as compared to 
baseline. 
• Next -day residual effect will be assessed based on changes from baseline (V isit 3) to 
Month 1 and Month 3 in: 
− Coding sub- test© 
− SDS© 
− Scores on the VAS (mm) 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 65/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
• SAEs up to 30 days after DB study treatment discontinuation  or until enrollment into 
the extension study. 
• TEAEs up to 30 days after DB study treatment discontinuation or until enrollment into 
the extension study. 
• AEs leading to premature discontinuation of the DB study treatment.  
• AEs o f special interest after adjudication by ISB:  
− narcolepsy -like symptoms (i.e. , EDS, cataplexy and complex sleep behavior 
events including hallucinations/sleep paralysis)  
− suicide/self -injury  
• Change from baseline (V isit 3) to Month 1 (V isit 6) and Month 3 ( Visit 8) in vital signs 
(mean of the 2 PSG nights in systolic and diastolic blood pressure [ BP] and pulse rate).  
• Change from baseline (V isit 1) to Month 3 (V isit 8) in body weight. 
• Marked ECG abnormalities on DB  study treatment.  
• Change from baseline (V isit 3) to Month 3 (V isit 8) and the end of the run- out period 
(Visit 10) in ECG parameters.  
• Marked laboratory abnormalities on DB  study treatment.  
• Change from baseline (V isit 3) to Month 1 (V isit 6) and Month 3 (V isit 8) in laboratory 
parameters.  
• Occurrence o f suicidal ideation and/or behavior on DB study treatment based on  
C-SSRS©. 
6.6 Pharmacokinetic endpoints  
ACT -541468 plasma concentrations 9–10 h post -dose (morning after the second PSG night 
at Visit 6 and Visit 8) or in the event  of excessive sleepiness based on the investigator ’s 
opinion. 
6.7 Patient preferences exploratory endpoints 
The preferences resulting from the choice sets collected in the third section of the PAUSe 
questionnaire will be used to derive the following endpoints: 
• Partial value of each treatm ent outcome at Visit 4 and Visit 8.  
• Partial value function and weights for each treatment outcome at Visit 4 and Visit 8.  
• Total value score for each treatment at Visit 4 and Visit 8.  
• Change in total value score for each treatment from Visit 4 to Visit 8.   
• Probability that patients would prefer a treatment at Visit 4 and Visit 8.  
• Change in probability that patients would prefer a treatment from Visit 4 to Visit 8.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 66/154 Confidenti al EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
7 VISIT SCHEDULE AND STUDY ASSESSMENTS 
7.1 Study visits 
The study visits are listed in  Table 1. Screening will last 2 0 to 31 days. For all visits  during 
the DB treatment phase , the subjects must be seen on the designated day and within a ±  2 
days visit window in comparison with randomization ( Visit 4 ). A follow -up safety 
telephone call must be performed 30 days (+ 7 days) after last DB study treatment intake  
if the subject is not enrolled in the ID-078A303 extension study. 
7.1.1 Screening  
At Visit 1 subjects will discuss and sign the ICF , and will undergo initial eligibility 
assessments. The date on which the ICF is signed corresponds to the date of the screening 
visit (Visit 1). 
It is the responsibility of the investigator/delegate (the latter may or may not be a  physician  
according to local legal requirements , in the EU  it must be a physician) to obtain written 
informed consent from each subject participating in this study after adequate face -to-face 
explanation of the objectives, methods, and potential risks of the study. The subjects who 
agree to participate in the stu dy and the investigator/delegate must sign the ICF prior to 
performing any study -related  assessment or procedure.  
Subjects who are in the screening phase when the enrollment target has been met may still be randomized. 
It is not permitted to re -screen subjects.  
7.1.2 Unscheduled visits  
Unscheduled visits may be performed at any time during the study. Depending on the 
reason for the unscheduled visit (e.g., AE), appropriate assessments will be performed based on the judgment of the investigator. Results of ECG s and laboratory assessments , 
and changes in concomitant treatment will be recorded in the eCRF. After an unscheduled visit, the regular scheduled study visits must continue according to the planned visit and assessment schedule [Table 1]. 
 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 67/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
Table 1 Visit and assessment schedule  
 SCREENING PHASE (20 –31 days)  TREATMENT PHASE (82 –86 days)  FU PHASE (30 –37 days)  
 Screening period  
(7–18 days)  Run-in period  
(13–24 days)  Double -blind tr eatment (84 days ± 2 days13) Run-out period  
(7 days + 2 days)  FU 
period  
(23 days 
+ 7 
days)16 
Visit  1  2 3 415 5 
(phone call)  6 7 8 9 10 11 
(phone 
call) 
Target Study Days     1st night  2nd night 1 7 to 14  1st night 13 
27/28 2nd night 
28/29 55 1st night 13 
83/84 2nd night 
84/85 85/86 92 
(+ 2 days)  115 
(+ 7 
days)  
Evening(PM) /  
Morning (AM )  
PM AM  PM AM PM AM   PM AM PM AM  
PM AM PM AM PM AM   
Informed consent  X                       
Inclusion and exclusion 
criteria  X X X X X X X X X               
Demog raphics  X                       
Medical history  X                      X 
Concomitant therapy  X X X X X X X X X X X X X X X X X X X6 X X X X 
Physical examination, 
body weight and height  9 X                  X6     
Vital signs  X  X X  X  X X   X  X X  X  X6  X X  
12-lead ECG  X       X           X6   X  
Hematology, blood 
chemistry  X       X      X X    X6     
Pregnancy test 1 X   X     X  X    X    X6   X  
Urine drug screen  X X  X X  X  X  X  X  X X  X  X  X  
Alcohol test  X X  X X  X  X  X  X   X  X  X  X  
PK sampling               X     X     
PSG   X4  X X   X X  X X X   
ISI© X       X      X     X6     
IDSIQ                         
Sleep diary (incl. VAS)  2                        
Neurological exam8   X   X  X    X  X   X  X  X   
C-SSRS© 7 X   X    X X     X X    X6  X X  
Coding sub -test© 7      X  X    X  X   X  X14  X   
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 68/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
 SCREENING PHASE (20 –31 days)  TREATMENT PHASE (82 –86 days)  FU PHASE (30 –37 days)  
 Screening period  
(7–18 days)  Run-in period  
(13–24 days)  Double -blind tr eatment (84 days ± 2 days13) Run-out period  
(7 days + 2 days)  FU 
period  
(23 days 
+ 7 
days)16 
Visit  1  2 3 415 5 
(phone call)  6 7 8 9 10 11 
(phone 
call) 
Target Study Days     1st night  2nd night 1 7 to 14  1st night 13 
27/28 2nd night 
28/29 55 1st night 13 
83/84 2nd night 
84/85 85/86 92 
(+ 2 days)  115 
(+ 7 
days)  
Evening(PM) /  
Morning (AM )  
PM AM  PM AM PM AM   PM AM PM AM  
PM AM PM AM PM AM   
ESS© X   X    X      X     X   X  
SDS© 7      X  X    X  X   X  X6  X   
BWSQ7        X      X     X6  X X  
MINI© X                       
MMSE©10 X                       
PGA-S11 X   X X                 X  
PGI-C11 daytime 
symptoms      X                 X  
PGI-C11 night -time 
symptoms       X                X  
PGI-S11 X   X  X                X  
Patient Preferences17         X          X     
Contact IRT  X   X     X  X    X     X    
Randomization12         X               
Dispense IMP wallet(s)     X     X  X    X     X    
Study drug intake3                        
SAEs and AEs 5                        
1. For women of childbearing potential, serum test at V1 and V 8 and urine test at V2, V4, V6, V7, V10. 2. The hand- held device is handed out to the subject and completed at home daily  from V1 to V 10. 3. 
Daily  placebo single-blind treatment  during run-in and run -out periods , and daily double -blind study treatment  during treatment phase. 4. The 1st PSG can be performed any nights between V1 and V2. It 
includes assessment of AHI, PLMAI, SpO 2. 5. SAE and  AE reporting and follow -up: all SAEs and AEs from signed ICF up to EOS . 6. In the event of permanent study treatment disco ntinuation, safety 
assessments of V 8 are recommended to be performed within 7 days of last  DB study drug intake. If the subject remains in the study, he or she will perform study visits and assessments as planned until EOS 
(Day 115), without the run- out pe riod ( including Visit 9 and Visit 10). 7. Approximately 30 to 60 minutes after PSG lights on. 8. Performed approximately 1 hour after lights on. 9. Height only at V1. 10. For 
elderly subjects only. 11. PGA-S , PGI -S and PGI -C (daytime symptoms and night -time symptoms  questionnaires)  will be completed at home once a week between V4  and EODBT. 12. Randomization will 
take place after all the V4 assessments have been performed and provided the subject fulfills all the eligibility criteria. 13. A time window of ±  2 days is allowed at each visit vs randomization visit (V4).  14. 
In the event of permanent study treatment discontinuation, next day residual as sessment  of V8 will only be performed if the subjects can be assessed within 24 h of last DB study drug intake.  15. Three 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 69/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
working days are required between V3 and V4 to obtain eligibility confirmation regarding objective sleep parameters. 16. If Run -out period exceeded by 2 days, then the follow -up period can only be 
exceeded by a maximum of 5 days ; 17. Patient preferences sub -study (PAUSe) available for sites in Germany and in the USA only.  
AE = adverse event; AHI = apnea/hypopnea index; BWSQ = Benzodiazepine Withdrawal Symptom Questionnaire; C -SSRS© = Columbia Suicide Severity Rating Scale; ECG  = electrocardiogram ; EODBT 
= End -of-Double -Blind -Treatment; EOS = End -of-Study ; ESS© = Epworth Sleepiness Scale©; FU = Follow -up; ICF = Informed Consent Form; IDSIQ = Insomnia Daytime Symptoms and Impacts 
Questionnaire; IMP = Investigational Medicinal Product; IRT = Interact ive Response Technology; ISI© = Insomnia Severity Index©; MINI© = Mini International Neuropsychiatric Interview©; MMSE© = 
Mini Mental State Examination©; PAUSe = PAtient Preferences StUdy in InSomnia; PGA-S = Patient Global Assessment of Disease Severity; PGI-C = Patient Global Impression of Change  (daytime 
symptoms and night -time symptoms) ; PGI-S = Patient Global Impression of Severity; PK = pharmacokinetic; PLMAI = periodic limb movement with arousal index; PSG = polysomnography; SAE = 
serious adverse event; SDS© = Sheehan Disability Scale©; SpO 2 = oxygen saturation by pulse oximetry; V = Visit; VAS = visual analog scale(s). 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 70/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
7.2 Study assessments 
The mandatory study assessments are listed in  Table 1. 
All study assessments are perform ed by qualified study personnel (medical, nursing, or 
specialist technical personnel) , and are recorded in the medical history and eCRF  unless 
otherwise specified. Study assessments performed during unscheduled visits will also be 
recorded in the eCRF.  
The following order of assessments is recommended:  
• In the evening before a PSG night: 
– Urine drug screen and alcohol test 
– IDSIQ  
– Evening questionnaire in sleep diary (including VAS) 
– PGA- S daytime symptoms (in the first evening at Visits 3, 6 and 8) 
– PGI-C dayt ime symptoms ( in the first evening at Visits 3, 6 and 8) 
– Recording of concomitant medications 
– AEs and SAEs  
– Study drug intake (30 minutes before lights off) 
• In the morning after a PSG night (subject fasted) : 
– Blood samples (hematology and blood chemistry, only second morning at Visits 3, 6 and 8; PK, only second morning at Visits 6 and 8.  
• In the morning after a PSG night and after completion of normal morning routine (e.g., using the bathroom, eating breakfast): 
– Vital signs  
– C-SSRS
© (only second morning at Visits 3, 6 and 8) 
– Coding sub- test© 
– ISI© (only second morning at Visits 3, 6 and 8) 
– ESS© 
– SDS© 
– BWSQ (only second morning at Visits 3, 6, 8 and  9) 
– Morning questionnaire in sleep diary (including VAS) 
– PGI-S night- time symptoms (in the first morning at Visits 3, 6 and 8) 
– PGI-C night- time symptoms (in the first morning at Visits 3, 6 and 8) 
– Recording of concomitant medications 
– AEs and SAEs  
– Neurological examination  
– 12-lead ECG (only second morning at Visits 3 and 8) 
– Patient preferences questionnaire (PAUSe ; only second morning at Visit 8) 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 71/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
The following assessments will be analyzed by an external provider (results will be transferred to the Idorsia database and to the investigators): 
• Laboratory parameters  
• ECG parameters  
• PSG recordings  
• Questionnaires completed using a hand -held device (listed below). 
If the Principal Investigator (PI) delegates any study procedure/assessment for a subject, to 
an external facility, he/she must inform Idorsia to whom these tasks are delegated. The set -
up and oversight must be agreed upon with Idorsia. The supervision of any external facilities remains the responsibility of the PI.  
Calibration certificates / evidence of equipment maintenance for the below -listed 
equipment used to perform study assessments must be available prior to the sc reening of 
the first subject. Calibration certificates of other equipment must be available as per local requirements:  
• Temperature measurement devices for study treatment and sample storage area.  
• Polysomnographic device. 
Use of hand-held and tablet devices 
Subjects  will be required to complete the following questionnaires on a hand- held device:  
Epworth Sleepiness Scale© (ESS©), ISI©, SDS©, BWSQ, IDSIQ, PGA-S daytime 
symptoms , PGI -C daytime and night -time symptoms , PGI-S night- time symptoms , sleep 
diary (including VAS ). 
Subjects will be required to complete the following questionnaires on a tablet at the site:  
Patient preferences questionnaire (PAUSe).  
Investigators , delegated physicians , specialist nurses or nurse practi tioners trained 
according to local requirements and local clinical practice will be required to complete the following questionnaires on a tablet at the site: C -SSRS
©, MMSE©. 
Sites will be properly trained on the accurate use of the hand -held and tablet  devices by the 
sponsor or an external CRO and are then expected to train their subjects on how to 
appropriately complete the questionnaires. Data collected from the hand- held devices will 
be electronically transferred to Idorsia by the CRO.  
For further details refer to the tablet and hand- held devices manual.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 72/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
7.2.1 Demographics 
Demographic data to be collected in the eCRF for all subjects include: age, sex, race and ethnicity. Relevant medical history  / current medical conditions (e.g., chronic and ongoing 
acute conditions, serious past conditions)  present before signing informed consent will be 
recorded on the medical history page. Where possible, diagnoses and not symptoms will be recorded.  
Characteristics of insomnia will be captured on a specific Diagnosis eCRF page. 
Subject ’s information regarding CBT will be captured on a specific Medical History eCRF 
page.  
For subjects who failed screening, the following data will be collected  in the eCRF if 
available:  
• Demographics (i.e., age, sex, race and ethnicity)  
• Informed c onsent date  
• Reason for screeni ng failure  
• AEs. 
7.2.2 Efficacy assessments  
7.2.2.1 Polysomnography 
PSG data will be used to assess objective sleep parameters (WASO and LPS) as well as 
data on sleep architecture (sleep stages).  
PSG recordings must be performed by technologists who are familia r with th e recording 
techniques described in the investigator site operations manual for the acquisition, 
processing, scoring, archiving , and transfer of digital PSG data (provided by the central 
scoring CRO). The quality of PSG recordings is monitored and quality -controlled on an 
ongoing basis. Technologists must be able to follow the procedures in this manual in order to produce technically acceptable tracings. Technologists are not required to be registered PSG technologists. Technologists must receive study -specific training prior to their 
participation in the study. Documentation of technologists ’ prior experience and training, 
and study -specific training will be maintained at each clinical trial site. The sites and 
scorers that participate in this study must be  certified by the CRO. The center conditions 
must allow an undisturbed environment and PSG recordings must be conducted in a sleep laboratory environment that meets the guidelines for sleep disorder centers [aasmnet.org ]. 
During the S creening period , a PSG night will be performed if the subject meets all 
inclusion criteria and none of the exclusion criteria checked so far, and assesses AHI, PLMAI, and SpO
2. At Visit 3, the first PSG recording starts (lights off) within ± 30 min of 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 73/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
usual bedtime (determined by sleep diary between V isit 2 and V isit 3); this time is then 
considered as the habitual bedtime and held constant (±  15 min) throughout the study. 
Study medication is administered 30 min (±  5 min) before the recording starts. The PSG 
recording is stopped after 480 min when 960 epochs of 30 seconds have been recorded. PSGs will be performed as per the visit and assessment s chedule [Table 1].  
During the PSG recording, the subject is requested to stay in bed and remains connected to 
the recording equipment. However, if the subject needs to go to the bathroom, he/ she may 
do so and will be disconnected for this short time from the recording device. Alternatively, urine flasks or bedpans may be provided. The subject  must be re -connected as quickly as 
possible. The time during which the subject is disconnected will be scored as time awake. The subject is not permitted to perform any cognitive activity (such as reading, listening to radio, etc.), and is recommended not  to have a watch or access to any clock. The lights 
remain switched off until the 480 min of recording are finished. After recording is stopped, the lights are turned on and the subject is awakened and asked to perform the morning 
assessments.  
The centers  are required to transfer PSG data to the CRO responsible for central scoring, 
after the Visit 3 PSG visit and after V isit 6, Visit 8 and V isit 9 PSG visits. During the 
screening phase, PSG data obviously not fitting eligibility criteria at the first PSG  and at 
Visit 3 according to site scoring (more than 10% deviation from protocol range) are not 
required to be sent for central scoring. If anything prevents any PSG night being scored, the center must contact the monitor for instructions. After V isit 3, the CRO will score the 
PSG data obtained at the first PSG  and at Visit 3 immediately upon receipt and the center 
will receive the complete Eligibility Assessment (AHI, PLMAI, and the presence of any apnea/hypopnea or event associated with SpO
2 < 80% as assessed at Visit 1, and WASO, 
LPS and  TST as assessed at Visit 3) within 3 business days following file receipt by the 
CRO. These PSG data are evaluated and scored centrally by an independent scorer (expert 
from central reading CRO, not otherwise involved in the study). Based on this information, the investigator assesses the subject ’s potential eligibility.  
Results of all  PSG nights ( 1
st PSG, Visit 3, Visit 6, Visit 8, and V isit 9) for the randomized 
subjects are sent to Idorsia from the central scoring CRO. The following sleep variables assessed by PSG  include but are not limited to : WASO, LPS, TST, sleep stages S1 (also 
called N1), S2 (N2), SWS (N3) , REM (R), and Wake time during sleep (W). The 
definitions of the sleep variables are given in the scoring procedures of the central scoring CRO manual.  
The sponsor reserves the right to  request the site s to provide PSG data from the 1
st PSG 
night of screened failed subjects  to further characterize the patient population. In such case, 
the sites will be informed in due time.   
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 74/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
For more detailed information, refer to the investigator site operations manual for the acquisition, processing, scoring, archiving, and transfer of digital PSG data (provided by central scoring CRO).  
7.2.2.2 Sleep diary 
The sleep diary (also called eDiary) will be uploaded into an electronic hand -held device 
and given to the subjects at Visit 1. Sleep diaries will be available  in the subject ’s language, 
and must be completed daily from Visit 1 at screening and until V isit 10. 
The self -administered sleep diary includes a morning and evening questionnaire, and VAS.  
For further information about the set -up and the use of the sleep diary on the hand-held 
device, refer to the investigator site electronic Clinical Outcome Assessment study information guide (provided by CRF Health).  
7.2.2.2.1 Morning and evening questionnaire 
These questions collect information on self -reported sleep characteristics (sleep induction 
and maintenance), habitual napping, bedtime, and timing of study treatment intake.  The subject ’s answer t o the sleep diary question “What time did you get in to bed? ” is 
expected to be in th e time window of 21:30 to 00:30 for at least 50% of the nights  between 
Visit 2 and V isit 3. The median of the values falling into the time window of 21:30 to 00:30  
is defin ed as the usual bedtime and will be used to set the habitual bedtime. The subject ’s 
regular time in bed (i.e. , time calculated from “What time did you get into  bed? ” until 
“What time did you get out of bed for the day ?”) is expected to be in the time windo w of 
6 to 9 h, for at least 50% of the nights between V isit 2 and V isit 3. 
For further details, see Appendix 8.  
7.2.2.2.2 Visual analog scales 
The VAS collect s information on quality of sleep, depth of sleep, morning sleepiness, 
daytime alertness, and daytime ability to function by asking the subjects to report their 
feelings by placing a mark on a visual analog scale.  
Self-reported quality of sleep, depth of sleep and morning sleepiness are assessed in the 
morning. Self -reported daytime alertness and daytime ability to function are assessed in 
the evening.  
For further details, see Appendix 8.  
7.2.2.3 Insomnia Severity Index
© 
The ISI© assesses the severity of a patient ’s insomnia by scoring the severity of sleep  onset 
and sl eep maintenance difficulties and any insomnia- related interference with daytime 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 75/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
functioning [see Appendix 5] . The assessment is on a 5 -point scale (0 –4), where the 
composite score is obtained by summing the 7 rated dimensions measuring the subject ’s 
perception of his or her insomnia. A score of 15–21 indicates a moderate level of insomnia and a score of 22–28 indicates severe insomnia. An ISI
© total score < 10 indicates that the 
subject ’s subjective ly-rated insomnia symptoms, dayti me impairment, and quality of life 
have improved to the minimal- to-none range [Morin  1993, Scharf  2007] . The ISI© will be 
completed by the subject on the hand- held device at V isit 1, V isit 3, Visit 6, and V isit 8.  
7.2.2.4 Patient Global Assessment of Disease Severity  (daytime symptoms)  
The PGA -S (daytime symptoms) is a question concerning the overall severity of daytime 
symptoms (e.g., sleepiness) and impacts (e.g., effort to perform daily activities) that the subject m ay have experienced due to his/her insomnia over the 7 days preceding the PGA -
S. It is a self -administered question programmed on the hand- held device and is to be 
completed at V isit 1, Visit 2, Visit 3 1
st evening , Visit 6 1st evening , Visit 8 1st evening , 
Visit 10, and weekly in the evening at home from Visit 4 until EO DBT.  
For further details, see Appendix 9.  
7.2.2.5 Patient Global Impression of Change (daytime s ymptoms ) 
The PGI -C (daytime symptoms ) is a question concerning the change in overall severity of 
daytime symptoms (e.g., sleepiness) and impacts (e.g., effort to perform daily activities) that the subject may have experienced due to his/her insomnia over the 7 days preceding the PGI -C daytime symptoms compared to the week before  he/she started treatment. The 
PGI-C daytime symptoms is a self -administered question on the hand -held device and is to 
be completed at V isit 3 1
st evening , Visit 6 1st evening , Visit 8 1st evening, V isit 10, and 
weekly in the evening at home  from Visit 4 until EO DBT. 
For further details, see Appendix 9.  
7.2.2.6 Patient Global Impression of Change (n ight-time symptoms ) 
The PGI -C (night- time symptoms ) is a question concerning the change in the subject’s  
insomnia symptoms at night (e.g., trouble falling asleep, total time asleep, or number of 
times they wake up)  over the past week (7 nights)  preceding the PGI -C night- time 
symptoms compared to the week before the subject started treatment. The PGI -C 
night- time symptoms is a self -administered q uestion on the hand- held device and is to be 
completed at Visit 3  1st morning , Visit 6  1st morning , Visit 8  1st morning , Visit 10, and 
weekly in the morning at home from Visit 4 until EODBT.  
For further details, see Appendix 10.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 76/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
7.2.2.7 Patient Global Impression  of Severity (night -time symptoms)  
The PGI -S is a question concerning the overall severity of the subject’s night- time 
symptoms (e.g., trouble falling asleep, total time asleep, or number of times they wake up)  
that the subject may hav e experienced due to his/her insomnia over the past week (7  nights) 
preceding the PGI -S. It is a self -administered question programmed on the hand- held 
device and is to be completed at Visit 1, Visit 2, Visit 3  1st morning , Visit 6  1st morning, 
Visit 8  1st morning , Visit 10 and weekly  in the morning  at home  from Visit 4 until EODBT.  
For further details, please see Appendix 10. 
7.2.2.8 Insomnia Daytime Symptoms and Impacts Questionnaire 
The IDSIQ  is programmed on the electronic hand -held devic e in the subject ’s language, 
and must be completed every day in the evening before the evening sleep diary by the subject without study staff input or interference from Screening (V isit 1) until EOT  
(Visit 10).  
The IDSIQ is structured in 3 domains (i.e., a lertness/cognition; negative mood; 
tiredness/sleepiness) and contains overall 1 4 items, each based on an 11 -point numeric 
rating scale. This tool is based on an existing instrument, the Daytime Insomnia Symptom Scale [Buysse  2007] . The psychometric validation of the IDSIQ instrument was performed 
in study ID -078A203. 
For further details, see Appendix 11.  
7.2.3 Safety assessments  
The definitions, reporting and follow -up of AEs, SAEs and pregnancies are described in 
Section  9. 
7.2.3.1 Weight and height 
Height will be measured at Screening only (V isit 1) and recorded in the eCRF. 
Body weight will be measured at Screening (V isit 1) and EO DBT visit (V isit 8), and 
recor ded in the eCRF. BMI will be calculated at V isit 1 according to the BMI formula 
(weight in kg/m
2) and displayed automatically upon entry of weight and height in the 
eCRF.  
7.2.3.2 Physical examination  
Physical ex amination will be performed at S creening (V isit 1) and EO DBT visit (V isit 8) 
according to site standard medical practice for subjects with insomnia disorders.  
Other exams will be performed if indicated, based on medical history and/or symptoms.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 77/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
Information for all physical examinations must be included in the source documentation at the study site. The observations will not be directly reported in the eCRF. Clinically 
significant findings that are present prior to signing of ICF must be recorded on the Medical 
History eCRF form. Clinically significant p hysic al examination findings made after 
signing of informed consent that meet the definition of an AE [Section 9.1.1]  must be 
recorded on the AE form of the eCRF. 
7.2.3.3 Vital signs  
Systolic and diastolic BP and  pulse rate will be measured non- invas ively at each study visit 
from S creening (V isit 1) to EOT  (Visit 10).  
Vital sign s measurements will be collected in the eCRF.  
7.2.3.4 Coding s ub-test
© 
The Coding sub- test©, formerly known as Digit Symbol Substitution Test , is a measure o f 
attention, perceptual speed, motor speed, visual scanning and memory.  On a sheet of paper, the subject is given 120 seconds to complete as many substitutions as 
possible, entering a symbol in numbered boxes according to a key shown on the top of the sheet (9 symbols).  
The Coding sub- test
© is performed at Visit 3, Visit 6, Visit 8 and Visit 9. The number of 
correct substitutions is recorded as the total Coding sub- test© score and collected in the 
eCRF . 
For further details, see Appendix 4.  
7.2.3.5 Sheehan Disability Scale© 
The SDS© consists of 3 questions on impairment of work, social life, and family life  / home 
responsibilities [see Appendix 6; Sheehan  1996] . The SDS© is a self -administe red 
questionnaire on the hand-held device performed at Visit 3, Visit 6, Visit 8 and Visit 9.  
7.2.3.6 Columbia Suicide Severity Rating Scale© 
The C -SSRS© is an instrument that reports the presence and severity of both suicidal 
ideation and behaviors [Posner 2007]. Suicidal ideation is classified on a 5 -item scale:  
1. Wish to be dead 
2. Non-specific active suicidal thoughts  
3. Active suic idal ideation with any methods (not plan) without intent to act 
4. Active suicidal ideation with some  intent to act, without specific plan  
5. Active suicidal ideation with specific plan and intent 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 78/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
The C -SSRS© also captures information about the intensity of ideation, specifically the 
frequency, duration, controllability, deterrents, and reasons for the most severe types of 
ideation. In addition, the C -SSRS© captures information using yes/no question and answers 
on suicidal behaviors, specifically actual, interrupted, and aborted attempts; preparatory acts or behaviors; and if suicidal behaviors were present during the assessment period. More than one classification can be selected provided they represent separate episodes. For actual attempts only, the actual or potential lethality is classified for the initial, most lethal, and most recent attempts. The C -SSRS
© will be completed at all study visits  except Visit 
5 and Visit 11 (i.e., telephone call s). At Visit 1 (Screening) the C -SSRS© will be completed 
for the subject lifetime history of suicidal ideation and behaviors. At all other visits, the C -
SSRS© will be  completed for ideation and behaviors since the previous visit.  
At each visit, the investigator, a delegated physician, a specialist nurse or a nurse practitioner, trained according to local requirements and local clinical practice will complete this questionnaire with the subject on a tablet and assess the findings. 
7.2.3.7 Benzodiazepine Withdrawal Symptom Questionnaire  
The BWSQ assesses the main symptoms which might be experienced by subjects during 
withdrawal from benzodiazepines [see Appendix 7 ; Tyrer  1990] . The questionnaire 
consists of 20 items. The symptoms will be rated from 0 (No), 1 (Yes -moderate) to 
2 (Yes -severe). The questionnaire will be self -administered using the hand- held device  at 
Visit 3, Visit 6, Visit 8, Visit 9 and Visit 10. 
7.2.3.8 Mini International Neuropsychiatric Interview
© 
The MINI© is a psychiatric examination [Sheehan  1999]  and will identify subjects with 
exclusionary psychiatric conditions. The MINI© will be administered at Screening (Visit  1) 
by the investigator, a delegated physician, a specialist nurse or a nurse practitioner, trained according to local requirements and local clinical practice. The MINI
© Version  7.0.2 will 
be administered on paper to asc ertain the psychiatric diagnoses , and any clinically relevant 
psychiatric conditions will be reported in the eCRF. 
7.2.3.9 Mini Mental State Examination© 
The MMSE© is a simplified, scored form of the cognitive mental status examination [ see 
Appendix 13; Folstein  1975] . The MMSE© assesses orientation, attention, immediate and 
short- term recall, language, and the ability to follow simple verbal and written commands. 
The MMSE© will be administered at Screening (Visit 1) for subjects ≥ 50 years at the site 
on a tablet by the investigator, a delegated physician, a specialist nurse or a nurse 
practitioner, trained according to local requirements and local clinical practice . A subject 
with a score between 25 and 30 will be  eligible and a subject with a score below 25 has 
greater cognitive impairment and will be excluded.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 79/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
7.2.3.10 Neurological examinations 
At 1st PSG night, V isit 3, Visit 6, Visit 8, and V isit 9, a set of examinations must be 
performed approximately 1 hour after lights on [see Section 7.2]. The neurological 
examinations will be done by the investigator, a delegated physician, a specialist nurse or a nurse practitioner, trained according to local requirements and local clinical practice. The following examinations will be performed to detect a possible next-day residual effect:  
• Gait 
• Tandem walking  
• Romberg t est 
In the event of clinical ly significant findings, the set of examinations must be repeated 
approximately every 30 min . until the subject is considered safe to leave the center  and the 
investigator must ensure  appropriate safety follow -up of the subject . All clinically 
significant findings must be recorded as AE s in the eCRF.   
Neurological examinations are recorded on the eCRF.  
7.2.3.11 Epworth Sleepiness Scale
© 
The ESS© is a validated questionnaire designed to provide a subjective measure of daytime 
sleepiness [Johns 1991 ]. The ESS© [see Appendix 12 ] will be self -administered at site 
visits ( Visit 1, Visit 2, Visit 3, Visit 6, Visit 8, and V isit 10) on a hand- held device  to assess 
daytime sleepiness . All clinically significant findings must be recorded as AE s in the eCRF.  
7.2.3.12 ECG assessment  
A standard 12-lead ECG is to be performed  at Visit 1, in the second morning of V isit 3, 
Visit 8 and at V isit 10. 
12-lead ECG will be recorded at rest with the subject in the supine position . Data records 
will be sent to the evaluation center for central reading.  
Details will be provided in the 12- lead E CG laboratory manual.  
The following parameters will be evaluated: PQ or PR (ms), QRS (ms), QT (ms), heart rate 
(HR; bpm), and rhythm. QTc (ms) will be calculated according to: 
• Bazett ’s formula: QTcB = QT / (RR)1/2 
and 
• Fridericia’ s formula: QTcF = QT / (RR )1/3, where RR = 60 / HR 
If the central review of the ECG detects a prolonged QTcB and/or QTcF interval greater 
than 450 ms for a subject at screening (V isit 1 or Visit 3), the ECG must be repeated (at 
least 30 min after first ECG). If the central review c onfirms that the repeated ECG shows 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 80/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
a QTcB and/or QTcF interval greater than 450 ms, the subject cannot be enrolled into the study.  
Clinically significant findings detected after signing of ICF which meet the definition of 
an AE must be recorded in the eC RF.  
ECG data collected by the CRO will be electronically transferred to Idorsia.  
7.2.4 Patient preferences questionnaire 
The DCE methodology requires the presentation of several possible comparative scenarios, 
(i.e., Treatment A and Treatment B) showing specif ic treatment outcomes (benefits and 
risks). After each treatment scenario, subjects will be asked to make choices about the type of treatment they would be willing to take. The patient preferences questionnaire is programmed on the tablet site device in the subject’s language (i.e., US English for USA and German for Germany), and if subjects consent to participate to this sub -study, must be 
completed at Randomization (Visit 4) and at EODBT visit (Visit 8, 2
nd morning). 
For further details, see Appendix 14.  
7.2.5 Laboratory assessments 
7.2.5.1 Type of laboratory 
A central laboratory (see central laboratory manual for contact details) will be used for all protocol- mandated laboratory tests  until EOS , including follow-up tests due to abnormal 
labora tory findings and laboratory tests performed at unscheduled visits. 
Local laboratory results of the parameters described in Section  7.2.5.2 will only be 
collected in exceptional circumstances (e.g., hospitalization of the subje ct due to a medical 
emergency).  The local laboratory results (with the corresponding normal ranges) must be 
recorded in the eCRF.  
If a central laboratory sample is lost or cannot be analyzed for whatever reason, it is 
recommended to the investigator to collect an additional sample as soon as possible for repeat analysis.  
No repeat test is allowed if the subject does not meet the eligibility criteria.  
Central laboratory reports will be sent to the investigator. In the event of specific (pre-defined) laborato ry abnormalities, the central laboratory will alert Idorsia  personnel 
and the concerned site personnel. 
All laboratory reports must be reviewed, signed, and dated by the investigator or delegate 
within 10 working days of receipt and filed with the source documentation. The 
investigator/delegate must indicate on the laboratory report whether abnormal values ar e 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 81/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
considered clinically significant  or not. Clinically significant  laboratory findings present 
before  signing of the ICF must be recorded on the Medical History page of the eCRF. Any 
clinically significant laboratory abnormalities detected after signing of ICF must be 
reported as an AE or SAE as appropriate [see Section  9], and must be followed up until the 
value returns to within the normal range or is stable, or until the change is no longer 
clinically significant. 
Details about the collection, sampling, storage, shipment procedures, and reporting of 
results and abnormal findings can be found in the laborator y manual.  Blood samples will 
be drawn under fasted condition (i.e., before breakfast) at Visit 3, Visit 6, Visit 7  and 
Visit 8. 
7.2.5.2 Laboratory tests 
Hematology  
• Hemoglobin  
• Hematocrit  
• Erythrocytes  
• Reticulocyte  
• Leukocytes with differential counts  
• Platelets  
Clinical chemistry  
• ALT  
• AST  
• Alkaline phosphatase  
• Creatine kinase  
• Total and direct bilirubin  
• Gamma -glutamyl transferase  
• Creatinine and c reatinine clearance  
• Blood urea nitrogen  
• Uric acid  
• Glucose  
• Cholesterol, triglycerides  
• Sodium, potassium, chloride, calcium  
• Albumin  
• Thyroid hormones, i.e., triiodothyronine (total and free) and thyroxine (total and 
free), and thyroid -stimulating hormone.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 82/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
Pregnancy test  
A serum pregnancy test for women of childbearing potential will be performed at S creening 
(Visit 1) and on the second morning of V isit 8. A urine pregnancy  test will be performed 
on Visit 2, Visit 4, on the first evening of V isit 6, Visit 7  and at run -out (V isit 10). If 
pregnancy is suspected during the study, a serum pregnancy test must be performed immediately.  
Other tests  
The urine drug screening kits (testing for presence of benzodiazepines, barbiturates, cannabinoids, opiates, amphetamines, phencyclidine  or cocaine) and the breathalyzer for 
alcohol detection in the exhaled breath will be provided by the central laboratory.  Should 
any technical issue arise with the breathalyzer,  alcohol saliva tests will be provided to be 
used as back -up. 
Study drug is administered as described in Section  5 only if the results of the pregna ncy 
tests and other tests are negative.  
7.2.6 Pharmacokinetic assessments  
PK samples will be collected in the morning after the second PSG night, after lights on, approximately 9 –10 h post -dose (i.e., 30–90 min after lights on) at V isit 6 and V isit 8 or in 
the event of excessive sleepiness based on the investigator’s opinion. 
The date and the time of blood sample collection will be entered in the eCRF. The date and time of the last study treatment dosing before blood draw will be entered in the eCRF. The site personnel will ship the plasma samples to the central laboratory. The central laboratory will ship the samples to Idor sia Drug Metabolism and Pharmacokinetics department, who 
are in charge of the PK sample analysis.  
Details about the collection, sampling, storage , and shipment procedures can be found in 
the laboratory manual.  
8 STUDY COMPLETION AND POST-STUDY TREATMENT / 
MEDICAL CARE 
8.1 Study completion as per protocol 
A subject who completes the study treatment phase and the safety follow -up phase is 
considered to have completed the study as per protocol. Subjects who completed the study 
until the end of the run-out period will have the possibility to participate in the extension 
study ID -078A303 and will complete the safety follow -up phase  at the end of  the exten sion.  
8.2 Premature withdrawal from study 
Subjects may voluntarily withdraw from the study without justification for any reason at any time. Subjects are considered withdrawn  from study  if they state an intention to 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 83/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
withdraw further participation in all compo nents of the study (i.e., withdrawal of consent), 
die, or are lost to follow -up. If a subject withdraws consent, no further data will be collected 
in the eCRF from the date of withdrawal onward. Withdrawal from the study may also result from a decision by Idorsia for any reason, including premature termination or 
suspension of the study. 
Subjects are considered as lost to follow -up if all reasonable attempts by the investigator 
to communicate with the individual failed. The site must take preventive measure s to avoid 
a subject being lost to follow -up (e.g., document different ways of contact such as 
telephone number, home address, email address, person to be contacted if the subject 
cannot be reached). If the subject cannot be reached, the site must make a r easonable effort 
to contact the subject, document all attempts, and enter the loss of follow -up information 
into the eCRF. The following methods must be used: at least three telephone calls must be 
placed to the last available telephone number and one regi stered letter must be sent by post 
to the last available home address. Additional methods may be acceptable if they are compliant with local rules/regulations (e.g., a visit by site personnel to the subject’ s home), 
respecting the subject ’s right to privac y. If the subject is still unreachable after all contact 
attempts listed above, he/she will be considered to be lost to follow-up. 
If premature withdrawal occurs for any reason, the reason (if known) for premature 
withdrawal from the study (e.g. , withdrawa l by subject, AE, lost to follow -up, death) must 
be recorded in the eCRF.  
If, for whatever reason (except death or loss -to-follow-up), a subject is withdrawn from the 
study, the investigator should make efforts to schedule a last appointment / telephone ca ll 
to assess the safety and well -being of the subject, collect unused study treatment and 
discuss follow -up medical care. Data obtained during this last appointment / telephone call 
will be recorded in the subjects ’ medical records but it will not be colle cted in the eCRF. 
The investigator must provide follow -up medical care for all subjects who are prematurely 
withdrawn from the study, or must refer them for appropriate ongoing care, as described in Section 8.4. 
8.3 Premature termination or suspension of the study 
Idorsia reserves the right to terminate the study at any time globally or locally. Investigators can terminate the participation of their site in the study at any time.  
If the study is prematurely suspended or terminated, Idorsia will promptly inform the 
investigators, IECs/IRBs  and health authorities, as appropriate, and provide the reasons for 
the suspension or termination. 
If the study is suspended or prematurely terminated for any reason, the investigator – in 
agreement with Idorsia – must promptly inform all enrolled subjects and ensure their 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 84/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
appropriate treatment and follow -up, as described in Section 8.4. Idorsia may inform the 
investigator of additional procedures to be followed in order to ensure that adequate consideration is given to the protection of the subjects’ interests.  
In addition, if the investigator suspends or terminates the part icipation in  the study without 
prior agreement from Idorsia, the investigator must promptly inform Idorsia personnel and the IEC/IRB, and provide both with a detailed written explanation of the termination or suspension. 
If the IEC/IRB suspends or terminates its approval / favorable opinion of the study, the 
investigator must promptly notify Idorsia personnel and provide a detailed written 
explanation of the termination or suspension. 
8.4 Medical care of subjects after study completion / withdrawal from study 
After the subject ’s study completion or premature withdrawal from the study, whichever 
applies, the investigator/delegate will explain to subjects what treatment / medical care is necessary and available according to local regulations.  
9 SAFETY DEFINITIONS AND REPORTING REQUIREMENTS 
9.1 Adverse events  
9.1.1 Definition of adverse event s 
An AE is any untoward medical occurrence, i.e., any unfavorable and unintended sign, including an abnormal laboratory finding, symptom, or disease that occurs in a subject during the course of the study, whether or not considered by the investigator as r elated to 
study treatment.  
A TEAE is any AE temporally associated with the use of study treatment ( i.e., emerging 
from DB study treatment initiation until up to 30 days after DB study treatment 
discontinuation or until enrollment into the extension study ) whether or not considered by 
the investigator as related to study treatment.  
AEs include: 
• Exacerbation of a pre- existing disease.  
• Increase in frequency or intensity of a pre- existing episodic disease or medical 
condition. 
• Disease or medical condition detected or diagnosed during the course of the study even 
though it may have been present prior to the start of the study. 
• Continuous persistent disease or symptoms present at study start that worsen following the signing of informed consent. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 85/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
• Abnormal assessmen ts, e.g., change on physical examination, ECG findings, if they 
represent a clinically significant finding that was not present at study start or worsened 
during the course of the study. 
• Laboratory test abnormalities if they represent a clinically signific ant finding, 
symptomatic or not, which was not present at study start or worsened during the course of the study, or led to interruption or permanent discontinuation of study treatment. 
Overdose, misuse, abuse of the study treatment and study treatment errors will be reported as an AE.  
The ISB will adjudicate treatment -emergent AESIs which are similar to, or indicate: 
• narcolepsy -like symptoms (i.e. , EDS, cataplexy and complex sleep behavior events 
including hallucinations/sleep paralysis)  
• suicide/self -injury 
A treatment -emergent AESI is any AESI emerging from DB study treatment initiation until 
up to 30 days after DB study treatment discontinuation or until enrollment into the 
extension study. 
9.1.2 Intensity of adverse events  
The intensity of clinical AEs is grad ed on a three -point scale – mild, moderate, severe – 
and is reported on specific AE pages of the eCRF.  
Any increases in intensity of an AE during the study will be reported in the eCRF.  The three categories of intensity are defined as follows:  
 Mild  
The ev ent may be noticeable to the subject. It does not usually influence daily activities, 
and normally does not require intervention. 
 Moderate  
The event may make the subject uncomfortable. Performance of daily activities may be 
influenced, and intervention may be needed.  
 Severe  
The event may cause noticeable discomfort and usually interferes with daily activities. The subject may not be able to continue in the study, and treatment or intervention is usually needed.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 86/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
A mild, moderate, or severe AE may or may not be serious [see Section  9.2.1 ]. These terms 
are used to describe the intensity of a specific event. Medical judgment should be used on a case -by-case basis.  
Seriousness, rather than intensity assessment, determines the regulatory reporting obligations. 
9.1.3 Relationship to study treatment  
Each AE must be assessed by the investigator as to whether or not there is a reasonable 
possibility of causal relationship to the study treatment, and reported as either related or unrelated. The de termination of the likelihood that the study treatment caused the AE will 
be provided by the investigator. 
9.1.4 Reporting of adverse events  
The investigator will ask the subject to report all AEs at each study visit, including the 
telephone calls.  
All AEs with  an onset date after signing of informed consent and up to EOS  for subjects 
that are not enrolled in ID-078A303 extension study must be recorded on AE pages of the 
eCRF.  
All AEs with an onset date after signing of informed consent , and up to enrol lment in the 
ID-078A303 (i.e., ID -078A302 EO T) for subjects that are participating  in the extension 
study, must be recorded on AE pages of the ID-078A302 eCRF. 
9.1.5 Follow- up of adverse events  
AEs still ongoing more than 30 days after EOS  for subjects that are not enrolled in the 
ID-078A303 extension study must be followed up until they are no longer considered 
clinically relevant or until stabilization. The follow -up information obtained after the 
subject ’s EOS telephone call will not be collected by Idorsia.  
For subjec ts enrolle d in ID-078A303, AEs that are ongoing at ID -078A302 EO T will be 
followed up in the extension study  and reported in the ID -078A303 eCRF on a dedicated 
page. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 87/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
9.2 Serious adverse events 
9.2.1 Definitions of serious adverse events  
An SAE is defined by the ICH guidelines as any AE fulfilling at least one of the following 
criteria:  
• Fatal.  
• Life-threatening: Refers to an event in which the subject was at risk of death at the time 
of the event. It does not refer to an event that hypothetically might have caused deat h 
had it been more severe.  
• Requiring in-patient hospitalization or prolongation of existing hospitalization. 
• Resulting in persistent or significant disability or incapacity.  
• Congenital anomaly or birth defect. 
• Medically significant: Refers to important medical events that may not immediately result in death, be life -threatening, or require hospitalization but may be considered to 
be SAEs when, based upon appropriate medical judgment, they may jeopardize the subject, and may require medical or surgical inter vention to prevent one of the 
outcomes listed in the definitions above. 
The following reasons for hospitalization are not considered as SAEs: 
• Hospitalization for cosmetic elective surgery, or social and/or convenience reasons. 
• Hospitalization for pre -planned (i.e., planned prior to signing informed consent) 
surgery or standard monitoring of a pre -existing disease or medical condition that did 
not worsen, e.g., hospitalization for coronary angiography in a subject with stable 
angina pectoris.  
However, complications that occur during hospitalization are AEs or SAEs (e.g., if a complication prolongs hospitalization). 
9.2.2 Reporting of serious adverse events  
All SAEs occurring after signing of informed consent  up to EOS  must be reported on AE 
pages in the eCRF and on an SAE form, regardless of the investigator -attributed causal 
relationship with study treatment or study -mandated procedures.  
All SAEs with an onset date after signing of informed consent and up to enrollment in 
ID-078A303 (i.e., ID -078A302 EO T) for subje cts that are participating in the extension 
study must be recorded on AE pages of the ID-078A302 eCRF. 
An SAE is defined as related to protocol -mandated procedures if it appears to have a 
reasonable possibility of a causal relationship to either the study design or to 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 88/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
protocol- mandated procedures (e.g., discontinuation of a subject ’s previous treatment 
during a washout period, leading to exacerbation of underlying disease). 
9.2.3 Follow- up of serious adverse events  
SAEs still ongoing more than 30 days after EOS  must be followed up until resolution or 
stabilization, or until the event outcome is provided. The follow -up information obtained 
after the subject ’s EOS telephone call must be reported to Idorsia Global Drug Safety, but 
it is not recorded in the eCRF. For subjects enrolled in  ID-078A303, SAEs that are ongoing at ID -078A302 EO T will be 
followed up in the extension study and reported in the ID -078A303 eCRF on a dedicated 
page.  
9.2.4 After the 30 -day follow- up period  
New SAEs occurring after the 30 -day follow- up period must be reported to Idorsia Global 
Drug Safety within 24 hours of the investigator ’s knowledge of the event, only if 
considered by the investigator to be causally related to previous exposure to the study 
treatment.  
9.2.5 Reporting procedures  
All SAEs must be reported by the investigator to Idorsia Global Drug Safety within 24 hours of the investigator’ s first knowledge of the event.  
All SAEs must be recorded on an SAE form, irrespective of the study treatment received by the subject, and whether or not this event is considered by the investigator to be related to study treatment.  
The SAE forms must be sent to Idorsia Global Drug Safety (contact details are provided on the SAE form). The investigator must complete the SAE form in English, and must assess the e vent’ s causal relationship to the study treatment.  
Any relevant information from source documents regarding the SAE, e.g., hospital notes or discharge summaries, etc., must be summarized on the SAE form. 
Follow- up information about a previously reported SAE must also be reported within 
24 hours of receiving it. Idorsia Global Drug Safety personnel may contact the investigator 
to obtain further information. 
If the subject is hospitalized in a hospital other than the study site, it is the investigator ’s 
respo nsibility to contact this hospital to obtain all SAE -relevant information and 
documentation. The expectedness of an adverse reaction is determined by Idorsia in the reference safety 
information (RSI) section provided in the most recent version of the IB fo r ACT -541468 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 89/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
[ACT -541468 IB]. Any SAE that is assessed as related and unexpected against the RSI of 
the ACT -541468 IB [ACT -541468 IB] is known as a SUSAR and must be reported b y 
Idorsia to concerned health authorities (including the EudraVigilance database if the study is conducted in Europe), IECs/IRBs and investigators. 
9.3 Pregnancy 
If a woman becomes pregnant while on study treatment, study treatment must be discontinued. The investigator must counsel the subject and discuss the risks of continuing with the pregnancy and the possible effects on the fetus. 
9.3.1 Reporting of pregnancy  
Irrespective of the treatment received by the subject, any pregnancy occurring after study 
start (i.e.,  signing of informed consent) up to EOS  must be reported within 24 hours of the 
investigator ’s knowledge of the event. 
Pregnancies must be reported on the Idorsia Pregnancy form, which is faxed to Idorsia Global Drug Safety (see contact details provided on the Pregnancy form), and on an AE 
page in the eCRF.  
9.3.2 Follow- up of pregnancy  
Pregnancies must be followed -up to their conclusion for all randomized subjects and the 
outcome must be reported to Idorsia Global Drug Safety. 
Any AE associated with the pregnancy  occurring during the follow -up period after DB 
study treatment discontinuation must be reported on separate AE pages in the eCRF. Any 
SAE occurring during the pregnancy must be reported on an SAE form as described in 
Section  9.2.5. 
9.4 Study safety monitoring 
Study safety information (AEs, SAEs, laboratory values, ECGs, vital signs, and study- specific examinations as required) is monitored and reviewed on a continuous basis 
by the Idorsia  Clinical Team (in charge of ensuring subjec ts’ safety as well as data quality). 
In addition, an IDMC and an ISB are monitoring safety data [see Section  3.2.2] . 
10 STATISTICAL METHODS 
All statistical analyses will be conducted by Idorsia or by designated CRO s supervised by 
Idorsia.  
A Statistical Analysis Plan (SAP) will provide full details of the analyses, data displays, and algorithms to be used for data derivations. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 90/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
10.1 Analysis sets 
A subject must have given informed consent before being included in any analy sis set.  
10.1.1 Screened Analysis Set  
The Screened Analysis Set includes all subjects who entered screening and have a subject 
identification number. 
10.1.2 Full Analysis Set  
The Full Analysis Set (FAS) includes all subjects assigned to a DB study treatment. In 
order to  adhere to the intention- to-treat principle as much as possible: 
• Subjects are evaluated according to the treatment and strata they have been assigned 
to, which may differ from t he treatment they have received;  
• All available data are included.  
10.1.3 Per-Protocol Set  
The Per -Protocol Set (PPS) comprises all subjects from the FAS who complied with the 
protocol sufficiently to be likely to exhibit the treatment effects. Criteria for sufficient compliance include exposure to treatment, availability of measurements , and absence of 
major protocol deviations that have an impact on the treatment effect. The full list of criteria will be finalized before unblinding treatment codes.  
10.1.4 Safety Set  
The Safety Set includes all subjects who received at least one dose of DB study treatment. 
Subjects will be evaluated according to the actual treatment they received, which may differ from the randomly assigned treatment. 
10.1.5 Treatment Withdrawal Set  
The Treatment Withdrawal Set comprises all subjects included in the Safety Set who 
received  single -blind placebo treatment in the run-out period. 
10.1.6 Pharmacokinetic Analysis Set  
The Pharmacokinetic Analysis Set (PK Set) includes all subjects in the Safety Set who have at least 1 PK sample collected after initiation of  DB study treatment. Subjects 
receiving placebo will be excluded from the PK set. 
10.1.7 Patient Preferences Analysis Set  
The Patient Preferences Analysis Set includes all subjects in the Safety Set who have 
answered at least one patient preferences questionnaire after initiation of study treatment.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 91/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
10.1.8 Usage of the analysis sets 
The analyses of efficacy endpoints including baseline and disease characteristics will be performed using the FAS, and the PPS for certain sensitivity analyses.  
The Safety Set will be used for the analys is of safety endpoints (including  previous and 
concomitant medications, and study treatment exposure). 
Subject data will be listed using the Safety Set, unless otherwise specified.  
The Treatment Withdrawal Set will be used for the analysis of endpoints used to assess 
withdra wal symptoms (e.g. , BWSQ total score) and rebound insomnia (e.g., objective and 
subjective sleep parameters: WASO, LPS, TST, sWASO, sLSO, and sTST).  
The analysis of ACT -541468 plasma concentrations 9–10 h post -dose will be performed 
using the PK Set.  
The Patient Preferences Analysis Set will be used for the analysis of endpoints to assess 
patient preferences.  
10.2 Variables 
Detailed description of study efficacy and safety variables (endpoints) can be found in 
Section  6 of this protocol.  
10.3 Description of statistical analyses 
10.3.1 Analysis of the primary and secondary efficacy variables 
10.3.1.1 Overall testing strategy  
The Type I error rate will be controlled for the testing of multiple null hypotheses associated with the primary and secondary endpoints assessed at 1 and 3 months of treatment  and the two dose levels included in this study, i.e., 10 mg and 25 mg. 
The eight statistical null hypotheses associated with the primary efficacy endpoints are: 
Sleep maintenance:  
• H1WASO : Higher Dose – Placebo = 0 for WASO at Month 1 
• H2WASO : Higher Dose – Placebo = 0 for WASO at Month 3 
• H3WASO : Lower Dose – Placebo = 0 for WASO at Month 1 
• H4WASO : Lower Dose – Placebo = 0 for WASO at Month 3 
Sleep onset:  
• H1LPS: Higher Dose – Placebo = 0 for LPS at Month 1 
• H2LPS: Higher Dose – Placebo = 0 for LPS at Month 3 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 92/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
• H3LPS: Lower Dose – Placebo = 0 for LPS at Month 1 
• H4LPS: Lower Dose – Placebo = 0 for LPS at Month 3 
The eight statistical null hypotheses associated with the secondary efficacy endpoints are:  
Sleep quantity: 
• H1sTST: Higher Dose – Placebo = 0 for sTST at Month 1 
• H2sTST: Higher Dose – Placebo = 0 for sTST at Month 3 
• H3sTST: Lower Dose – Placebo = 0 for sTST at Month 1 
• H4sTST: Lower Dose – Placebo = 0 for sTST at Month 3 
Next day performance:  
• H1IDSIQ: Higher Dose – Placebo = 0 for IDSIQ sleepiness domain score at Month 1 
• H2IDSIQ: Higher Dose – Placebo = 0 for IDSIQ sleepiness domain score at Month 3 
• H3IDSIQ: Lower Dose – Placebo = 0 for IDSIQ sleepiness domain score at Month 1 
• H4IDSIQ: Lower Dose – Placebo = 0 for ID SIQ sleepiness domain score at Month 3 
where ‘Higher Dose ’, ‘Lower Dose ’, and ‘ Placebo ’ represent the mean change from 
baseline for the given endpoint (WASO, LPS, sTST or IDSIQ sleepiness domain score) 
and time  point (Month 1 or Month 3) for the 25 mg, 10 mg and placebo treatment group, 
respectively.  
Each null hypothesis will be tested against the alternative hypothesis: that ACT -541468 
improves WASO  / LPS / sTST / IDSIQ sleepiness domain score at the given dose ( 10 or 
25 mg) and time  point (Month 1 or Month 3) compared to placebo. 
The order of testing and the alpha level applied to each null hypothesis will be based on the Bonferroni -based gatekeeping procedure [Bretz  2009 ] (shown in Figure 2 below as a 
direct ed graph) that will control the study -wise Type I error at a two -sided 5% significance 
level. To account for the concurrent evaluation (multiple comparison) of two distinct 
endpoint categories (i.e., sleep maintenance and sleep onset) a Bonferroni correcti on is 
applied. Both endpoint categories will be tested at half of the two- sided 5% significance 
level. This supports the sponsor’ s intention  to make a su periority claim versu s placebo for 
efficacy in either a sleep maintenance and/or sleep onset indication . The remaining 
hypotheses will be tested following the gatekeeping strategy moving from Month 1 to Month 3 for higher dose ACT -541468 vs placebo and then from Month 1 to Month 3 for 
lower dose ACT -541468 vs  placebo. The pre -specified proportion of alpha t hat will be 
distributed once a given null hypothesis (node) is rejected is shown on the arrow in the directed graph. If a certain null hypothesis cannot be rejected, then the alpha level used for that test is absorbed at that node and not distributed further.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 93/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
Figure 2 Hypothesis testing strategy 
 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 94/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
10.3.1.2 Hypotheses and statistical model 
The main analysis will be performed using the FAS. 
A longitudinal data analysis method (i.e., linear mixed effects model) will be used for t he 
analysis of change from baseline in WASO, LPS, sTST, and IDSIQ scores, separately.  All 
available data, regardless of occurrence of intercurrent events (e.g., study treatment discontinuation, the use of prohibited medication), will be included in the model.  
The analysis model will adjust for the baseline value of the relevant response variable (either WASO, LPS, sTST or IDSIQ sleepiness domain score), age group (<  65; 
≥ 65 years), treatment (higher dose; lower dose; placebo), time point (Month 1; Month 3), and the interaction of treatment by time  point, and baseline by time point. 
To evaluate the efficacy hypotheses, appropriate contrasts will be used to test the treatment differences of interest (i.e., the difference in Least Squares  mean change from baseline  
between higher dose ACT -541468 vs  placebo and lower dose ACT -541468 vs  placebo at 
Month 1 and Month 3). An unstructured covariance matrix will be used to model the correlation among repeated measurements. This approach relies on the missing at random (MAR ) assumption. 
A term for ‘center ’ is not included in the statistical model due to the low numbers of 
subjects expected in many centers.  Randomization was not stratified by center for the same 
reason.  
10.3.1.3 Handling of missing data 
For WASO and LPS values, if one  of the two values is missing either for baseline, Month 1 
or Month 3, the single value available will be used a s the mean for this time point. 
Otherwise, the mean value will be considered missing for that time point. 
For sTST values, subjects must have at  least 3 days of data during each week to calculate 
a weekly mean. Otherwise, the mean value will be considered missing for that week.  
For IDSIQ sleepiness domain scores, subjects must have at least 4 days of data during each 
week to calculate a weekly mean. Otherwise, the mean value will be considered missing for that week. 
Note that the above implies implicit imputation: the missing data point(s) is(are) given the 
same value as the mean of the non -missing data point(s)  of that same week or time point. 
10.3.1.4 Supportive/sensitivity analyses  
The impact of deviations from the MAR assumption underlying the linear mixed effects model as well as the incidence and pattern of missing values will be explored in order to evaluate the possible impact on results and will be described in the SAP. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 95/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
The analysis performed for the primary and secondary endpoints will be repeated using the PPS in order to assess the effect protocol deviations have on the results. 
10.3.2 Analysis of other efficacy variables 
Summary statistics will be provided for other efficacy endpoints using either number (%) 
of subjects for categorical variables or descriptive statistics (e.g. , mean, SD, median, min ., 
max.) for continuous variables. Further details will be described in the SAP.  
10.3.3 Analysis of the safety var iables  
Analyses of safety endpoints will be performed using the Safety Set, unless noted otherwise.  
Adverse events  
AEs will be coded using MedDRA. The number (%) of subjects experiencing a TEAE  
(including SAE s, AESIs  after adjudication by  the ISB, and AE s leading to premature 
discontinuation of the DB study treatment) will be summarized by System Organ Class 
(SOC ) and/or PT, and maximum intensity. A subject with multiple intensities reported for 
an AE will be summarized under the maximum intensity recorded for the event. A subject with multiple occurrences of an AE is counted only once in the AE category (e.g., SOC, PT). 
Laboratory data 
Laboratory analyses will be based on data received from the central laboratory. Observed 
values and changes from baseline t o Month 1 and Month 3 in both hematology and blood 
chemistry laboratory parameters will be summarized. The number (%) of subjects having a marked laboratory abnormality during DB  study t reatment  will be tabulated.  
Vital signs  and weight  
Observed values and  changes from baseline to Month 1 and Month 3 in vital signs (mean 
of the two PSG nights in systolic and diastolic  BP, and  pulse rate) will be summarized.  
Observed values and changes from baseline to Month 3 in body weight will be summarized . 
Electrocardio grams  
Observed values and changes from baseline to Month 3 for each ECG parameter (QT cB, 
QTcF, heart rate, PR, QRS) will be summarized. The number (%) of subjects having a 
marked ECG abnormality during DB  study treatment will be tabulated.  
Withdrawal sympt oms 
The Treatment Withdrawal Set will be used to assess the potential for withdrawal 
symptoms.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 96/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
The BWSQ total score will be summarized using descriptive statistics for the observed values and changes from the last assessment on DB treatment (Visit 8, 2
nd morning) to the 
beginning and the end of the treatment withdrawal period (in the morning at V isit 9 and at 
Visit 10, respectively).  
In addition, withdrawal symptoms after DB study treatment withdrawal will be assessed 
through the incidence of AEs and marked ECG abnormalities occurring during the 
treatment withdrawal period. The number (%) of subjects having, separately, an AE and a marked ECG abnormality during the treatment withdrawal period will be tabulated.  
Insomnia rebound effect  
The Treatment Withdrawal Set will be used to assess the potential for rebound insomnia. 
The changes from baseline to the treatment withdrawal period (V isit 9, run- out) in 
objective sleep parameters (WASO, LPS and TST) will be summarized using descriptive statistics.  
The changes from baseline ( mean value based on the screening sleep diary entries 
performed at home  in the 7 days immediately preceding the first PSG at V isit 3) to the 
treatment withdrawal period (after PSG night at V isit 9) in subjective sleep parameters 
(sWASO, sLSO, and sTST) will be summarized using descriptive statistics.  
Next -day residual effect  
Observed values and changes from baseline to Month 1 and Month 3 in Coding sub- test
©, 
SDS©, and VAS scores (mm) assessing morning sleepiness, daytime alertness and daytim e 
ability to function, will be summarized.  
C-SSRS© 
Number (%) of subjects with suicidal ideation, suicidal behavior, and/or self -injurious 
behavior without suicidal intent based on the C -SSRS© during DB treatment will be 
tabulated.  
Shifts from baseline showing any changes in suicidal ideation and suicidal behavior during DB treatment will also be provided. Subjects will be summarized under the worst of the 
following three categories, shown here in the order from best to worst: 1) No suicidal ideation or behavior, 2) Suicidal ideation only, and 3) Suicidal ideation and behavior. 
10.3.4 Analysis of p harmacokinetic variables 
PK analyses will be performed using the PK S et. 
Descriptive statistics (n, mean, standard deviation, coefficient of variation [ CV% ], m 
[number of  non- zero concentrations], geometric mean, geometric standard deviation, 
geometric CV%, median, minimum and maximum) of the ACT -541468 plasma 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 97/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
concentrations collected approximately 9–10 h post -dose (morning after the second PSG 
night) at Visit 6 and V isit 8 will be provided. 
Exposure-safety analysis  
The exposure -safety relationship will be explored using C 9–10h (plasma concentrations of 
ACT -541468 in the morning after the second PSG night at V isit 6 and V isit 8) and will be 
based on the PK Set. Safety param eters considered for this analysis will likely include 
selected AEs (e.g., somnolence), changes from baseline in C oding sub- test©, SDS©, VAS 
scores (mm) assessing morning sleepiness, daytime alertness and daytime ability to function, and other parameters a s relevant. Further details will be described in the SAP.  
10.3.5 Subgroup analyses 
Subgroup analyses will be conducted to explore the uniformity of the overall treatment effects with regards to efficacy and safety variables and  will be described in the SAP. 
10.3.6 Analy sis of the patient preferences variable 
Discrete choice data from the PAUSe sub -study will be analyzed using multinomial logit, 
random parameter logit, latent class and heteroscedastic conditional logit models. Socio -demographic and clinical characteristics, and health literacy and numeracy data will 
be collected from the study participants, and used as covariates for assessing preference and scale heterogeneity. The results of the DCE may be used to specify the weights and partial value functions in a quantitative benefit- risk assessment (BRA) of insomnia 
treatments. The BRA will be run both deterministically and probabilistically and will facilitate a stochastic multicriteria acceptability analysis (SMAA). The SMAA will involve running up to 10,000 iterations of the BRA, each time sampling weights and performance inputs from pre -specified distributions. Further details on analysis of the PAUSe sub- study 
will be provided in a separate SAP.  
10.4 Interim analyses 
No formal interim analysis will be performed for determining whether to stop (or modify) the study early (i.e., no hypothesis testing will be conducted ad interim ). Therefore, no 
adjustment for multiple testing is required. This study includes an IDMC and ISB that will assess the safety of ACT -541468 on a regular basis as per the IDMC and ISB charter s, 
respectively. To support the review of the safety and efficacy data by the IDMC, blinded 
data will be provided by Idorsia (or designated CRO) for the open sessions, and unblinded data will be provided by the ISAC for the closed sessions. 
10.5 Sample size  
The assumptions used to calculate sample size are provided in Table 2. 
ACT-541468 
Insomnia disorder 
Protocol ID-078A302 
Version 5 8 November 2018, 
page 99/154 Confidential  EudraCT 2017-004643-20 
Doc No D-18.262 
 
 Figure 3 Effect of testing multiple null hypotheses on power at  a given sample 
size 
 
11 DATA HANDLING 
11.1 Data collection 
The investigator/delegate is responsible for ensuring the accur acy, completeness and 
timeliness of the data reported. All source documents are recom mended to be completed 
in a neat, legible manner to ensure accurate inter pretation of the data. Data reported in the 
eCRF derived from source documents must be consistent with the source documents. 
eCRF data will be reported through electronic data capture (a w eb-based tool). The 
investigator and site personnel will be trained to enter and ed it the data via a secure 
network, with secure access features (username, password, and identification – an 
electronic password system). A c omplete electronic audit trail will be maintained. The 
investigator/delegate will approve the data (i.e., confirm the accuracy of the data recorded) 
using an electronic signatur e (ref. to US 21 CFR Part 11). 5060708090100Effect size = 0.37
Number of independent null hypothesesPower (%)based on two-sample z-test (alpha = 2.5% two-sided)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20N = 350 per group
N = 300 per group
N = 250 per group
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 100/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
Entries recorded by the subject on the hand- held device (i.e., ESS©, sleep diary, VAS, ISI©, 
IDSIQ, PGA -S daytime symptoms , PGI -C daytime and night -time symptoms , PGI-S 
night- time symptoms , SDS©, BWSQ) and on paper (i.e., Coding sub- test©) as well as the 
physician -reported global assessment on a tablet  at site (i.e., C -SSRS©, MMSE©, PAUSe ) 
and on paper (i.e., MINI©) are considered source data. Site personnel will review and 
ensure completeness and  readability of the subjects ’ entries.  Site personne l will be allowed 
to instigate correction or deletion of subject metadata or answers  in physician -reported 
assessments. Site personnel will not be allowed to alter subject -generated data. A data 
correctio n form will be completed by the site personnel to request any  data changes and 
sent to the CRO provider that will process the changes as per CRO data management procedures. 
Subject screening and enrollment data will be completed for all subjects (i.e., eli gible and 
non-eligible) through the IRT system and eCRF.  
For each subject enrolled, regardless of study treatment initiation, an eCRF must be 
completed and signed by the investigator/delegate. This also applies to those subjects who fail to complete the study. If a subject withdraws from the study, the reason must be noted on the eCRF. 
11.2 Maintenance of data confidentiality 
The investigator/delegate must ensure that data confidentiality is maintained. On eCRFs or other documents (e.g., documents attached to SA E forms / Pregnancy forms) submitted to 
Idorsia and any CROs, subjects must be identified only by number and never by their name or initials, date of birth, hospital numbers, or any other identifier. The investigator/delegate must keep a subject identifica tion code list at the site, showing the screening/randomization 
number, the subject ’s name, date of birth, and address or any other locally accepted 
identifiers. Documents identifying the subjects (e.g., signed ICFs) must not be sent to Idorsia, and must be kept in strict confidence by the investigator/delegate.  
11.3 Database management and quality control 
eCRFs will be used for all subjects. The investigators will have access to the site eCRF 
data until the database is locked. Thereafter, they will have read -only access. The eCRF 
must be kept current to reflect subject status at any time point during the course of the study.  
While entering the data, the investigator/delegate will be instantly alerted to data queries 
by validated programmed checks. Additional dat a review will be performed by Idorsia 
personnel on an ongoing basis to look for unexpected patterns in data and for study 
monitoring. If discrepant data are detected, a query specifying the problem and requesting 
clarification will be issued and visible to  the investigator/delegate via the eCRF. All 
electronic queries visible in the system either require a data correction (when applicable) 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 101/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
and a response from the investigator/delegate to clarify the queried data directly in the eCRF, or simply a data correction in the eCRF.  
This process will continue until database closure. The investigator/delegate must, on request, supply Idorsia with any required background 
data from the study documentation or clinical records. This is particularly important when errors in data transcription are suspected. In the event  of health authority queries, it is also 
necessary to have access to the complete study records, provided that subject confidentiality is protected.  
Laboratory samples, ECGs, PSGs and hand- held device data w ill be processed through a 
central laboratory / CRO and the results will be electronically sent to Idorsia.  
If local laboratory data is obtained, as may be required per protocol in certain instances, it 
must be entered in the eCRF by the site personnel.  
AEs are coded according to the latest version of MedDRA used by Idorsia. 
After the database has been declared complete and accurate, the database will be locked. 
Any changes to the database after that time may only be made as described in the appropriate Idorsia QS doc ument s. After database closure, the investigator will receive the 
eCRFs of the subjects of his/her site (including the audit trail) on electronic media or as a 
paper copy.  
12 PROCEDURES AND GOOD CLINICAL PRACTICE 
12.1 Ethics and Good Clinical Practice 
Idorsia personnel and the investigators will ensure that the study is conducted in full 
compliance with ICH -GCP Guidelines, the principles of the “Declaration of Helsinki” , and 
with the laws and regulations of the country in which the study is conducted. 
12.2 Independent Ethics Committee / Institutional Review Board 
The investigator will submit this protocol and any related document(s) provided to the subject (such as the ICF) to an IEC/IRB. Approval from the committee/board must be obtained before starting the study, and must be documented in a dated letter to the investigator, clearly identifying the study, the documents reviewed, and the date of approval. 
Modifications made to the protocol or the ICF after receipt of the approval must also be 
submitted as amend ments by the investigator to the IEC/IRB in accordance with local 
procedures and regulations [see Section 12.6].  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 102/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
A list of members participating in the IEC/IRB meetings must be provided, including the names, qualifications, and functions of these members. If that is not possible, the attempts made to obtain this information along with an explanation as to why it cannot be obtained or disclosed must be documented in the study documentation.  
If a member of the study personnel was  present during an IEC/IRB meeting, it must be 
clear that this person did not vote. 
12.3 Informed consent  
It is the responsibility of the investigator/delegate to obtain informed consent according to 
ICH-GCP and Declaration of Helsinki guidelines and local regulations from each 
individual participating in this study. The investigator/delegate must explain to subjects that they are completely free to refuse to enter the study, or to voluntarily withdraw from the study at any time for any reason without having to provide any justification. Special attention shall be paid to the information needs of specific subject populations and of individual subjects, as well as to the methods used to give the information. Adequate time shall be given for the subject to consider  his or her decision to participate in the study and 
it shall be verified that the subject has understood the information (e.g., by asking the subject to explain what is going to happen). 
The ICF will be provided in the country local language(s). 
Site pers onnel authorized (according to local regulation) to participate in the consent 
process and/or to obtain consent from the subject will be listed on the Delegation of 
Authority (DoA) form supplied by Idorsia. A study physician must always be involved in the consent process.  In European countries, the informed consent must be obtained by a 
physician.  
The subject and authorized site personnel listed on the DoA form supplied by Idorsia must sign, personally date, and time (if the first study -mandated procedure i s to be performed on 
the same day informed consent is obtained) the ICF before any study -related procedures 
(i.e., any procedures required by the protocol) begin.  
A copy of the signed and dated ICF is given to the subject, the original is filed in the sit e 
documentation. The informed consent process must be fully documented in the subject ’s 
medical records. This must include at a minimum the study reference, the subject number, 
the date and, if applicable, time when the subject was first introduced to the study, the date 
and, if applicable, time of consent, who participated in the consent discussion, who consented the subject, and any additional person present during the consent process (e.g., subject ’s family member[s]), and the information that a copy of the signed ICF was given 
to the subject. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 103/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
12.4 Compensation to subjects and investigators 
Idorsia provides insurance in order to indemnify (with both legal and financial coverage) 
the investigator/site against claims arising from the study, except for claims tha t arise from 
malpractice and/or negligence.  
The compensation of the subject in the event of study -related injuries will comply with 
applicable regulations. Study subjects will be reimbursed for the study -related expenses 
(e.g., travel costs, meals, hotel), and may be offered financial compensation for their 
participation in the study only to the extent permitted by applicable local regulations.  
12.5 Protocol adherence/compliance 
The investigator must conduct the study in compliance with the IEC/IRB and/or the regulatory authority -approved version of the protocol and must not implement any 
deviation/change from the protocol, except when deviation is necessary to eliminate an immediate hazard to the subject.  
If a protocol deviation occurs, the investigator/delegate  will inform Idorsia or its 
representative in a timely manner. The investigator/delegate must document and explain any deviation from the approved protocol. Deviations considered to be a violation of ICH-GCP must be reported to the IEC/IRB and regulatory authorities according to Idorsia 
or (overruling) local requirements. 
All protocol deviations will be reported in the CSR. IECs/IRBs will be provided with 
listings of protocol deviations as per local requirements. 
12.6 Protocol amendments 
Any change to the protocol can only be made through a written protocol amendment. An amended protocol must be submitted to the IEC/IRB and regulatory authorities, according to their requirements.  
12.7 Essential documents and retention of documents 
The investigator/delegate must mainta in adequate records necessary for the reconstruction 
and evaluation of the study. A number of attributes are considered of universal importance to source data and the records that hold those data. These include that the data and records are accurate, legib le, contemporaneous, original (or certified copy), attributable, complete, 
consistent, enduring, and available when needed. 
These records are to be classified into two different categories of documents: ISF and 
subjects ’ source documents. 
These records mus t be kept by the investigator for 25 years  to comply with Idorsia ’s 
requirements (i.e., as specified in the clinical study agreement), and national and/or 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 104/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
international regulations, whichever would be the longest period. If the investigator cannot guarante e this archiving requirement at the site for any or all of the documents, special 
arrangements, respecting the data confidentiality, must be made between the investigator and Idorsia to store these documents outside the site, so that they can be retrieved in the 
event  of a regulatory inspection. No study document should be destroyed without prior 
written approval from Idorsia. Should the investigator wish to assign the study records to another party, or move them to another location, Idorsia must be notified in advance. 
If the site is using an electronic/computerized system to store subject medical records, it 
can be used for the purpose of the clinical study if it is validated (as per US 21 CFR Part  11 
or equivalent standard) and if the CRA has been provide d personal and restricted access to 
study subjects only, to verify consistency between electronic source data and the eCRF during monitoring visits.  
If the site is using an electronic/computerized system to store subject medical records but it could not be  confirmed that the system is validated or if the CRA could not be provided 
access to the system, the site is requested to print the complete set of source data needed for verification by the CRA. The print outs must be numbered, stapled together with a 
coversheet, signed and dated by the investigator/delegate to confirm that these certified 
copies are exact copies having the same information as the original source data. The printouts will be considered as the official clinical study records and must be file d either 
with the subject’s medical records or with the subject’ s eCRF.  
In order to verify that the process the site uses to prepare certified copies is reliable, the CRA must be able to observe this process and confirm that the comparison of the source documents and the certified copy did not reveal inconsistencies. The CRA does not need to verify this process for all data of all subjects but at least for some of them (e.g., first subject; regular check during the study of critical data like inclusion/exclusion criteria, endpoints for some subjects) as per Idorsia ’s instructions. If it were not possible for the 
CRA to observe this process, it would not be possible to rely on the site ’s certified copies 
and therefore the site cannot be selected for the clinical study.  
12.8 Monitoring 
Prior to study start, a Site Initiation Visit (SIV) will be performed after the required 
essential study documents are approved by Idorsia. The study treatment will be shipped to the site upon approval of the required essential documents. 
The PI must ensure that all site personnel involved in the study are present during the SIV 
and will dedicate enough time to it. Site Information Technology support should also be available during the SIV.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 105/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
The SIV must be completed before the site can  start the screening of study subjects. 
Following the SIV, a copy of the completed initiation visit report and follow- up letter will 
be provided to the PI and filed in the ISF. 
During the study, the CRA will contact and visit the site regularly and must be  permitted, 
on request, to have access to study facilities and all source documents needed to verify 
adherence to the protocol and the completeness, consistency, and accuracy of the data being entered in the eCRFs and other protocol -related documents. Idorsia monitoring standards 
require full verification that informed consent has been provided, verification of adherence to the inclusion/exclusion criteria, documentation of SAEs, and the recording of the main efficacy, safety, and tolerability endpoints. Additional checks of the consistency of the source data with the eCRFs will be performed according to the study -specific monitoring 
guidelines. The frequency of the monitoring visits will be based on subject recruitment rate and critical data- collection time s. 
The PI must ensure that the eCRF is completed after a subject ’s visit (site visit or telephone 
call), and that all requested subject files (e.g., ICFs, medical notes/charts, other documentation verifying the activities conducted for the study) are avail able for review by 
the CRA. The required site personnel must be available during monitoring visits and allow adequate time to meet with the CRA to discuss study -related issues.  
The investigator agrees to cooperate with the CRA(s) to ensure that any issues detected in the course of these monitoring visits are resolved. If the subject is hospitalized or dies in a hospital other than the study site, the investigator is responsible for contacting that hospital in order to document the SAE, in accordance with local regulations.  
A close- out visit will be performed for any initiated site when there are no more active 
subjects and all follow-up issues have been resolved. If a site does not enroll any subjects, the close- out visit may be performed prior to study data base closure at the discretion of 
Idorsia.  
12.9 Investigator Site File 
Each site will be provided with an ISF prior to the SIV. It will contain all the essential documents that are required to be up- to-date and filed at site as per ICH -GCP section 8. 
The ISF wi ll include a table of content s listing the essential documents. All study -related 
documentation must be maintained in the ISF. 
In some cases, exceptions can be discussed with the CRA regarding the filing of the study 
documents outside the ISF. It should be  clearly documented where each document is filed. 
This note to file should be present in the specific tab of the document in the ISF. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 106/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
The ISF must be stored in a secure and access -restricted area during and after the study. It 
must be kept by the site for as long as needed to comply with any applicable rules and 
regulations, ICH- GCP, as well as instructions from Idorsia. If the site needs to transfer the 
ISF to another location and/or if site facility can no longer store the ISF, the PI must immediately inf orm Idorsia. 
If the PI will change, or if the site will relocate, the CRA must be notified as soon as possible. 
12.10  Audit  
Idorsia ’s Pharmaceutical Development group  representatives or delegates may audit the 
investigator site (during the study or after its completion). The purpose of this visit will be to determine the investigator ’s adherence to ICH -GCP, the protocol, and applicable 
regulations; adherence to Idorsia’s requirements (e.g., standard operating procedures) will also be verified. Prior to initiating  this audit, the investigator will be contacted by Idorsia 
to arrange a time for the audit.  
The investigator and site personnel must cooperate with the auditor(s) and allow access to all study documentation (e.g., subject records) and facilities. 
12.11  Inspectio ns 
Health authorities and/or IEC s/IRB s may also conduct an inspection of this study (during 
the study or after its completion) at the site.  
Should an inspection be announced by a health authority and/or IEC/IRB, the investigator must immediately inform Ido rsia (usually via the CRA) that such a request has been made.  
The investigator and site personnel must cooperate with inspector(s) and allow access to all study documentation (e.g., subject records) and study facilities. 
12.12  Reporting of study results and publication 
Idorsia will post the key elements of this protocol and the summary of results on Idorsia ’s 
Clinical Trial Register and within the required timelines on publicly accessible databases (e.g., clinicaltrials.gov, EU database), as required by law and regulation. 
Study results will be documented in a CSR (the PAUSe sub -study results from both 
ID-078A301 and ID -078A302 studies will be reported in a separate CSR) that will be 
signed by Idorsia representatives and the Coordinating Investigator. 
In accordanc e with the Good Publication Practices and ethical practice, the results of the 
study will be submitted for publication in a peer -reviewed journal. Study results can be 
submitted for presentation at a congress before submission to a peer-reviewed journal. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 107/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
Authorship will be determined in accordance with the International Committee of Journal 
Editors criteria, and be based on: 
• substantial contributions to the conception or design of the study, or the acquisition, 
analysis, or interpretation of data; and 
• draft ing of the publication or critical review for important intellectual content; and  
• providing final approval of the version to be published; and 
• agreement to be accountable for all aspects of the work in ensuring that questions 
related to the accuracy or int egrity of any part of the work are appropriately 
investigated and resolved. 
The list of authors of any publication of study results may include representatives of Idorsia and will be determined by mutual agreement.  
Any study -related publication written ind ependently by investigators must be submitted to 
Idorsia for review at least 30 days prior to submission for publication or presentation at a congress. Upon review, Idorsia may provide comments, and may also request alterations and/or deletions for the sole purpose of protecting its confidential information and/or patent rights. Neither the institution nor the investigator should permit publication during such a review period. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 108/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
13 REFERENCES 
[D-15.653] Double -blind, placebo- controlled, randomized, single ascending dose study to 
investigate the tolerability, safety, pharmacokinetics, pharmacodynamics, absolute 
bioavailability, mass balance, and metabolism of ACT -541468 in healthy male 
subjects. Actelion Pharmaceuticals Ltd. Clinical Study Report AC -078- 101. 4 Ma rch 
2016. 
[D-16.087] A single -center, open- label, randomized, two- way crossover study to 
investigate the effect of multiple -dose diltiazem on the pharmacokinetics of a single 
dose of 25 mg ACT -541468 in healthy male subjects. Actelion Pharmaceuticals Ltd. 
Clinical Study Report AC -078-103. 28 April 2016.  
[D-16.386] Double -blind, placebo- controlled, randomized study to investigate the 
tolerability, safety, pharmacokinetics, and pharmacodynamics of ACT -541468: Part 
A: Multiple -ascending doses in healthy young  adults after morning administration; 
Part B: Single -ascending doses in healthy elderly subjects after morning 
administration; Part C: Repeated doses in both healthy young adults and elderly subjects after evening administration. Actelion Pharmaceuticals Ltd. Clinical Study Report AC-078-102. 7 November 2016. 
[D-17.098] A single -center, open- label study to investigate the food effect on the 
pharmacokinetics of ACT -541468 and the effect of single - and multiple -dose 
ACT -541468 on the pharmacokinetics of midaz olam and its metabolite 
1-hydroxymidazolam in healthy male subjects. Idorsia Pharmaceuticals Ltd. Clinical 
Study Report AC-078-104. 28 November 2017. 
[ACT -541468 IB] Investigator ’s Brochure for ACT -541468 version 5. Idorsia 
Pharmaceuticals Ltd . January  2018. 
[aasmnet.org] American Academy of Sleep Medicine Standards and Guidelines for the 
Practice of Sleep Medicine, [regularly updated]. Available from:   
http://www.aasmnet.org  
[Ambien
® USPI] Ambien® (zolpidem) US Package Insert. United States Food and Drug 
Administration full prescribing information;  
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019908s038lbl.pdf  
[Ancoli- Israel  1999] Ancoli- Israel S, Roth T. Characteristics of insomnia in the United 
States: results of the 1991 National Sleep Foundation Survey. Sleep. 1999;22 Suppl 
2:S354-58. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 109/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
[APA 2013] American Psychiatric Association. Diagnostic and statistical manual of 
mental disorders , Fifth Edition . Arlington, VA: American Psychiatric Publishing ; 
2013. 
[Balter  1991] Balter MB, Uhlenhuth EHJ. The beneficial and adver se effects of hypnotics. 
J Clin  Psychiatry . 1991;52 Suppl:16-23.  
[Belsomra® USPI] Belsomra® (suvorexant) US Package Insert. United States Food and 
Drug Administration full prescribing information; http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204569s000lbledt.pdf 
[Benca 2004] Benca RM, Ancoli -Israel S, Moldofsky H. Special considerations in 
insomnia diagnosis and management: depressed, elderly, and chronic pain populations. J Clin Psychiatry. 2004;65 Suppl 8:26-35. 
[Bowli ng 2001] Bowling A, Ebrahim S. Measuring patients’ preferences for treatment and 
perceptions of risk. Quality in Health Care. 2001;10(Supplement 1):i2–i8  
[Bretz  2009] Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to 
sequentially rejective mu ltiple test procedures. Stat Med . 2009;28:586-604. 
[Bridges  2011] Bridges JFP, Hauber AB, Marshall D, Lloyd A, Prosser L.A, Regier DA, 
et al. Conjoint Analysis Applications in Health —a Checklist: A Report of the ISPOR 
Good Research Practices for Conjoint A nalysis Task Force, Value in Health 
2011;14,403– 413. 
[Buscemi  2007] Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M, et 
al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta -
analysis of RCTs. J Gen Intern Med. 2007;22(9):1335-50. 
[Buys se 2007] Buys se DJ, Thompson W, Scott J, Franzen PL, Germain A, Hall M, et al. 
Daytime symptoms in primary insomnia: a prospective analysis using ecological momentary assessment. Sleep Med. 2007 Apr;8(3):198–208. 
[Citrome  2014] Citrome L. Suvorexant for insomnia: a systematic review of the efficacy 
and safety profile for this newly approved hypnotic - what is the number needed to 
treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract . 
2014;68(12):1429-41.  
[Clark 2014] Clark MD, Determann D, Petrou S, Moro D, de Bekker -Grob EW. Discrete 
choice experiments in health economics: a review of the literature. Pharmacoeconomics. 2014;32(9):883-902. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 110/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
[Coyle  2001] Coyle D, Wells G, Graham I, et al. The impact of risk on preference values: 
Implications for evaluations of postmenopausal osteoporosis therapy. Value in Health. 2001;4(5):385–91.  
[de Lecea 1998] de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, et al. 
The hypocretins: hypothalamus -speci fic peptides with neuroexcitatory activity. Proc 
Natl Acad Sci USA . 1998;95:322–7. 
[Desarnaud  2004] Desarnaud F, Murillo- Rodriguez E, Lin L, Xu M, Gerashchenko D, 
Shiromani SN, et al. The diurnal rhythm of hypocretin in young and old F344 rats. Sleep . 2004;27:851–6. 
[EMA  2011] European Medicines Agency  guideline on medicinal products for the 
treatment of insomnia . EMA/CHMP/16274/2009 Rev. 1. 7 February 2011. Available 
from:   
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/02/WC500102351.pdf 
[FDA  1977] Food and Drug Administration (US): Guideline for the clinical evaluation of 
hypnotic drugs. September 1977; Available from:  https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071711.pdf 
[FDA  2007] Food and Drug Administration (US) Requests Label Change for All Sleep 
Disorder Drug Products.  Available from:   
https://www.ptcommunity.com/news/20170421/fda- requests -label -change- all-
sleep -disorder- drug-products 
[FDA  2017] Food and Drug Administration (US): Assessment of Abuse Potential of 
Drugs. January 2017; Available from:  https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm198650.pdf 
[Folstein  1975] Folstein MF, Folstein SE, McHugh PR. “Mini- mental state ”: A p ractical 
method for grading the cognitive state of patients for the clinician. J. Psychiat. Res. 1975;12:189-98 
[Ford  1989] Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and 
psychiatric disorders. An opportunity for prevention? JAMA . 1989;262(11):1479-
84. 
[Fortier -Brochu 2014] Fortier -Brochu E, Morin CM. Cognitive impairment in individuals 
with insomnia: clinical significance and correlates. Sleep . 2014;37(11):1787-98.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 111/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
[Hagan  1999] Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S, et al. 
Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci USA . 1999;96:10911–6. 
[Herring  2016] Herring WJ, Connor KM, Ivgy -May N, Snyder E, Liu K, Snavely DB, et 
al. Suvorexant in patients with insomnia: Results from two 3- month randomized 
controlled clinical trials. Biol Psychiatry. 2016;79(2):136-48. 
[Hohagen 1994] Hohagen F, Käppler C, Schramm E, Riemann D, We yerer S, Berger M. 
Sleep onset i nsomnia, sleep maintaining insomnia and i nsomni a with early mor ning 
awakening -tempo ral stability of subtypes in a longitudinal study on general practice 
attenders. Sleep . 1994;17(6):551-4.  
[Holbrook 2000] Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta -analysis 
of benzodiazepine use in the treatment of insomnia. CMAJ. 2000;162(2):225-33. 
[Johns 1991] Johns MW. A new method for measuring daytime sleepiness: the Epworth 
Sleepiness Scale. Sleep. 1991;14(6):540-5. 
[Kales  1978] Kales A, Scharf MB, Kales JD. Rebound insomnia: a new clinical syndrome. 
Science. 1978;201(4360):1039-41.  
[Kilduff 2000] Kilduff TS, Peyron C. The hypocretin/orexin ligand- receptor system: 
implications for sleep and sleep disorders. Trends Neurosci. 2000;23:359–65. 
[Kuriyama  2014] Kuriyama A, Honda M, Hayashino Y. Ramelteon for the treatment of 
insomnia in adults: a systematic review and meta -analysis. Sleep Med . 
2014;15(4):385-92.  
[Léger  2002] Léger D, Guilleminault C, Bader G, Lévy E, Paillard M. Medical and socio-
professional impact of insomnia. Sleep. 2002;25(6):625-9. 
[Lieberman  2007] Lieberman JA. Update on the safety considerations in the management 
of insomnia with hypnotics: incorporating modified -release formulations into 
primary care. Prim Care Companion J Clin Psychiatry. 2007;9(1):25-31. 
[Lin 1999] Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, et al. The sleep disorder 
canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999;98(3):365-76. 
[Lunesta
® USPI] Lunesta® (eszopiclone) US Package Insert. United States Food and Drug 
Administration full prescribing information;  http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 112/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
 
[McCall  2004] McCall WV. Sleep in the elderly: Burden, diagnosis, and t reatment. Prim 
Care Companion J Clin Psychiatry. 2004;6(1):9–20. 
[Mignot 2002] Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S, et 
al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002;59(10):1553–62. 
[Morin  1993] Morin CM, Kowatch RA, Barry T, Walton E. Cognitive -behavior therapy 
for late -life insomnia. J Consult Clin Psychol. 1993;61(1):137-46.  
[Neubauer  2014] Neubauer DN. New and emerging pharmacotherapeutic approaches for 
insomnia. Int  Rev Psychiatry. 2014;26(2):214-24. 
[NIH  2005] N ational Institutes of Health, State -of-the- Science Conference Statement on 
Manifestations and Management of Chronic Insomnia in Adults. NIH Consensus and State -of-the- Science Statements . 2005 Jun;13-15;22(2):1-30. 
[Nutt  2006] Nutt D. GABAA receptors: subtypes, regional distribution, and function. J 
Clin Sleep Med . 2006;2(2):Suppl S7-11.  
[Ohayon 2001] Ohayon MM, Zulley J, Guilleminault C, Smirne S, Priest RG. How age 
and daytime activities are related to insomnia in the general population: consequences for older people. J Am Geriatr Soc. 2001;49(4):360–6. 
[Ohayon 2002] Ohayon MM, Smirne S. Prevalence and consequences of insomnia 
disorders in the general population of Italy. Sleep Med. 2002;3(2):115–20. 
[Ohayon 2004] Ohayon MM, Carskadon MA, Guilleminault C, Vitiello MV. Meta -
analysis  of quantitative sleep parameters from childhood to old age in healthy 
individuals: developing normative sleep values across the human lifespan. Sleep. 2004;27(7):1255–73. 
[Ohayon 2010] Ohayon MM, Sagales T. Prevalence of insomnia  and sleep characteristics 
in the general population of Spain. Sleep Med. 2010;11(10):1010–8. 
[Pauker  1981] Pauker SG, McNeil BJ. Impact of patient preferences on the selection of 
therapy. J Chronic Dis. 1981; 34(2–3):77–86 
[Petursson 1981] Petursson H, La der MH. Benzodiazepine dependence. Br J Addict . 
1981;76(2):133-45. 
[Pigeon 2007] Pigeon WR, Crabtree VM, Scherer MR. The future of behavioral sleep 
medicine. J Clin Sleep Med. 2007;3(1):73-9. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 113/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
[Pigeon  
2010] Treatment of adult insomnia with cognitive -behavio ral therapy. J Clin 
Psychol. 2010;66(11):1148–60. 
[Posner 2007] Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia 
Classification Algorithm of Suicide Assessment (C -CASA): classification of suicidal 
events in the FDA ’s pediatric suicidal risk ana lysis of antidepressants. Am J 
Psych iatry. 2007 Jul;164(7):1035-43. 
[Rosenthal 1993] Rosenthal L, Roehrs TA, Rosen A, Roth T. Level of sleepiness and total 
sleep time following various time in bed conditions. Sleep. 1993;16(3):226-32 
[Roth 2007] Roth T. Insomnia: Definition, Prevalence, Etiology, and Consequences. J Clin 
Sleep Med . 2007;3 Suppl 5:S7-10. 
[Sakurai  2007] Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and 
wakefulness. Nat Rev Neurosci. 2007;8:171–81. 
[Samson  2010] Samson WK, Bagley SL, Ferguson AV, White MM. Orexin receptor 
subtype activation and locomotor behaviour in the rat. Acta Physiol (Oxf) . 
2010;198:313–24. 
[Scharf  2007] Scharf MB, Black J, Hull S, Landin R, Farber R. Long -term nightly 
treatment with indiplon in adults with primary insomnia: results of a double -blind, 
placebo -controlled, 3-month study. Sleep. 2007;30(6):743-52.  
[Schutte-Rodin 2008] Schutte -Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical 
guideline for the evaluation and management of chronic insomnia in adults. J Clin 
Sleep Med.  2008;4:487–504. 
[Sheehan  1996] Sheehan DV, Harnett -Sheehan K, Raj BA. The measurement of disability. 
Int Clin Psychopharmacol 1996;11 Suppl 3:S89-95. 
[Sheehan  1999] Sheehan D, Janavs J, Baker R, Harnett-Sheehan K, Knapp E, Sheehan M. 
MINI international neuropsychiatric interview. J Clin Psychiatry . 1999:60(18):39-
60. 
[Simon  1997] Simon GE, VonKorff M. Prevalence, burden, and treatment of insomnia in 
primary care. Am J Psychiatry. 1997;154(10):1417-23. 
[Simpson 2008] Simpson D, Curran MP. Ramelteon: a review of its use in insomnia. 
Drugs . 2008;68(13):1901-19. 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 114/154 Confidential  Eudr aCT 2017 -004643 -20 
Doc No D- 18.262 
[Tervonen 
2017] Tervonen T, Gelhorn H, Sri Bhashyam S, Poon JL, Gries KS, Rentz A, 
et al. MCDA swing weighting and discrete choice experiments for elicitation of 
patient benefit -risk preferences: a critical assessment. Pharmacoepidemiol Drug Saf. 
2017;1–9. 
[Thannickal 2000] Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, 
Aldrich M, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuro n. 2000;27(3):469–74. 
[Treat  Guidel Med  Lett 2009] Drugs for insomnia. Treat Guidel Med Lett. 2009;7:23-6. 
[Tyrer  1990] Tyrer P, Murphy S, Riley P. The Benzodiazepine Withdrawal Symptom 
Questionnaire. J Affect Disord. 1990;19:53-61 
[Zammit 1999] Zammit GK, Weiner J, Damato N, Sillup GP, McMillan CA. Quality of 
life in people with insomnia. Sleep . 1999;22 Suppl 2:S379-85. 
[Zeitzer  2003] Zeitzer JM, Buckmaster CL, Parker KJ, Hauck CM, Lyons DM, Mignot E. 
Circadian and homeostatic regulation of hypocretin in a  primate model: implications 
for the consolidation of wakefulness. J Neurosci. 2003;23:3555–60.
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November  2018,  page 115/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 
14 APPENDICES 
Appendix 1 Alcohol restrictions during the study  
The subjects must not drink alcohol for at least 24 hours prior to the start of the PSG 
assessments, as well as during the PSG assessments including the morning after the second 
PSG assessment, until they leave the center.  
On non- PSG nights, the subjects will be instructed to limit alcohol to a maximum of 
2 drinks per day, and to refrain from drinking alcohol at least 3 hours before going to bed. 
A drink is defined as: 
a.A bottle/can of 33 cL / 12 ounces of beer (≈14 grams alcohol)
b.A glass of 10 –12 cL / 4 ounces of wine (≈12 grams alcohol)
c.A small glass of 3 –4 cL  / 1 ounce of liquor (≈9 grams alcohol)
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November  2018,  page 116/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 
Appendix 2 C
affeine content of common beverages  
The content of caffeine in common caffeine beverages is approximately:  
a.A standard cup of brewed or restaurant- style coffee contains approximately
150–200 mg caffeine.
b. A can of most soda drinks (unless decaffeinated soda drinks) contains approximately
50 mg caffeine.
c.A can of energy drink contains approximately 150–200 mg caffeine.
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November  2018,  page 117/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 
Appendix 3 F
orbidden and restricted concomitant medications  
1. Forbidden (F) or restricted (R) concomitant medications due to CNS side effects.
To be eligible, subjects must not be treated with CNS- active drugs for 5 half -lives of
the respective drug (but at least 2 weeks) prior to V isit 1. The use of CNS- active
drugs is forbidden or restricted until 24 hours after EOT  (Visit 10).
Drug Class  Examples  Forbidden 
/ Restricted  Comment  
Centrally Acting 
Anticholinergics  e.g., tropatepine, oxybutynin,
solifenacin , dimenhydrinate,
dextromet horphan.F 
Antihistamines  Sedating : e.g., carbinoxamine, 
triprolidine HCl, acrivastine, 
azatadine, chlorpheniramine, 
doxylamine, hydroxyzine, ketotifen, promethazine & timeprazine, 
diphenhydramine HCl.  F 
Non-sedating : e.g., cetirizine, 
desloratidine, fexofenadine, levocabasteine, loratidine.  R 
Non-sedating 
antihistamines may be used 
maximum t wice weekly for 
allergic symptoms.  
Psychotropics  Stimulants:  e.g., amphetamine 
derivatives, eph edrine derivatives, 
modafinil, armodafinil, 
methylphenidate , aripiprazole, 
pramipexole, levodopa.  F 
Antidepres sants:  e.g., bupropion, 
citalopram, doxepin, du loxetine, 
escitalopram, fluoxetine, fluvoxamine, nefazodone, paroxetine, sertraline, trazodone,  
amitriptyline, clomipramine, desipramine, imipramine, mirtazapine, nortriptyline, 
trimipramine , venlafaxine , 
hydracarbazine, moclobemide, selegiline.  F 
Antip sychoti cs, including depot 
neuroleptics : e.g., quetiapine, 
olanzapine. F 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November  2018,  page 118/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 
Anxiolytics:  e.g., alprazolam, 
buspirone, clorazepate, diazepam, 
flurazepam, lorazepam, midazolam, 
quazepam, t emazepam, triazolam . F 
Hypnotics:  e.g., ramelteon, 
suvorexant, zolp idem and OTC . F 
Cholineste rase inhibitors : e.g., 
donepezil, galantamine. 
Mood stabiliz ers, e.g., 
carbamazepine, gabapentin, 
lamotrigine, lithium, oxcarbazepine, pregabalin, valproic acid, tiagabin e. F 
Opioids/Na rcotics : e.g., codeine, 
oxycodone, heroin, marijuana . R Use of narcotics for pain relief must be avoided if 
there are effective alternative medications 
(such as NSAIDs)  
Centrally  acting muscle relaxants 
with psychotropic effects : e.g., 
methocarbamol , tetrazepam. R Use of centrally acting 
muscle relaxants must be 
avoided if there are 
effective alternative medications (such as 
NSAIDs)  
Herbal prepar ations with possible 
psychotropic effects : e.g., St John ’s 
Wort, valerian, passiflora , 
hypericum.  F 
Others:  e. g., tryptophan , melatonin.  F 
Anticonvulsants  Barbiturates, b enzodiazepines,  
GABA analogs, hydantoins  
phenyltriazines (e.g ., lamotrigine)  
succinimides (e.g., ethosuximide)  F 
Other  Warfarin, heparin, t iclopidine  F 
Isotrenito in  F 
Systemic  glucocorticoids:  e.g., 
dexamethasone, methylprednisone, prednisone . F Inhaled corticosteroids are 
permitted  
Diet pills (pr escription and OTC) . F 
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November  2018,  page 119/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 
Pseudoephedrine  R May only be used before 
2 pm, and no more than 
twice a week. Dosage is 
limited to 30 mg of active 
ingredient in each tablet. Extended release 
formulations are forbidden.  
Anti-emetics:  e.g., domperidone, 
metoclopramide.  F 
GABA = gamma-aminobutyric acid; NSAID = nonsteroidal anti -inflammatory drug; OTC = over -the-counter.  
2.Non-exhaust
ive list of forbidden concomitant medications and diets due to potential
drug interactions with CYP3A4 (moderate and strong inhibitors, inducers).
Those medications must be discontinued no later than within 1 week prior to V isit 2
and are forbidden until 24 hours after EOT  (Visit 10).
CYP3A4 moderate and strong inhibitors and CYP3A4 moderate and strong inducers: 
Inhibitors of CYP3A4  Inducers of CYP3A4  
HIV antivirals: atazanavir, boceprevir, cobicistat, 
darunavir, delaviridine, fosamprenavir, indinavir, 
lopinavir, nelfinavir, ritonavir, saquinavir, 
telaprevir  HIV an tivirals: efavirenz, etravirine  
Antibiotics: ciprofloxacin, clarithromycin, 
erythromycin, norfloxacin, quinupristin, telithromycin, troleandomycin  Antibiotics: nafcillin, rifabutin, rif ampin  
Antifungal: fluconazole, itraconazole, 
ketoconazole, posaconazole, voriconazole 
CNS -active: fluvoxamine, nefazodone  CNS -active: carbamazepine, fenobarbital, 
modafinil, phenytoin, St. John’ s Wort  
Cardiovascular: amiodarone, diltiazem, 
dronedarone, verapamil  Cardiovascular: bosentan  
Aprepitant, coniv aptan, cimetidine, imatinib  
Grapefruit and grapefruit juice  
Seville oranges (bitter) and Seville oranges juice  
CNS = central nervous system; CYP = cytochrome P450; HIV = human immunodeficiency virus.  
ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November  2018,  page 120/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November  2018,  page 122/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November  2018,  page 123/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November  2018,  page 124/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November  2018,  page 125/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November  2018,  page 126/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November  2018,  page 127/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November  2018,  page 128/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November  2018,  page 129/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November  2018,  page 130/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November  2018,  page 131/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November  2018,  page 132/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November  2018,  page 133/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November  2018,  page 134/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November  2018,  page 135/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November  2018,  page 136/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
  

ACT-541468 
Insomnia disorder 
Protocol ID-078A302 Version 5 
8 November 2018, 
page 137/154 Confidential  EudraCT 2017-004643-20 
Doc No D-18.262 
 

ACT-541468 
Insomnia disorder 
Protocol ID-078A302 Version 5 
8 November 2018, 
page 138/154 Confidential  EudraCT 2017-004643-20 
Doc No D-18.262 
 

ACT-541468 
Insomnia disorder 
Protocol ID-078A302 Version 5 
8 November 2018, 
page 139/154 Confidential  EudraCT 2017-004643-20 
Doc No D-18.262 
 

ACT-541468 
Insomnia disorder 
Protocol ID-078A302 Version 5 
8 November 2018, 
page 140/154 Confidential  EudraCT 2017-004643-20 
Doc No D-18.262 
 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 141/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
 

ACT-541468 
Insomnia disorder 
Protocol ID-078A302 
Version 5 8 November 2018, 
page 142/154 Confidential  EudraCT 2017-004643-20 
Doc No D-18.262 
 
 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 143/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 144/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 

ACT-541468 
Insomnia disorder 
Protocol ID-078A302 
Version 5 8 November 2018, 
page 145/154 Confidential  EudraCT 2017-004643-20 
Doc No D-18.262 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 146/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 

ACT-541468 
Insomnia disorder 
Protocol ID-078A302 
Version 5 8 November 2018, 
page 147/154 Confidential  EudraCT 2017-004643-20 
Doc No D-18.262 

ACT-541468 
Insomnia disorder 
Protocol ID-078A302 
Version 5 8 November 2018, 
page 148/154 Confidential  EudraCT 2017-004643-20 
Doc No D-18.262 

ACT-541468 
Insomnia disorder 
Protocol ID-078A302 
Version 5 8 November 2018, 
page 149/154 Confidential  EudraCT 2017-004643-20 
Doc No D-18.262 

ACT-541468 
Insomnia disorder 
Protocol ID-078A302 
Version 5 8 November 2018, 
page 150/154 Confidential  EudraCT 2017-004643-20 
Doc No D-18.262 

ACT-541468 
Insomnia disorder 
Protocol ID-078A302 
Version 5 8 November 2018, 
page 151/154 Confidential  EudraCT 2017-004643-20 
Doc No D-18.262 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 152/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 153/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 
 
 

ACT -541468  
Insomnia disorder  
Protocol ID -078A302  
Version 5  
8 November 2018,  page 154/154 Confidential  EudraCT 2017 -004643 -20 
Doc No D- 18.262 
